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Chapter 1
Introduction to subject
In his book, released in 2008, Harvard professor dr. John Ratey described Brain-Derived 
Neurotrophic factor (BDNF) as miracle-gro for the brain (Ratey, 2008). He writes that BDNF 
helps to build and maintain neurons by acting as a fertilizer for neuron growth. As such, 
BDNF has received a lot of attention in the popular media, making appearances from the 
New York Times (Reynolds, 2011) to the Oprah Winfrey show (Winfrey, 2008). These articles 
focused mainly on the effect of exercise on BDNF.  In scientific literature BDNF has been 
described in relation to many other areas of interest, of which depression has been quite 
prominent. This has led to a multitude of studies on BDNF in relation to depression. Due 
to easy accessibility, BDNF is often measured in serum or plasma. Current reports show 
significantly lower peripheral BDNF levels in depressed subjects (Brunoni et al., 2008). In 
broad, this thesis addresses the validity of peripheral assessments of BDNF and the biological 
role of BDNF in studying depression.   
The neurotrophic hypothesis of depression
Since 1960 depression has been diagnosed as “major depressive disorder” (in short 
depression) by a set of diagnostic criteria set forth by the American Psychiatry Association. 
These criteria are described in the fourth edition of the Diagnostic and Statistical Manual 
(DSM-IV-tr, 2000) and have remained unchanged in the recently published fifth edition (DSM-
5, 2013), consisting of two core criterion symptoms and seven minor criterion symptoms.
The two core criterion symptoms are a depressed mood and loss of interest, also called 
anhedonia. The seven minor criterion symptoms are: gain/loss of weight, sleep disturbance, 
fatigue, suicidal thoughts, psychomotor agitation/retardation, thoughts of worthlessness or 
guilt and problems with concentration. In total at least 5 symptoms should be present, of 
which one core criterion, to diagnose a major depressive episode. In addition symptoms 
should be present for the duration of at least 2 weeks and should lead to a clinically 
significant distress or impair ment in social, occupational, or other important areas of life.
Depression is a debilitating disease that is associated with a high loss of disability adjusted 
life years (Murray and Lopez, 1997). This is mainly due to a high lifetime prevalence of 19.2% 
(Kessler et al., 2010), a peak incidence in the second decade and an often chronic course 
with different depressive episodes being interspersed with relatively healthy episodes 
(Penninx et al., 2011). 
As the broad range of symptoms might suggest, depression is a heterogeneous disease. In 
the development of depression both genetic and environmental factors are concerned. A 
symptomatic diagnosis is the current standard to diagnose depression, and biochemical or 
radiological methods are lacking. None-the-less, biological correlates of depression have 
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been investigated and are incorporated in the current understanding of the pathophysiology 
of depression. 
The first and most dominant hypothesis on the biological underpinnings of depression is 
the monoamine hypothesis of depression, which states that a shortage of monoamines, 
most importantly serotonin, leads to the occurrence of depressive symptoms (Prins et al., 
2011). Various other biological systems have been implicated to account for the etiology 
of depression, including the hypothalamic-pituitary-axis (HPA-axis) (Anacker et al., 2011), 
circadian rhythm (McClung, 2007) and inflammation (Miller, 2010). Recently the neurotrophic 
hypothesis of depression has been proposed (Duman and Monteggia, 2006). It states that 
aberrant neurotrophic support causes depression due to hippocampal atrophy (Schmidt 
and Duman, 2007). In addition it states that antidepressants are effective due to their ability 
to elevate hippocampal neurotrophin levels. The detrimental effects of stress are in part 
ascribed to its effect on decreasing brain neurotrophin levels (Duman and Monteggia, 2006). 
This hypothesis was formed based upon a myriad of papers on stress paradigms, which are 
used to model depression. Stress is known to have a causal association with depression 
and to induce neural atrophy in the hippocampus (McEwen, 2000; Schmidt and Duman, 
2007). Numerous studies have shown lower BDNF mRNA expression in hippocampal tissue 
in stress paradigms (Smith et al., 1995), while higher mRNA expression can be induced by 
antidepressant treatment (Russo-Neustadt et al., 2000).
Brain-Derived Neurotrophic Factor
Function and production
BDNF is among the most frequently investigated neurotrophins. BDNF shows strong affinity 
for the Tyrosine Kinase B (TrKB) receptor, which leads to several intracellular signaling 
cascades that lead to activation of prosurvival pathways and/or inactivation of proapoptotic 
signaling (Di Lazzaro et al., 2007). These signaling cascades eventually stimulate arborization 
of dendrites (Lazo et al., 2013) and consolidate synaptic connections (reviewed in (Costa-
Mattioli et al., 2009)). Conversely, BDNF also binds to the p75 receptor, leading to apoptosis 
(Chao, 2003). 
The production of BDNF starts in the cell’s nucleus, where as many as seven promoters are 
known to transcribe BDNF (Liu et al., 2006). All transcripts are transported to the endoplasmic 
reticulum, where they are translated into pro-BDNF. Consecutively, pro-BDNF is folded in the 
trans-Golgi and packaged into secretory vesicles where it is sorted into either constitutive 
or secretory pathways (Mowla et al., 1999).  A non-synonymous polymorphism of the BDNF 
gene, which results in a valine-to-methionine change at position 66 of the pro-BDNF protein 
(rs6265, Val66Met) is associated with impaired intraneuronal protein trafficking and thus 
activity-dependent secretion (Alexander et al., 2010). Extracelullar proteases convert pro-
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BDNF into mature BDNF, yet the precursor pro-BDNF remains present in serum at a ratio of 
about 1:3 relative to mature BDNF (Yoshida et al., 2012)
Besides animal and laboratory studies, several human studies have been carried out to address 
the neurotrophin hypothesis of depression. Depressed patients using antidepressants 
had higher BDNF levels in post-mortem brain tissue than their non-antidepressant-using 
counterparts (Chen et al., 2001). In vivo human studies have been largely limited to 
measuring BDNF in peripherally drawn blood. Two meta-analyses had been performed prior 
to the start of this thesis on these data (Brunoni et al., 2008; Sen et al., 2008), both of which 
concluded that depressed subjects had significantly lower BDNF levels compared to healthy 
subjects. One of the limitations of the studies included in these meta-analyses however 
was that the major determinants of BDNF were unknown, hence they did not correct for 
all potential confounders. In this thesis these limitations will be addressed in a population 
based cohort and a clinical cohort of patients suffering from either depression and/or 
anxiety disorders which are both much larger than the (clinical) studies conducted hitherto. 
BDNF outside the nervous system
Although BDNF and its receptor are highly expressed in the central nervous system, it is 
also found in peripheral tissue, most prominently in vascular (Amoureux et al., 2012; Lorgis 
et al., 2009; Nakahashi T., 2000) and immunological tissue (Rezaee et al., 2010). As such, 
BDNF is readily measurable in the blood. As BDNF in platelets does not originate from 
megakaryocytes or other precursor cells of the mature platelet (Fujimura et al., 2002), it is 
likely that most of the BDNF in human platelets is sequestered from blood (Nakahashi et al., 
2000). Due to the high concentration of BDNF in platelets (Karege et al., 2005), serum levels 
are generally about a hundredfold to a two hundredfold higher than plasma levels (Fujimura 
H, 2002; Rosenfeld et al., 1995). Although direct evidence linking brain and peripheral BDNF 
levels together is lacking, it has been established that BDNF is actively transported across 
the blood-brain barrier (Pan W., 1998). In addition, in animal models, serum BDNF is highly 
correlated with central nervous system levels (Karege, 2002; Klein et al., 2011; Sartorius et 
al., 2009). Hence, BDNF in blood samples may stem from either peripheral sources and/or 
sources in the central nervous system.
Reason for investigation
Although much work had been carried out before the start of this thesis, some important 
question remained to be answered in order to gain a better understanding of the 
neurotrophic hypothesis of depression. 
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First, determinants of peripheral measures of BDNF are largely unknown. Unlike its name 
suggests, BDNF is not solely secreted by neurons. As a result, large quantities of circulating 
BDNF may have originated in peripheral tissue. Previously, no study had systematically 
investigated the determinants of peripheral BDNF. Hence, the results found in prior work on 
the subject of BDNF in depression may have been confounded since potential confounders 
were uncorrected for.
Secondly, no study has specifically distinguished whether low BDNF in depression is a state 
or a trait characteristic. First of all, cross-sectional studies on BDNF in depression have never 
included a group of patients with a remitted depressive disorder. Secondly, no longitudinal 
studies have been conducted on the course of BDNF levels over a longer period, i.e. when 
transiting from a depressive state to a remitted state etc.
Thirdly, no previous study has explicitly addressed the question whether low BDNF levels in 
depression can be related to specific clinical characteristics or symptom profiles. Depression 
is regarded as a heterogeneous disease due to the multiple possibilities of combinations 
of symptoms that can be present when diagnosing a depression. Low BDNF levels may 
therefore be driven by individual symptoms or symptom clusters rather than by the presence 
of depression as a whole.
Main research questions
In the first part of this thesis, I will focus on determinants of serum BDNF levels in humans. 
In the second part, clinical studies will be conducted on the neurotrophic hypothesis in 
affective (primarily depressive) disorders in humans, taking the determinants identiefied in 
the first studies into account. The main research questions can therefore be formulated as 
follows:
1. What are the main determinants of serum BDNF levels? (Chapters 2, 3 and 4)
2. Is low BDNF associated with depression? (Chapters 3, 5 and 8)  
3. Can lower BDNF levels in depressed subjects be ascribed to specific symptoms of 
depression? (Chapters 6 and 7)
4. Are lower BDNF levels in depressed patients a state or a trait characteristic? (Chapter 5 
and 8)
Studies used in thesis
All studies in this thesis have been based on two cohort studies, i.e. a population-based 
cohort (Nijmegen Biomedical Study) and a clinical cohort (Netherlands Study of Depression 
and Anxiety). Both cohorts will be described shortly below.
14
Chapter 1
 
Netherlands Study of Depression and Anxiety (NESDA)
The design of NESDA has been described in detail elsewhere (Penninx et al., 2008). NESDA 
was set out to investigate the long-term course of depression and anxiety and to study 
the clinical, psychosocial, biological and genetic determinants of the long-term course 
of depression and anxiety. To do so, 2981 subjects were sampled from different health 
care settings. Besides healthy controls, patients were included from both a primary care 
setting and the second line clinic. In order to establish a DSM-IV diagnosis, patients were 
interviewed with the Composite International Diagnostic Interview (CIDI). Additional 
information was gathered by additional questionnaires, blood collection and several 
biometric measurements. Baseline interviews took place between 2004 and 2007. A follow-
up was performed after 2 years. Of the initial 2981 participants 2596 (87%) were interviewed 
for the 2-year follow-up.
Nijmegen Biomedical Study (NBS)
The NBS is a population-based survey conducted in 2002 and 2003 by the department of 
epidemiology and biostatistics and the department of clinical chemistry of the Radboud 
University Medical Centre. A total of 21.756 questionnaires were sent to age (18-49 years, 50-
70 years and 70+ years) and sex stratified, randomly selected inhabitants of the municipality 
of Nijmegen. Questionnaires contained questions, among others, regarding sex, age, length, 
body weight, smoking habits, physical exercise and medication use. The response rate to 
the initial questionnaire was 43%. Data in this dissertation were collected in a subsample of 
subjects aged 50-70 years old. This data was acquired by sending a secondary questionnaire 
to all responders (n=2807). This secondary questionnaire contained additional items such as 
a comprehensive health history and Beck depression inventory. A total of 2253 persons were 
invited to participate in a study of non-invasive measurements of atherosclerosis of which 
1315 persons gave informed consent. Blood was drawn in which, besides other biomarkers, 
BDNF was measured. 
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Abstract
Brain-Derived Neurotrophic factor (BDNF) belongs to the neurotrophin family of growth 
factors and affects the survival and plasticity of neurons in the adult central nervous system. 
The high correlation between cortical and serum BDNF levels has led to many human 
studies on BDNF levels in various populations, however knowledge about determinants that 
influence BDNF is lacking.
In 1168 people aged 18 through 65, free of antidepressants and current psychiatric disease, 
from the Netherlands study of depression and anxiety four categories of determinants 
(sampling, socio-demographics, lifestyle indicators and diseases) were measured as well as 
BDNF level. We used univariate analyses as well as multivariate linear regression analyses in 
particular to determine which of the possible determinants significantly influenced serum 
BDNF levels. 
The mean BDNF level was 8.98 ng/ml (SD 3.1 ng/ml) with a range from 1.56 ng/ml through 
18.50 ng/ml. Our final multivariate regression analysis revealed that a non-fasting state of 
blood draw (β = -.067; p = .019), later measurement (β = -.065; p = .022), longer sample 
storage (β = -.082; p = .004) and being a binge drinker (β = -.063; p = .035) all resulted in 
attenuated BDNF levels. This was in contrast to smoking (β = .098; p = .001) and living in an 
urban area (β =.109; p < .001), which resulted in increased BDNF levels. Moreover we found 
that older subjects also had higher BDNF levels, but this only applied to women (β = .226; 
p < .001).
Future studies on serum levels of BDNF in humans should correct for the time of blood 
withdrawal, storage, urbanicity, age, sex, smoking status and food and alcohol intake. 
Determinants of serum brain-derived neurotrophic factor 
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Introduction
Brain-Derived Neurotrophic Factor (BDNF) belongs to the neurotrophin family of growth 
factors and affects the survival and synaptic plasticity of neurons in the adult central nervous 
system (Mossner et al., 2007). BDNF binds with the TrkB tyrosine kinase receptor (Chao, 
2003), which results in intracellular phosphorylation and activation of intracellular signaling 
cascades that lead to activation of prosurvival pathways and/or inactivation of proapoptotic 
signaling (Ullrich and Schlessinger, 1990). BDNF is expressed throughout the whole central 
nervous system (Binder and Scharfman, 2004) and significant concentrations are also found 
in peripheral blood  (Brunoni et al., 2008; Sen et al., 2008). BDNF crosses the blood-brain 
barrier by a high capacity, saturable transport system (Pan et al., 1998). In animal models, 
cortical BDNF levels are highly correlated with peripheral serum BDNF levels (Karege et al., 
2002; Sartorius et al., 2009), but evidence on the contrary has been shown as well (Elfving et 
al., 2009). Inconsistencies might be explained by the fact that BDNF expression and its TrkB 
receptor is not specific for neuronal cells in the brain, but can also be found in endothelial 
cells, smooth muscles cells, endocrine cells and immune cells in peripheral tissues (Ernfors 
et al., 1990; Maisonpierre et al., 1990; Yamamoto and Gurney, 1990;  Maisonpierre et al., 
1991; Scarisbrick et al.,1993;Esteban et al.,1995; Hiltunen et al., 1996; Nemoto et al., 1998; 
Kerschensteiner et al., 1999; Donovan et al., 2000).
The supposed importance of neuroplasticity in both the etiology and recovery of psychiatric 
disorders, has led to many studies linking serum BDNF to a wide variety of psychiatric and 
neurodegenerative diseases (Nakazato et al., 2003; Binder and Scharfman, 2004; Azoulay et 
al., 2005; Yasutake et al., 2006; Hashimoto et al., 2006; Ciammola et al., 2007; Gratacos et 
al., 2007; Machado-Vieira et al., 2007; Ikeda et al., 2008). For proper interpretation of serum 
BDNF levels in humans, however, knowledge about the key determinants of serum BDNF 
levels are essential for adequate control of confounding factors.
 
As touched above, BDNF is not only considered to be a neurotrophin, but also an 
immunotrophin, epitheliotrophin and metabotrophin (Chaldakov et al., 2007). As of yet 
somatic conditions that have been correlated to BDNF mainly include cardiovascular disease 
or cardiovascular risk factors or disease (Ejiri et., 2005; Fujinami et al., 2008; Hristova and 
Aloe, 2006; Suwa et al., 2006; Geroldi et al., 2006; Krabbe et al., 2007). For example, patients 
with acute coronary syndrome as well as patients with diabetes mellitus do have lower 
plasma levels of BDNF (Manni et al., 2005; Fujinami et al., 2008). One may thus hypothesize 
that BDNF is an underlying mechanism linking psychiatric and somatic illnesses. However, 
spurious associations may be explained due to (unknown) confounding factors, since health 
indicators like alcohol use, smoking and physical exercise have also been linked to BDNF 
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(Chan et al., 2008; Montag et al., 2008; Tang et al., 2008; Currie et al., 2009; Umene-Nakano 
et al., 2009).
Even more basic determinants, like socio-demographic variables and sampling characteristics 
have not specifically been examined. Although most human studies control for sex and 
age effects, reported effects of sex and age are contradictory. These mixed results may be 
explained by small sample sizes ranging from as low as 10 (Marano et al., 2007) through 
a maximum of 465 participants (Ziegenhorn et al., 2007), as well as failure to control for 
potentially confounding factors. (Shimizu et al., 2003; Lang et al., 2004; Aydemir et al., 
2007; Ziegenhorn et al., 2007). Recently, it has been suggested that BDNF exerts sex-specific 
stress-related effects in mice (Autry et al., 2009). Nevertheless, human studies report similar 
serum BDNF levels in men and women (Lang et al., 2004; Laske et al., 2007; Ziegenhorn 
et al., 2007), with the exception of one study in which the sex-differences reported could 
be explained by confounding depressive symptoms (Karege et al., 2002). As BDNF-levels 
have been associated with estrogen levels (Sohrabji and Lewis, 2006) we might even expect 
different age-related effects in women and men around the menopausal age. Finally, the 
effect of sampling characteristics on serum BDNF levels have hardly been examined. The 
few studies available, however, do suggest a decrease of BDNF levels after long-term storage 
(Trajkovska et al., 2007) and a diurnal variation within individuals (Piccinni et al., 2008). 
Considering the broad interest in BDNF, the many factors associated with serum BDNF levels 
and the conflicting results of even basic variables, it is surprising that no studies have been 
conducted to examine the independent effects of potential determinants of serum BDNF 
levels in humans.
Therefore, we conducted the present study to examine the determinants of serum BDNF in 
a large and well-defined cohort of people without current psychiatric or neurologic diseases. 
Potential determinants are based on prior literature and categorized in four blocks: sampling 
characteristics, socio-demographic variables, lifestyle indicators and (chronic) diseases. 
Methods
Population
Data are from the baseline measurement of the Netherlands Study of Depression and 
Anxiety (NESDA). NESDA is a multi-site naturalistic cohort study aimed to describe the 
8-year course and consequences of depressive and anxiety disorders and to integrate 
biological and research paradigms within an epidemiological approach. Recruitment took 
place in the general population, in general practices and in mental health organizations. The 
baseline sample consists of 2,981 participants aged 18 through 65 years of which 2,625 were 
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selected on the basis of a current or life-time history of depression and/or anxiety disorder, 
belonging to a high-risk group because of a family history or subthreshold depressive or 
anxiety symptoms, and 356 healthy controls. Patients with a primary psychiatric disorder 
not subject of NESDA, such as psychotic disorder, obsessive compulsive disorder, bipolar 
disorder, or severe addiction were excluded as well as those not being fluent in Dutch. 
The Medical Ethics Commission of participating institutes approved of this study and all 
respondents provided written informed consent before participation. All respondents 
received a structured diagnostic interview using the Composite International Diagnostic 
Interview (CIDI version 2.1) in order to assess current and liftetime DSM-IV diagnoses. The 
4-hour baseline assessment further included written questionnaires, interviews, a medical 
examination, a cognitive computer task and collection of blood and saliva samples, in order 
to gather extensive information about key (mental) health outcomes and demographic, 
psychosocial, clinical, biological and genetic determinants. All measurements and interviews 
took place at 5 different sites and were carried out by our specially trained staff according 
to a previously determined protocol. For a more detailed description of the objectives and 
methods of NESDA, we refer to Penninx et al. (2008). 
Based on our previous study (Molendijk et al, in revision) showing that BDNF was associated 
with both current psychopathology and antidepressant usage (in line with previous studies), 
but not with trait psychopathology or subthreshold symptoms, we excluded only participants 
with a current DSM-IV diagnosis of a depressive disorder or anxiety disorder in the last six 
months (n = 1.688) and those who were using any kind of antidepressant medication (n=736). 
This resulted in a study population of 1.198 participants. Of these, 30 did not have serum 
BDNF assessment, 3 samples were below the detection limit and therefore also excluded, 
leaving a final sample of 1,165 for the present study. Reasons for these missing data mainly 
consisted of technical problems: i.e. not enough blood was collected for BDNF assessment 
or problems occurred with storage. Missing data were considered to be randomly missing.
BDNF assessment
Blood was collected prior to the interview (between 0620h and 1230h) after an overnight 
fast and immediately transferred to one of the five local laboratory-sites to start processing 
within one hour. Serum samples for BDNF assessment were stored at -85 °C. After concluding 
the baseline assessment, serum samples were sent (ranging from 22 to 60 months after 
withdrawal) to the Department of Psychiatry and Neuropsychology in Maastricht (The 
Netherlands) for BDNF measurements. Serum BDNF protein levels were measured within 
three months after their receipt using the Emax Immuno Assay system from Promega 
according to the manufacturer’s protocol. The undiluted serum was acid treated, which 
in a dilution-dependent way reliably increased the detectable BDNF. Subsequently, serum 
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samples were diluted 100 times and stored again at -80°C for BDNF assay the next day. 
After dilution, the BDNF levels were well within the range of the standard curve. The assay 
sensitivity threshold was ascertained at 1.56 ng/ml reflecting the minimum level of BDNF 
in the serum that could be reliably determined. Three samples were below this threshold 
and deleted for all subsequent analyses (see also above). In our pilot study we had found 
that BDNF levels of acid-treated samples with subsequent dilution the day preceding the 
BDNF assay did not differ from the levels obtained in samples following acid treatment 
only (i.e. without subsequent dilution) on the preceding day, or from those derived after 
acid treatment conducted the day of the BDNF measurement. The serum samples used 
in our pilot study were stored samples of six individuals who did not participate in the 
present study. The samples’ coefficients of variance ranged from 2.9% to 8.1%. To gauge 
the intra-assay variance for the present study, we analyzed two of our current samples on 
two different plates on the same day. The resultant coefficients of variance of 0.0% and 
3.1% were both well below the maximum intra-assay variance of 8.8% as specified by the 
manufacturer. Greiner Bio-One high affinity 96-well plates were used and the resulting 
absorbance was read in duplicate using a Biorad Benchmark microplate reader at 450 nm. 
Serum BDNF protein levels were expressed in ng/ml.
 
Potential determinants of BDNF
Based on previous studies various determinants were included and grouped into sampling 
variables, socio-demographic variables, lifestyle indicators and (chronic) diseases. 
Sampling variables – These consisted of time of blood withdrawal (minutes after 6.00 a.m.), 
the number of minutes a sample was kept in a cool box before being processed in the local 
laboratory, the duration of sample storage at -85 °C (days) and finally non-adherence to the 
pretest fasting protocol (yes/no).
Socio-demographic variables – These consisted of sex (male/female), age (years), urbanicity 
of living environment of participant (urban/not urban) and years of education. An urban 
environment was defined according to the classification of the Dutch Office for statistics 
(CBS) and dichotomized in more or less than 1000 addresses per square kilometer. 
As a previous study of our group suggested the presence of an age effect only in women 
(B.Bus et al., 2010, unpublished observations), we were also interested in the interaction 
between age and sex a priori. 
Health indicators – This included presence of metabolic syndrome (yes/no), smoking (yes/
no), physical activity (Met-minutes) and drinking (abstainers/mild/moderate/excessive) and 
body mass index (BMI).
Metabolic syndrome was defined according to the updated Adult Treatment Panel III (ATP 
III) guidelines of the US national cholesterol education program (Grundy 2005) in which 
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metabolic syndrome is considered present if a participant meets at least three of the following 
criteria: 1) elevated waist circumference (men ≥ 102cm; women ≥ 88cm); 2) elevated 
triglycerides (≥ 150mg/dL); 3) reduced HDL cholesterol (men < 40mg/dL; women < 50mg/
dL); 4) elevated blood pressure (≥ 130/85mmHg or use of medication for hypertension); or 
5) elevated fasting glucose (≥5.6mmol/L or use of medication for hyperglycemia).
As a measure for physical activity we used Metabolic Equivalent of Task (MET)-minutes. 
A MET-minute is a ratio of the amount of energy expenditure during an activity to the 
expenditure at rest, which was calculated on the basis of the international physical activity 
questionnaire (Craig 2003). Smoking was dichotomized into current smokers versus non-
smokers. In addition to current smoking (yes/no), we also collected information on smoking 
status in the past, i.e. age of starting, age of quitting and the average number of cigarettes 
smoked a day. The number of package years were calculated with one package year defined 
as smoking 25 cigarettes a day for the period of one year (=9125 cigarettes). The fagerstrom 
questionnaire was used to measure the severity of nicotine dependence (Heatherton et al., 
1991).  
Alcohol use was evaluated by creating four groups: abstainers, mild drinkers (drinking less 
than 7 units a week), moderate drinkers (drinking 8-13 units a week) and excessive (drinking 
14 units or more a week). Alcohol categories were entered as dummy variables. In addition 
the AUDIT was used to measure alcohol dependence (Babor et al., 1989).
BMI was calculated by dividing weight (kg) by the squared height (m) and entered as a 
continuous variable. 
Disease – Based on previous associations with serum BDNF levels in humans, we evaluated 
the presence (yes/no) of Chronic Non-Specific Lung Disease (CNSLD) (including asthma, 
chronic bronchitis and chronic emphysema) and coronary artery disease (Manni et al., 
2005; Fujinami et al., 2008). The latter was defined as self-reported vascular events due 
to atherosclerotic disease, i.e. stroke, angina pectoris, myocardial infarction or a history of 
percutaneous transluminal coronary angioplasty or coronary artery bypass grafting. Stroke, 
myocardial infarction and angina pectoris were only considered present if supported by 
appropriately prescribed medication use. Participants were asked to bring their medication 
containers with them in order to record their medication use (Wittchen, 1994).
Statistical analysis
Serum BDNF levels were normally distributed, with the exception of 12 (0,5%) positive 
outliers (i.e. level higher than 3SD above mean). Outliers were handled by trimming all 
serum BDNF levels above 3 standard deviations (SD) of the mean to the 3SD value to prevent 
that results are driven by potential outliers. 
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Univariate analyses were carried out using univariate linear regression. We performed 
multiple linear regression analyses to assess independent determinants of BDNF. To facilitate 
the interpretation of the age-sex interaction, rather than taking their absolute ages, we 
calculated and included the deviation from the mean, so that the participants’ ages were 
centered around the sample’s mean age. We generated multivariate models within each 
domain first by entering sampling characteristics, sociodemographic characteristics, health 
indicators and disease variables in four separate models. Subsequently, the independent 
predictors from all domain-specific models with p-values less than .15 were fitted into a final 
multivariate model using an enter method. No collinearity or heteroscedasticity problems 
emerged. All tests were two-sided. A p-value of 0.05 was considered statistically significant. 
All analyses were carried out using SPSS 16.0.
Results 
Sample characteristics (see table 2.1)
The 1165 participants had a mean age of 42.5 years (SD=14.1) and 65.0% (757) were female. 
The mean BDNF level was 8.98 ng/ml (SD 3.1 mg/ml) with a range from 1.56 ng/ml through 
18.50 ng/ml. Table 1 presents all further characteristics as well as the univariate associations 
of these characteristics with the serum BDNF level. As shown in table 1, a lower serum BDNF 
level was associated with non-adherence to pretest fasting protocol (β = - .072; p = .014), 
sampling at a later day-time (β = -.068; p =.022), a longer time of storage (β = -.092; p = .002), 
high alcohol intake (Excessive drinkers vs. others (β = -.073; p = .020) and finally increased 
physical activity (β = -.063; p = .032). A higher BDNF serum level was found in older patients 
(β = .21; p <.001), a higher degree of urbanicity (β = .145; p <.001), current smokers (β = 
.074; p = .012) and in patients suffering from the metabolic syndrome (β = .064; p = .030) or 
coronary artery disease (β = .082 ; p = .005).
Multivariate analyses (see table 2.2)
From the four models, categorized by variable type, we identified eleven significant 
determinants. Participant that had eaten prior to blood withdrawal resulted in a significantly 
lower serum BDNF levels. (β = -.069; p = .020). Sampling later during the morning resulted 
in a lower serum BDNF level (β = -.073; p = .013) as well as longer sample storage (β = -.084; 
p = .005). Serum BDNF levels in women significantly increase with age (β = .234; p < .001), 
but also in men (β = .103; p = .029). The age change was significantly different in women 
compared to men, as was indicated by the significant interaction between sex and age (β = 
-.083; p = .023). Subjects who were living in a more urbanized area had higher BDNF levels 
(β = .094; p = .002). Excessive drinkers had significantly lower serum BDNF levels compared 
with subject with more restraint drinking habits, as was indicated by the significant dummy 
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variable (β = -.079; p = .009). Current smokers had a significantly higher BDNF level compared 
to non-smokers (β = .089; p =.003). Subjects with more physical activity had lower serum 
BDNF levels (β = -.058; p = .047). Patients with cardiovascular disease had higher serum 
BDNF levels (β = .082; p = .005). All these variables were entered in the final model. The 
presence of metabolic syndrome did not reach statistical significance (β = .053; p = .12), but 
was entered into our subsequent model as well on the basis of a statistical significance at a 
p < .15 level.
Our final multivariate regression analysis revealed that, when accounting for all potential 
determinants at once, having eaten prior to blood withdrawal (β = -.067; p = .019), 
measurement later on the day (β = -.065; p = .022), longer sample storage (β = -.082; p = 
.004), and being an excessive drinker (β = -.063; p = .035) all resulted in attenuated serum 
BDNF levels. This was in contrast to smoking (β = .098; p = .001) and living in an urban area 
Table 2.1
Sample characteristics (n=1165) and univariate associations with serum BDNF levels by 
linear regression
Mean (SD) value Linear regression
Variables in four blocks or % (n) beta p-value
Sampling variables
   % fasting on withdrawal day (n) 95.3 (1110) -,072 ,014
   Time of sampling (mean minutes past 0600h, SD)      168 (20) -,068 ,022
   Time in coolbox (mean minutes, SD) 60 (43) ,028 ,351
   Duration of sample storage (days, SD) 1286 (228) -,092 ,002
Sociodemographics
   % female (n) 65.0 (757) ,024 ,418
   Age (mean in years, SD) 42.5 (14.1) ,21 <,001
   % living in urban area (n) 85.9 (1001) ,145 <,001
   Education level (mean in years, SD) 12.7 (3.1) ,046 ,118
Lifestyle indicators
   % currently smoking (n) 30.3 (353) ,074 ,012
   % with metabolic syndrome (n) 19.1 (222) ,064 ,030
   Physical activity (mean MET-minutes , SD) 3708 (3108) -,063 ,032
   % abstinent of alcohol (n) 44.8 (522) Ref.
   % mild drinker; <1U/day  (n) 34.2 (399) -007 ,817
   % moderate drinkers; 1-2U/day (n) 5.9 (69) -,018 ,571
   % excessive drinkers; >2U/day (n) 3.6 (42) -,073 ,020
  BMI (height/weight2, SD) 25.3 (4.5) ,036 ,219
Disease
   % with coronary artery disease (n) 5.3 (62) ,082 ,005
   % with CNSLD (n) 10.0 (117) ,001 ,981
Abbrevations: SD = standard deviation; U = unit; BMI = body mass index; CNSLD = chronic non-specific 
lung disease, BMI = body mass index, MET = Metabolic equivalent of task
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(β = .109; p < .001). which resulted in increased BDNF levels. Moreover we found that older 
subjects also had higher BDNF levels, but this was only true for women (β = .226; p < .001). 
(See Figure 2.1.) The age change did not reach statistical significance for men (β = .060; 
p < .26) and was significantly different from age change in women, hence the significant 
interaction (β = -.098; p < .007). For an overview of these results also see figure 2.2.
Post-hoc analyses 
Significant associations in the univariate or multivariate analysis were analyzed in more 
depth by post-hoc analyses using other definitions for the variable or including potentially 
explanatory variables. For example, in order to explain sex-differences, we examined the use 
of oral contraception and menstrual cycle.
Sex differences – In order to further explore the sex differences identified, we assessed the 
influence of menopausal status and contraceptive pill use in women on BDNF levels. Since 
age and menopausal status are two highly interwoven variables, we selected women in a 
narrow age range of 48 to 52 years of age. Since pre- and postmenopausal women were 
evenly dispersed (premenopausal n=41; postmenopausal n=40) in this age range, we were 
able to minimize the confounding influence of age. The age variable was centered around 
this sample’s mean and entered in a multiple regression together with a dichotomous 
menopausal status variable (0 = premenopausal; 1 = postmenopausal) and the interaction 
between these two variables. In this analysis we corrected for variables previously found to 
be of influence. Premenopausal women had a significant BDNF increase with age ( β = .460; 
p = .019) and differed significantly (p = .031) from postmenopausal women who showed a 
Figure 2.1
Interacting effect of gender and age on serum BDNF
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Figure 2.2
Overview of significant findings
*Denotes a statistical significance of p<.001 after correction for confounders in the final model
** Denotes a statistical significance of p<.05 after correction for confounders in the final model
Whiskers reflect the standard error of the mean
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decrease ( β = -.185; p = .43), however non-significant, as can be seen in figure 2.3. Pre- and 
postmenopausal women’s BDNF serum levels did not significantly differ ( β = .123; p = .43) 
at the age of 50.1 years (mean age of this sample). 
To test whether contraceptive pill use influenced BDNF levels we selected all premenopausal 
women and entered the dichotomous variable ( 0 = no contraceptive pill; 1 = use of 
contraceptive pill) in our final model. This, however, revealed a non-significant result for 
contraceptive pill use ( β = -.03; p = .53).     
Smoking- We created dummy variables for former and current smokers and subjects who 
have never smoked and entered these into our final model, thus correcting for potentially 
confounding factors. This revealed that current smokers had significantly higher BDNF levels 
compared to those who have quit smoking ( β = -.145; p < .001). However, no significant 
difference was found between current smokers and those who have never smoked ( β = 
-.053; p = .11). Furthermore, no effect on serum BDNF levels was found of package years, 
actual number of cigarettes a day among smokers, as well as the severity of nicotine 
dependence as assessed with the Fagerstrom questionnaire (data not shown). 
Alcohol use- In order to check whether the effect of alcohol intake on the serum BDNF  levels 
could be explained by the degree of alcohol dependence, we replaced the alcohol variables 
in our final model with the sum score of the AUDIT. No significant effect was found for the 
AUDIT in this model (β = -.05; p =.10). 
Figure 2.3
Interaction of menopausal state on the association between age and BDNF in women
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Cardiovascular disease – Since the metabolic syndrome and cardiovascular disease were 
associated with serum BDNF levels in the univariate analysis, we further investigated this 
by repeating our multivariate analysis in a stepwise manner. We found that significance for 
both metabolic syndrome and cardiovascular disease was lost after the introduction of age 
as a variable.
Moreover we investigated the individual components of metabolic syndrome, by adding 
these to our final regression model as described above. Only hypertriglyceridemia 
significantly contributed to the variation in serum BDNF level (β = .074; p = .018). The four 
other individual criteria did not reach a significant level:  low HDL cholesterol (β = -.003; p = 
.91), abdominal obesity (β = -.024; p = .44), hypertension β = -.005; p = .87), hyperglycemia 
(β = -.044; p = .17).
Discussion
Main findings
Within a large cohort of people free from psychiatric disorders and neurodegenerative 
diseases, we identified eight independent determinants of serum BDNF levels, i.e. time of 
blood withdrawal, time of storage, food intake before sampling, urbanicity, age, sex, smoking 
status and drinking behavior. Below we will discuss these determinants in more depth.
Sampling variables 
Three sampling variables had an independent effect on serum BDNF levels in our study. 
First, although the overall decline was small, BDNF levels were significantly lower after long-
term storage over a mean period of about 3.5 years. This is in line with previous results 
showing that serum BDNF had significantly decreased after five years of storage, but not yet 
after twelve months (Trajkovska et al., 2007). In our study, however, this decline of serum 
BDNF was far less pronounced. Most likely, this can be explained by storage temperature, 
which was much lower in our study, i.e. -85 °C compared to -20 °C. It is important to know, 
especially for epidemiological studies taking blood samples outside the hospital, that the 
time kept in a cool box before initial processing does not affect BDNF serum levels. 
Secondly, we found attenuated serum BDNF levels when blood was drawn later in the 
morning. Diurnal variation has been reported for plasma BDNF levels, but not for serum 
BDNF levels (Piccinni et al., 2008). Acknowledging the limited time-interval in which serum 
BDNF levels were measured in our study, a much larger diurnal variation in BDNF can be 
expected. This should be explored in more detail in subsequent studies.
Finally, to our knowledge, we are the first to show that food intake prior to sampling results 
in lower serum BDNF levels. Although we cannot exclude that these results were caused by 
selection bias, it does plead for taking this into consideration in future research. 
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Socio-demographic variables
In contrast with men, in whom change in BDNF levels by age is far less pronounced, in 
our sample of people aged between 18 and 65 years we found increasing serum BDNF 
levels in women with advancing age. In a previous study of our group among community-
dwelling older people aged 50 through 72 years we found constant BDNF serum levels in 
men, whereas in women an age-related decrease was found (Bus 2010, submitted). At a 
first glance, these results seem puzzling, but the difference between men and women, as 
well as the opposite age-related effects in younger and older women, might be explained by 
sex-hormone differences between men and women. In post-hoc analyses we have found a 
significant interaction of age and menopausal state in women, with an age-related increase 
of serum BDNF in premenopausal women and an age-related decrease in postmenopausal 
women. As estrogen levels are significantly associated with BDNF levels (Monteleone et 
al., 2007), the postmenopausal drop in estrogen levels could possibly result in decreasing 
BDNF serum levels. These results thus suggest that in women serum BDNF levels peak at 
the climacteric age. However, since age and menopausal status are inextricably linked, it 
remains difficult to draw any conclusions in this cross-sectional approach, hence warranting 
future longitudinal research. 
Furthermore, participants living in an urban environment had significantly higher serum 
BDNF levels compared to their rural counterparts. The effect of urbanicity might be 
hypothesized to be an indirect effect mediated by different factors. On the one hand, one 
may expect decreased BDNF-levels due to a higher exposure to stress factors (Godfrey 2005) 
and higher frequency of psychopathology (Peen et al., 2009). On the other hand, one may 
expect increased BDNF levels due to a higher environmental enrichment, which has shown 
to induce BDNF gene expression (Kuzumaki et al., 2010). As we excluded participants with 
current psychopathology (and associated the highest stress levels), this latter effect might 
have outweighed the effect of stress and psychopathology. 
 
Health indicators
Only two health indicators were associated with serum BDNF levels. First, current smoking 
was associated with higher BDNF levels. Interestingly, an opposite effect has been reported 
on plasma BDNF-levels in two previous studies. (Kim et al., 2007; Bhang et al., 2010). 
Assuming that previous results are not chance findings due to low patient numbers, these 
opposite effects might be explained by dysfunctioning platelets in smokers resulting in 
impaired BDNF-release from platelets, which would affect plasma but not serum levels of 
BDNF (Nowak et al., 1987).
Despite the clear effect of current smoking, we neither detected a dose-response effect 
measured by package years (in smokers and ex-smokers) nor a dose-response effect 
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measured by number of cigarettes a day (in current smokers). Different hypotheses seem 
valid. First these findings might indicate a direct toxic effect of smoking, as in animal 
research a direct relationship between nicotine and BDNF-expression in the brain has been 
reported  (Kim et al., 2007). Secondly, the association might be caused by an underlying 
third factor related to serum BDNF levels as well as smoking habits (vulnerability for starting 
smoking or being able to quit when started), as preliminary evidence has found an effect of 
Val66Met polymorphism of the BDNF gene on smoking habits (Lang et al., 2007), although 
a replication was negative (Montag et al., 2008). Moreover, in our sample we could not find 
an association between the degree of nicotine dependence and serum BDNF levels and 
previous studies (performed in plasma BDNF) showed that subjects had BDNF levels similar 
to non-smokers after 12 weeks of smoking cessation (Bhang et al., 2010). This evidence 
points towards a direct involvement of the inhalation of smoke in influencing BDNF levels. 
High alcohol intake, but not the severity of alcohol dependence, was associated with lower 
BDNF serum levels in our sample. BDNF has been hypothesized to be implicated in ethanol-
induced neurodegeneration in the adult brain, but to date, the role of BDNF in alcohol use 
disorders is still a matter of debate  (Davis, 2008). The only study of serum BDNF levels in 
patients with alcohol dependence found only diminished BDNF levels in case of co-morbid 
depression, but not in patients with alcohol dependence without co-morbid depression 
(Umene-Nakano et al., 2009). This picture becomes even more complicated acknowledging 
the possible role of the val66met polymorphism of the BDNF gene in relapse of alcohol use 
disorders (Wojnar et al., 2009). More research on the role of BDNF in alcohol use disorders 
is clearly warranted. Thus far, studies investigating BDNF outside the area of alcohol use 
disorder should exclude people who use more than 14 standardized units of alcohol a week. 
The small inverse relationship between physical activity and BDNF serum levels showed a 
tendency toward statistical significance. Previous studies reported increased serum BDNF 
levels directly after exercise (Tang et al., 2008), but decreased basic BDNF levels at rest 
in physically more active humans (Currie et al., 2009). Although we used a well-validated 
questionnaire to estimate the average level of physical activity, such measures are per 
definition less precise compared to controlled activity in an experimental setting. Moreover, 
we could not control for the time between the last period of (severe) physical activity and 
blood withdrawal. This might explain why we were not able to replicate previous findings 
(Currie et al., 2009). 
Chronic disease
Although there is evidence that BDNF may play a role in the pathogenesis of cardiovascular 
disease (Chaldakov et al., 2004; Ejiri et al., 2005; Manni et al., 2005; Cai et al., 2006), BDNF 
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serum levels were not associated with prevalent cardiovascular diseases or (components of) 
the metabolic syndrome. 
A closer look on previous studies of BDNF in cardiovascular disease suggests that positive 
results can be explained by methodological differences. First, some studies have reported 
an elevated expression of BDNF in atherosclerotic plaques (Ejiri et al., 2005), but to date it 
is not clear to what extent BDNF expression in atherosclerotic plaques contributes to the 
overall BDNF serum levels. Secondly, others have reported lower plasma levels of BDNF 
in patients in the acute phase of coronary syndromes (Manni et al., 2005), which may be 
explained by both the acute phase of the coronary syndrome as well as the differences 
between BDNF measurements in plasma versus serum. The lack of an association between 
BDNF serum levels and prevalent cardiovascular disease is relevant for future studies in 
the role of BDNF serum levels in late-life depression and neurodegenerative disorders in 
which cardiovascular diseases are highly prevalent. Lung diseases were not associated with 
BDNF level either. Elevated serum BDNF levels have been reported in patients with asthma 
(Lommatzsch et al., 2005), but even when we investigated asthma and chronic obstructive 
pulmonary disease (COPD) separately, no effect was found (data not shown). 
Strengths and weaknesses 
Although we conducted the largest study to date on serum BDNF levels in human and included 
a large number of possible determinants, one important methodological issue has to be 
addressed for proper interpretation. Results for serum BDNF levels cannot be generalized 
to studies of BDNF in plasma or platelets. Because of the storage of BDNF in platelets, the 
concentration of BDNF in serum and plasma differs by a factor of 200 (Rosenfeld et al., 
1995). As BDNF in platelets does not originate from megakaryocytes or other precursor cells 
of the mature platelet  (Fujimura et al., 2002), it is likely that most of the BDNF in human 
platelets is sequestered from blood (Nakahashi et al., 2000). Furthermore, BDNF is released 
by platelets during the clotting process (Rosenfeld et al., 1995). This means that differences 
in platelet functioning, either by their ability to release BDNF or sequester BDNF from blood, 
may result in differences between serum and plasma BDNF levels.
A possible disadvantage of measuring BDNF in serum may be a decline in BDNF levels after 
long-term storage of serum, which may not occur for BDNF stored in platelets (Trajkovska 
et al., 2007). In our study, serum was stored at -85 °C for a period varying between 22 
and 60 months. Although we have found that serum BDNF significantly declines in long-
term storage, this decline was relatively small and was corrected for.  Furthermore, only one 
samples had a BDNF level below the lower detection limit. Therefore, we can conclude that 
reliable conclusions can be made after a long-term storage at -85 °C.
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Final conclusions
Future studies on serum BDNF levels in humans should correct for the time of day of blood 
withdrawal, storage, age, sex, urbanicity, smoking status and alcohol use. Although effect 
sizes are generally small and clinical relevance needs to be tested in subsequent clinical 
samples, we would suggest to exclude smokers, excessive alcohol drinkers and subjects 
who did not adhere to the pretest fasting protocol from clinical studies and to keep storage 
time limited. Moreover, for diseases with a diurnal variation, like mood disorders, it would 
be interesting to examine whether other parameters of BDNF serum levels, e.g. change of 
BDNF over the day, would be of more relevance than one measure in the morning.
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Abstract
Brain-derived neurotrophic factor (BDNF) is involved in major depressive disorder and 
neurodegenerative diseases. Clinical studies, showing decreased serum BDNF levels, are 
difficult to interpret due to limited knowledge of potential confounders and mixed results 
for age and sex effects. We explored potential determinants of serum BDNF levels in a 
community sample of 1230 subjects.
Multiple linear regression analyses with serum BDNF level as the dependent variable were 
conducted to explore the effect of four categories of potential BDNF determinants (sampling 
characteristics, sociodemographic  variables, lifestyle factors and somatic diseases)  and of 
self-reported depressive symptoms (Beck’s Depression Inventory (BDI).
Our results show that BDNF levels decline with age in women, whereas in men levels remain 
stable. Moreover, after controlling for age and gender, the assays still showed lower serum 
BDNF levels with higher BDI sum scores. Effects remained significant after correction for two 
main confounders (time of sampling and smoking), suggesting that they serve as molecular 
trait factors independent of lifestyle factors.
Given the age-sex interaction on serum BDNF levels and the known association between 
BDNF and gonadal hormones, research is warranted to delineate the effects of the latter 
interaction on the risk of psychiatric and neurodegenerative diseases.
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Introduction
Brain-derived neurotrophic  factor (BDNF) belongs to the neurotrophin family of growth 
factors and regulates aspects of neural plasticity of neurons in multiple brain regions 
(Mossner et al.  2007). Significant concentrations of BDNF are also found in peripheral blood 
(Brunoni et al.,  2008; Sen et al.,  2008). In animals high correlations between cerebral BDNF 
expression and peripheral serum-BDNF levels have been shown (Karege et al.,  2002b), 
suggesting a comparable relationship in humans. Along these lines, BDNF levels in humans 
have been linked to a wide variety of brain diseases, among which neuropsychiatric (Binder 
and Scharfman, 2004; Gratacos et al.,  2007; Machhado-Vieira et al.,  2007; Hashimoto 
et al.,  2004; Hashimoto et al.,  2006; Ikeda et al.,  2008; Nakazato et al.,  2003) and 
neurodegenerative diseases (Azoulay et al.,  2005; Yasutake et al.,  2006).
Two recent meta-analyses confirmed significantly lower serum BDNF levels for depressed 
patients relative to the concentrations found in healthy controls, with levels normalizing 
after treatment with antidepressants (Brunoni et al.,  2008; Sen et al.,  2008). The studies 
included in the meta-analyses were restricted to clinically depressed patients, most of 
whom were women. As experimental findings suggest that alterations in BDNF signaling are 
associated with depression-related behaviors in women only (Lee et al.,  2007; Monteggia 
et al.,  2007), generalization to men is questionable.
Furthermore, mixed results have been reported for associations between serum 
BDNF levels and age (Aydemir et al.,  2007; Lang et al.,  2004), although the only study 
conducted in older people found decreased BDNF levels with age (Ziegenhorn et al.,  2007). 
Furthermore, in dementia patients, lower BDNF serum levels have been associated with a 
higher risk of neurodegenerative processes (Yasutake et al.,  2006), which is in line with the 
neuroprotective effects of BDNF.  The correlation between estrogen and BDNF levels may 
not necessarily offer an explanation for the potential sex differences (Monteleone et al., 
2007), but may also result in sex-specific correlations with age due to a post-menopausal 
drop in estrogen levels (Simpkins and Singh, 2008). 
To be able to study age, sex and depressive symptoms as determinants of serum BDNF 
levels in humans, potential confounders have to be taken into account. Not only is BDNF 
increasingly considered a neurotrophin, it is also seen as an immunotrophin, epitheliotrophin 
and metabotrophin (Chaldakov et al.,  2007), which would explain why, besides psychiatric 
and neurodegenerative diseases, somatic illnesses have also been related to BDNF. 
Somatic conditions that have been shown to correlate with BDNF levels mainly concern 
cardiovascular disease or cardiovascular risk factors (Ejiri et al.,  2005; Fujinami et al.,  2008; 
Geroldi et al.,  2006; Hristova and Aloe, 2006; Krabbe et al.,  2007; Suwa et al.,  2006), which 
is not surprising given that serum levels may be affected by lifestyle factors such as chronic 
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or excessive alcohol use, lack of physical exercise and smoking (Chan et al.,  2008; Currie et 
al.,  2009; Montag et al.,  2008; Tang et al.,  2008; Umene-Nakano et al.,  2009). One study 
has further identified a diurnal variation in BDNF levels, suggesting the need to correct for 
time of sampling (Piccinni et al.,  2008).
Taken together, there is ample evidence to suggest that BDNF is linked to a variety of 
molecular abnormalities underlying neuropsychiatric and neurodegenerative diseases. 
However, the findings to date were obtained in relatively small and mostly clinical samples 
and are thus of modest statistical power and limited generalizability, without large-scale 
studies having replicated the data in non-clinical cohorts or studied distinct factors affecting 
serum BDNF levels.
The present study was designed to do so: we looked for determinants of serum BDNF levels 
in a large community sample of middle-aged and elderly, with a particular emphasis on 
potential associations with age, sex and depressive symptoms.
Methods
Study population - The present study sample was drawn from the Nijmegen Biomedical 
Study (NBS), a population-based survey of people aged between 20 and 90 years. For details 
we refer to a previous publication (Hoogendoorn et al.,  2006). A total of 2253 respondents 
were then invited to participate in a study of non-invasive measurements of atherosclerosis 
of whom 1517 gave their informed consent. They subsequently visited the hospital for 
measurements and blood sampling, as described in detail elsewhere (Holewijn et al.,  2009). 
This latter group was hence eligible for participation in the present study. The only exclusion 
criterion was the use of antidepressant medication, as this has consistently been associated 
with BDNF levels and might mask the effect of other determinants (Brunoni et al.,  2008; 
Sen et al.,  2008). 
In accordance with the Declaration of Helsinki the study protocol was approved by The 
Medical Ethics Committee of the Radboud University Nijmegen Medical Centre and 
informed, written consent was obtained from all participants.
Serum BDNF -Following the baseline assessment and ranging from 9 to 44 months after having 
been drawn, serum samples were sent to the Department of Psychiatry and Neuropsychology 
in Maastricht (The Netherlands) for BDNF measurement, where they were stored at -80°C. 
Serum BDNF protein levels were measured within three months after their receipt using the 
Emax Immuno Assay system from Promega according to the manufacturer’s protocol. The 
undiluted serum was acid treated, which in a dilution-dependent way reliably increased the 
detectable BDNF. Subsequently, serum samples were diluted 100 times and stored again 
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at -80°C for BDNF assay the next day. After dilution, the BDNF levels were well within the 
range of the standard curve. The assay sensitivity threshold was ascertained at 1.56 ng/
ml reflecting the minimum level of BDNF in the serum that could be reliably determined. 
In our pilot study we had found that BDNF levels of acid-treated samples with subsequent 
dilution the day preceding the BDNF assay did not differ from the levels obtained in samples 
following acid treatment only (i.e. without subsequent dilution) on the preceding day, or 
from those derived after acid treatment conducted the day of the BDNF measurement. The 
serum samples used in our pilot study were stored samples of six individuals that did not 
participate in the present study. The samples’ coefficients of variance ranged from 2.9% 
to 8.1%. To gauge the intra-assay variance for the present study, we analyzed two of our 
current samples on two different plates on the same day. The resultant coefficients of 
variance of 0.0% and 3.1% were both well below the maximum intra-assay variance of 8.8% 
as specified by the manufacturer. Greiner Bio-One high affinity 96-well plates were used and 
the resulting absorbance was read in duplicate using a Biorad Benchmark microplate reader 
at 450 nm. BDNF protein levels were expressed in ng/ml.
Depressive symptoms - Depressive symptoms were assessed using the Beck Depression 
Inventory (BDI), a 21-item self-report questionnaire with excellent psychometric 
characteristics (Beck and Steer, 1984). Each item is rated on a 4-point scale, with 0 reflecting 
the absence of symptoms and 1-3 increasing levels of symptom severity. The BDI yields a 
total score ranging from 0 to 63. Individual items of the BDI can be consider to belong to 
a cognitive subscale or a somatic subscale (Beck and Steer, 1987). Separate sumscores for 
both of these subscales were calculated. History of depression was assessed by a self-report 
question with a dichotomous outcome (yes/no).
Possible determinants  - Potential confounders of any associations between BDNF levels 
and depression were determined based on previous studies and categorized in four groups: 
sampling characteristics, sociodemographic variables, health indicators and chronic diseases.
Sampling characteristics were the time of blood withdrawal and the number of months the 
serum was stored at -80°C. Age, sex, and marital status were taken as the sociodemographic 
variables of interest. Health indicators were the presence of metabolic syndrome (MS), 
smoking status, physical activity, and alcohol use. MS (defined according to the International 
Diabetes Federation criteria (IDF, 2009) was determined by physical examination and 
fasting vena punction. Participants were diagnosed with the syndrome if they had central 
obesity (BMI ≥30 or above ethnic-specific waist circumference) and two or more of the 
following abnormalities: high blood pressure (≥130/85 mm Hg), hyperlipidemia (triglyceride 
concentration ≥150 mg/dl [1.695 mmol/l]) or specific medication for this lipid abnormality, 
HDL cholesterol <40 mg/dl [1.03 mmol/l] in men and <50 mg/dl [1.29 mmol/l] in women 
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or specific medication for this lipid abnormality, and fasting plasma glucose >100 mg/dl 
[5.6mmol/l] or previously diagnosed type II diabetes mellitus. Systolic and diastolic blood 
pressure were measured using an oscillometric sphygmomanometer (Criticon model no. 
1846, Criticon Inc., Tampa, USA), while waist circumference was determined at the level 
of the umbilicus and triglycerides (TG) and glucose concentrations established using 
commercially available enzymatic reagents (AEROSET® System, Abbott, Chicago Illinois).
Smoking status, physical activity and alcohol use were assessed during a short interview and 
all operationalized as dichotomies: current smoker versus non-smoker, 0-1 hours of weekly 
physical (sport) activity versus 2 hours or more (Stampfer et. al., 2000), and severe (>21 
units for males and >14 units for females) versus non-severe use of alcohol, respectively. 
As to chronic diseases, we screened for coronary artery disease (CAD) and other somatic 
conditions. CAD was defined and coded as present/absent based on a history of treated 
angina pectoris, myocardial infarction, a history of percutaneous transluminal coronary 
angioplasty or coronary artery bypass grafting. Other solitary or comorbid somatic conditions 
were lumped together as they have never been linked to BDNF serum levels before. All were 
coded as present/absent, with somatic disease being operationalized as receiving treatment 
for rheumatic disorder (or arthritis), COPD, liver disease, kidney disease or a history of or 
current treatment for Crohn’s disease or ulcerative colitis. Dementia was determined by 
self-report and, if reported, cross-checked against the respondents’ medical records.
Data analysis
The BDNF levels were normally distributed in our sample. Levels above three standard 
deviations (SDs) were trimmed to the 3-SD value, i.e., 17.8 ng/ml, which occurred in 11 
(0.9%) cases.
Respondents with more than two missing item scores on the BDI were excluded from the 
analyses. In case of 1 or 2 missing items on the BDI, missings were replaced by the series 
mean rounded to the nearest full digit (necessary in 73 subjects (5.7%); in total 88 of 25.830 
(≈0.3%) items). Imputation by the series mean is a reliable method with up to 10% missing 
items (Shrive et al.,  2006). Since the BDI scores showed a skewed distribution (skewness: 
1.52, kurtosis: 3.01), we used the log-transformed BDI scores in all analyses (skewness: 0.32, 
kurtosis: -0.50).
Pearson’s correlation coefficients were used for all univariate analyses. We performed 
multiple linear regression analyses to evaluate the independent determinants of serum-BDNF. 
To facilitate the interpretation of the age-sex interaction, rather than taking their absolute 
ages, we calculated and included the deviation from the mean, so that the participants’ 
ages were centered around the sample’s mean age. First, we generated multivariate models 
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within each domain by entering sampling characteristics, sociodemographic characteristics, 
health indicators and health-status variables in four separate models. Subsequently, the 
independent predictors from all domain-specific models with p-values lower than .15 were 
fitted into a final multivariate model using an enter method. The association between 
serum BNDF level and depression was examined by adding current depressive symptoms 
as indicated by the log-transformed BDI sum score to the final model. All analyses were 
conducted with SPSS, version 16.0. 
Results
Of the 1517 older adults who consented to participate in the study of non-invasive 
measurements of atherosclerosis, 59 were excluded from our study because they were 
currently using antidepressants. Of the 1458 eligible subjects a further 228 (15.6%) were 
excluded due to missing data: non-return of the postal questionnaire containing the BDI 
(n=175); three or more missing BDI item scores (n=37); violation of the rules for a reliable 
MS or BDNF measurement (i.e. having smoked prior to testing (n=3); non-adherence to the 
pretest fasting protocol (n=2); non-adherence to abstinence from lipid-lowering medication 
(n=5)); unavailability of serum-BDNF values due to technical problems (n=6).
The subjects with missing data (228/1458, 15.6%) differed from the final study sample 
(n=1230) with respect to age (62.0 yrs vs. 61.2 yrs, t(df1456) = 2.17, p = .03), somatic 
comorbidity (3% versus 11%, t(df1456) = -3.93, p < .001), level of alcohol use (severe 6% 
versus 12%, t(df1455) = -2.25, p = .012), and smoking (current smokers 26% versus 16%, 
t(df1454) = 3.46, p < .001). The serum BDNF levels obtained in the excluded participants 
with non-missing serum-BDNF levels, however, did not differ from those found in the study 
population.
The final study population (n=1230) had a mean age of 61.1 years (SD=5.9 years) with ages 
ranging from 50 through to 72 years. Of this group 614 participants (49.9%) were female. 
The BDI median score was 4 (interquartile range 2-7, range 0-29) and the mean serum BDNF 
7.79 ng/ml (SD=3.32 ng/ml).  None of the participants was diagnosed with dementia. Table 
3.1 gives an overview of the characteristics of all participants.
The first multiple regression models in which every domain was entered separately yielded 
three significant determinants. As can be seen in Table 3.2, significantly lower BDNF levels 
were found when measured in the afternoon (B =-0.57, 95% CI -1.03 – -0.12; t =-2.46, p 
=.014), with higher age in female respondents (Age-sex interaction term: B =-0.15, 95% CI 
-0.21 – 0.09; t =- 4.73, p <.001; see also see Figure 3.1), and non-smokers (B =0.87, 95% CI 
0.37 – 1.38; t = 3.38, p =.001). Although the other somatic co-morbidity variable remained 
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Table 3.1. 
Population characteristics
N = 1230
   BDNF (ng/ml, SD) 7.79 (3.32)
   BDI sum score (median, IQR) 4 (2-7)
   % with history of depression (n) 16.9 (208)
Sampling
   %  sampling in the morning (n) 79.2 (974)
   Months in storage (SD) 23.7 (9.5)
Sociodemographics
   % female (n) 49.9 (614)
   Age (mean in years, SD) 61.2 (5.9)
   % living alone (n) 21.4 (263)
Health indicators
   % current smoker (n) 16.1 (195)
   % severe alcohol use (n) 11.8 (145)
   % 2 or more hours of physical activity p/w (n) 36.6 (450)
Disease
   % metabolic syndrome (n) 27.8 (342)
   % coronary artery disease (n) 6.7 (83) 
   % somatic co-morbidity other than CAD (n) 11.0 (135)
Abbreviations: BDNF = brain-derived neurotrophic factor, SD = standard deviation, BDI = Beck Depres-
sion inventory, IQR = inter quartile range, CAD = coronary artery disease 
Table 3.2. 
Results of the univariate and multivariate analyses per category
Univariate Multivariate 
r p B 95% CI of B SE β t p
Model 1 (Sampling variables)
Time of day (0=AM, 1=PM) -.069 .008 -,573  -1,03 – -,12 ,233 -,070 -2,459 ,014
Time in storage (days) -.014 .31 ,000  ,00 – ,00 ,000 -,017 -,610 ,54
Model 2 (Demographic variables)
Age (yrs deviating from mean age) -.112 <.001 ,012  -,03 – ,06 ,022 ,022 ,561 ,58
Sex (0=male, 1=female) .035 .11 ,181  -,19 – ,55 ,190 ,027 ,956 ,34
Interaction age * sex n/a n/a -,151  -,21 – -,09 ,032 -,187 -4,734 <,001
Marital status (1=living alone, 2=living together) -.041 .08 -,276  -,73 – ,18 ,231 -,034 -1,199 ,23
Model 3 (Healthvariables)
Alcohol use (male>21/week; female > 14/week) -.028 .16 -,401  -,98 – ,17 ,294 -,039 -1,362 ,17
Current smoker (0=no, 1=yes) .094 <.001 ,872  ,37 – 1,38 ,258 ,097 3,379 ,001
Physical activity (0=≤ 1 hrs/week, 1=≥2 hrs/
week) -.023 .22 -,082  -,47 – ,30 ,197 -,012 -,416 ,68
Model 4 (Disease variables)
Metabolic Syndrome (IDF) (0=no, 1=yes) .007 .39 ,035  -,32 – ,39 ,182 ,005 ,191 ,85
Coronary artery disease (0=no, 1=yes) .011 .35 -.043  -,71 – ,63 ,341 -,003 -,126 ,90
Somatic co-morbidty other than CAD (0=no, 
1=yes)
.044 .05 ,473  -,08 – 1,02 ,280 ,044 1,690 ,09
r= Pearson’s correlation coefficient; B = Regression coefficient; CI = Confidence interval; SE = Standard 
error of the mean; β = Standardized correlation coefficient, CAD= coronary artery diseas
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under the p = 0.15 level, it did not reach statistical significance at the p = .05 level (B =0.47, 
95% CI -0.76 – 1.02; t = 1.69, p =.091).
As Table 3.3 shows, our final model uncovered a significantly lower in BDNF levels with 
higher BDI sum scores (B = -0.56, 95% CI -1.1 – -0.02; t = -2.03, p =.042). Re-analysis of the 
age effect stratified for a low BDI (<14) and high BDI (≥14) score revealed that the age effect 
for women was present and statistically significant in both groups (B = -1.25, 95% CI -1.76 
– -0.75; t = -4.86, p <.001, respectively B = -1.59, 95% CI -3.13 – -0.004; t = -2.07, p =.04) 
Figure 3.1
Association between age and serum BDNF for males and females
Table 3.3.
Final model with BDI scores corrected for potential confounders
B 95% CI of B SE β t p
Constant 7,959 7,6 – 8,4 ,208 38,277 ,000
BDI (log-transformed) -,607 -1,13 – -0,09 ,265 -,060 -2,296 ,022
Age (yrs) -.006 -,05 – 0,03 ,020 ,011 -.304 ,761
Sex (0=male; 1=female) ,293 -,04 – 0,63 ,170 ,045 1,724 ,085
Interaction age * sex -,110 -,17 – -0,05 ,028 -,138 -3.873 ,000
Time of day (0=AM; 1=PM) -,405 -,80 – -0,01 ,204 -,050 -1.985 ,047
Current smoker (0=no; 1=yes) ,613 ,19 – 1,06 ,215 ,072 2,843 ,005
Somatic co-morbidity (0=no; 1=yes) ,515 -,03 – 1,06 ,278 ,047 1,857 ,063
B = Regression coefficient; CI = Confidence interval; SE = Standard error of the mean; β = Standardized 
correlation coefficient
52
Chapter 3
and also absent in both males with high BDI (≥14) and a low BDI (< 14)  sum scores (both 
p-values > .61). 
Separate evaluation of the different subscales of the BDI, revealed that the cognitive subscale 
was significantly associated with serum BDNF levels (B = -.544, 95% CI -1.07 – -0.016; t = 
-2.02, p =.043), whereas the somatic subscale was not (B = -.312, 95% CI -1.03 – 0.406; t = 
-0.85, p =.39). 
Subsequent analysis, also revealed that persons with a self-reported history of depressive 
illness have lower serum BDNF-levels (B = -.606, 95% CI -1.05 – -0.163; t = -2.68, p =.007), 
when corrected for potential confounders. Including a history of depressive illness and 
current depressive symptoms in one multivariate regression analysis led to collinearity 
problems. Therefore, we could not disentangle whether low serum BDNF levels reflect a 
state or trait characteristic.
Discussion
To our knowledge, this is the first study of a large community sample of middle-aged and 
older people providing clear evidence that BDNF levels significantly decline in women 
with increasing age, while levels remain stable in men (see Figure 3.1). Moreover, and 
equally important, even after controlling for age and gender effects our analysis showed 
that BDNF levels are lower with increased levels of depressive symptoms. These effects 
remained significant even after correction for time of sampling and smoking, two important 
confounders. 
BDNF and sex and age - If the interaction is not taken into account, the sex-specific decline of 
BDNF levels with age may result in opposite sex effects, with higher BDNF values being found 
in younger women and lower BDNF values in older women relative to the levels obtained 
in age-matched men (Karege et al.,  2002a; Laske et al.,  2007). Given that the effects of sex 
and age were quite small, most previous studies were probably underpowered, preventing 
detection of significant sex differences (Laske et al.,  2007). Several, mostly underpowered, 
studies indeed failed to find an age effect (Aydemir et al.,  2007; Shimizu et al.,  2003), while 
a small-scale study of healthy adult volunteers (mean age 41.1 years old) even reported 
increased BDNF levels with age (Lang et al.,  2004). The only study conducted in older adults, 
however, did show lower serum BDNF levels with higher age (Ziegenhorn et al.,  2007), a 
finding we were able to replicate and extend by showing an interaction between age and sex 
effects. As the age effect in women was also present in subjects with a high score on BDI (≥ 
14), this should also be taken into account in studies with a clinically depressive sample. A 
possible explanation for the age-sex interaction with respect to BDNF serum levels might be 
its relationship with gonadal hormones, as BDNF synthesis is induced by estrogen (Nagahara 
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et al.,  2009) and high correlations between plasma-BDNF and estrogen levels have been 
reported in humans (Monteleone et al.,  2007). Moreover, both estrogen depletion and 
low serum BDNF levels have been identified as risk factors for Alzheimer’s disease (Craig 
and Murphy, 2009). Despite the cross-sectional character of the studies reviewed, the 
hypothesis may be put forward that a post-menopausal drop in estrogen levels results 
in reduced BDNF levels, explaining the increased vulnerability of middle-aged and older 
women to neurodegenerative disease (Craig and Murphy, 2009; Reitz et al.,  2010). This 
hypothesis should however be tested in longitudinal studies.
BDNF and depression -Our results extend previous studies reporting lower serum BDNF levels 
in patients with major depressive disorder (MDD) relative to healthy controls (Molendijk et. 
al., 2010) (Brunoni et al.,  2008; Sen et al.,  2008) to a broader, continuous relationship 
between BDNF levels and depressive symptoms in a community sample. An association 
between BDNF serum levels and severity of depressive symptoms has also been identified 
in two studies of patients with depressive disorder (Gonul et al.,  2005; Shimizu et al.,  2003), 
although one other study reported a negative result (Lang et al.,  2006). Taken together, the 
findings suggest a linear association between the two variables that is independent of the 
current categorical boundaries for depression.
BDNF and determinants –serum BDNF levels were significantly lower if blood was drawn 
in the afternoon. Diurnal variations have previously been found for BDNF plasma level 
(Piccinni et al.,  2008). However, since we only recorded whether sampling occurred before 
(AM) or after noon (PM), we are unable to describe the variation in BDNF levels in more 
detail. Of the health-behavior variables, smoking was the only factor to show an association 
with BDNF levels (elevated levels in smokers). Interestingly, nicotine use has been linked to 
a decreased risk of dementia (Wang et al.,  2009), which might point to a mediating role for 
BDNF. Nonetheless, as a case-control study (n=40) reported reverse effects of smoking on 
plasma BDNF levels (Kim et al.,  2007), additional research is necessary to establish whether 
this apparent inconsistency might be explained by altered platelet functioning in smokers, 
which would affect BDNF serum but not plasma levels (Nowak et al.,  1987). 
Strengths and weaknesses- It remains unclear whether lower levels of circulating BDNF result 
from lower brain BDNF concentration. Although high correlations between serum BDNF and 
cerebral-BDNF levels have been shown in animal models (Karege et al.,  2002b), this has, 
thus far, not been confirmed in humans. Despite well-established findings of lower serum 
BDNF in a depressed population, inferences of BDNF as a causal marker for depression are 
still limited. Platelets have been described as one of the many sources of BDNF: the factor 
is released by platelets during the clotting process resulting in a 200-fold increase in BDNF 
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serum relative to the levels found in plasma (Rosenfeld et al.,  1995). As BDNF in platelets 
does not originate from megakaryocytes or other precursor cells of the mature platelet 
(Fujimura et al.,  2002), it is likely that most of the BDNF in human platelets is sequestered 
from blood (Nakahashi et al.,  2000). Differences in platelet functioning as described in 
depressed patients (Ziegelstein et al.,  2009), therefore, may affect BDNF independently of 
cerebral BDNF expression. 
Due to collinearity problems between the actual level of depressive symptoms and a history 
of depressive illness, we weren’t able to distinguish between a state or a trait effect. This 
may in part be explained by recall bias in assessing the history of depressive illness in our 
sample (as depressive symptoms may have primed persons to recall a history of depressive 
illness or to consider previous depressive symptoms as a depressive disorder). Future 
longitudinal or prospective research should be carried out to disentangle whether lower 
BDNF-levels reflect a state or trait characteristic.
Although we had to exclude a small proportion of our study sample,. Moreover, our 
comparison of the excluded participants and study population did not show a selection bias 
on the relevant parameters. 
Although we had a large sample size, one could argue that our study be underpowered to 
reveal small effects, given our sample size (n=1230), the largest number of predictors in 
one analysis (n=6, see results), a power of 80% and a two-sided alpha of .05, the smallest 
detectable beta was calculated to be 0.08. As, by convention, a beta of 0.1 is considered a 
small effect, our study has sufficient statistical power to detect small effects.
In terms of generalizability it could be considered a limitation that our sample consisted of 
subjects in the age range 50 – 72 years. Replication in samples with a broader or other age 
range should be carried out. Moreover, for a proper interpretation of our results it needs 
mentioning that the cross-sectional design of our study does not allow causal inferences. To 
date, no prospective studies are available in this area of research. 
Rather than a clinical population, we charted depressive symptoms in a non-hospitalized 
sample of middle-aged and older adults. Although there may be some bias towards the 
healthier individuals in the sample, we were still able to show a significant correlation 
between serum BDNF and depressive symptoms in this community population.   
Conclusion - Our results underscore that serum BDNF levels in humans are determined by 
smoking status, diurnal variation, age, sex and depressive symptoms, but that duration of 
storage (if at -80°C) has no impact. Future studies on BDNF in (neuro)psychiatric disorders 
should control for these characteristics. Moreover, the interaction between age and sex 
might have important implications as it may point to a clinical effect of gonadal hormones 
on neurotrophic growth factors. For example, BDNF might be implicated in the increased 
vulnerability to dementia in post-menopausal women. Here also, further corroboration of 
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the interplay of gonadal hormones and BDNF on psychiatric illnesses and neurodegenerative 
diseases is warranted. 
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Abstract
Association studies of the Val66Met polymorphism and serum BDNF levels have yielded 
conflicting results. Recently, sex-specific differences in BDNF levels were demonstrated. As 
these might explain the reported  inconsistencies, we tested sex interactions with Val66Met 
genotype on serum BDNF level.
Participants (n=548, age range 50-72 years; mean 62.8 ± 5.4 years, 267 males) were tested 
for rs6265 genotype and serum BDNF levels. A regression analysis with BDNF level as the 
dependent variable and BDNF Val66Met genotype as independent variable, was used to test 
the sex interaction, corrected for age, smoking and depressive symptoms. Subsequently we 
examined the effect of genotype on BDNF levels stratified for sex.
We found a significant interaction between sex and genotype on BDNF levels (p=.02). Male 
Met-carriers had significantly higher BDNF levels than Val/Val homozygotes (β = 0.17, p = 
.013), while in females no effect of Val66Met genotype was found (β = -.07, p = .28).
Our findings may partly explain inconsistent findings of earlier studies, with results of studies 
influenced by male-female ratios. We hypothesize that higher BDNF levels in male Met-
carriers may reflect a compensation for a less accurate response to stress due to carrying 
the less functional allele.
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Introduction
The neurotrophic hypothesis of depression postulates that depressive disorder is caused 
and/or maintained by insufficient neurotrophic support within the brain, with brain-derived 
neurotrophic factor (BDNF) as one of the most important growth factors (Duman and 
Monteggia, 2006). This hypothesis is supported by both animal and human studies. Stress-
related depression models in rats show decreased cerebral BDNF expression, that increases 
after antidepressant treatment (Angelucci et al., 2005). In line with these findings, lowered 
serum BDNF levels have consistently been reported in depressed humans, which also 
restore after treatment (Sen et al., 2008). The relevance of human data is further supported 
by the existence of a correlation between serum BDNF levels and cerebral BDNF-expression 
in rats (Karege et al., 2002). Nevertheless, the genetic underpinning of BDNF expression has 
yielded inconsistent results with respect to the neurotrophic hypothesis of depression. 
The BDNF gene has a non-synonymous polymorphism, which results in a valine-to-
methionine change at position 66 of the pro-BDNF protein (rs6265, Val66Met). The Met-
allele impairs intraneuronal protein trafficking and thus activity-dependent secretion 
(Alexander et al., 2010). One would expect the Met-allele to be a vulnerability marker for 
depression, but empirical data are not unequivocal. First, the prevalence of depression is not 
significantly higher in Asian populations, yet Met-allele carriership is about six times more 
frequent in Asian populations compared to Caucasians (Verhagen et al., 2010). Secondly, a 
recent meta-analysis identified an association of depressive disorder with the Met-variant 
of the Val66Met polymorphism only in men (rs6265) (Verhagen et al., 2010). 
If the Val66Met polymorphism would underlie the neurotrophic hypothesis in humans, 
one would expect a moderating effect of this polymorphism on serum BDNF levels. Genetic 
association studies, however, have yielded conflicting results, as higher (Lang et al., 2009; 
Minelli et al., 2011), lower (Ozan et al., 2010) and similar (Yoshimura et al., 2011; Zhou et 
al., 2011) BDNF levels in Met-allele carriers of the Val66Met polymorphism were shown. 
Inconsistencies may be explained by psychopathology, race and/or gender. First, two studies 
investigating the relationship between genotype and serum BDNF levels were performed in 
depressed subjects (Ozan et al., 2010; Zhou et al., 2011), whereas others were performed 
in healthy subjects (Lang et al., 2009; Minelli et al., 2011; Yoshimura et al., 2011). Secondly, 
two studies were carried out in Asian populations (Yoshimura et al., 2011; Zhou et al., 2011), 
whereas others included only Caucasians (Lang et al., 2009; Minelli et al., 2011; Ozan et 
al., 2010). Studying a Caucasian community sample, we were especially interested in sex-
effects. Recently, sex-specific differences in BDNF genetics as well as serum BDNF levels 
have been demonstrated (Licinio and Wong 2010). Although depression is more prevalent 
among women, a recent meta-analysis showed that the Met allele is a risk factor for major 
depressive disorder in males specifically (Karege et al., 2002). On the other hand, age-effects 
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on BDNF levels were found in women, but not in men (Bus et al., 2011; Bus et al., 2012). We 
hypothesized therefore, that the association between serum BDNF levels and the Val66Met 
polymorphism might be sex-specific. More specifically, we expected altered BDNF levels 
in male Met-allele carriers only (Karege et al., 2002). If so, this could provide important 
biological evidence for sex-differences in depressive disorder and/or other brain disorders. 
Methods
The present study sample was drawn from the Nijmegen Biomedical Study (NBS), a 
population-based survey of people aged between 20 and 90 years (N=9371). The Nijmegen 
Biomedical study has been described elsewhere in detail (Monteggia et al., 2007). Several 
studies have been performed within the NBS. The overlap between two of these studies 
provided the opportunity for the present study. First, respondents aged 50-72 years were 
invited to participate in a study of non-invasive measurements of atherosclerosis of whom 
1517 (54%) gave their informed consent. They subsequently visited the hospital for a 
detailed cardiovascular assessment and blood sampling for BDNF levels as well as other 
measurements. Secondly, a partly overlapping sample of NBS respondents (n=1981) has 
acted as a control group for genetic studies (Hoogendoorn et al., 2006). For those individuals, 
rs6265 genotype was determined. Overlap between these two samples resulted in a total 
sample of 548 healthy volunteers for whom both rs6265 genotyping data and serum BDNF 
levels were available. Being a population based survey, no further exclusion criteria were 
applied. The group of 1517 subjects with available serum BDNF differed from the subgroup 
of 548 subjects with available genotype with respect to age (60.3 years versus 62.8 years; p 
< .001) and BDNF serum level (respectively 7.92 ng/ml versus 7.59ng/ml; p = .045), but no 
significant differences in sex distribution were found (p = .68).
 In accordance with the Declaration of Helsinki the study protocol was approved by The 
Medical Ethics Committee of the Radboud University Nijmegen Medical Centre and 
informed, written consent was obtained from all participants.
Genotyping - Genotypes for rs6265 (Val66Met) were available from HumanCNV370-duo 
Bead arrays. Genotypes were in Hardy Weinberg equilibrium (p=.08) in the NBS sample 
and part of the sample was genotyped twice for this polymorphism, showing a 100% 
concordance between samples, indicating that no genotyping errors were made (Kiemeney 
et al., 2010). 
Serum BDNF -Following the baseline assessment and ranging from 9 to 44 months after 
having been drawn, serum samples were sent to the Department of Psychiatry and 
Neuropsychology in Maastricht (The Netherlands) for BDNF measurement, where they 
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were stored at -80°C. Serum BDNF protein levels were measured within three months 
after their receipt using the Emax Immuno Assay system from Promega according to the 
manufacturer’s protocol. Greiner Bio-One high affinity 96-well plates were used and the 
resulting absorbance was read in duplicate using a Biorad Benchmark microplate reader at 
450 nm. BDNF protein levels were expressed in ng/ml. Serum BDNF assaying is described 
elsewhere in more detail (Bus et al., 2012).
Covariates – Covariates were selected based on previous research (Bus et al., 2011; Bus et 
al., 2012) and consisted of age, smoking status (never / former / current) and depressive 
symptoms as measured by the Beck depression inventory, a 21-item self-report questionnaire 
with excellent psychometric characteristics (Beck and Steer 1984).
Statistical analysis – Differences between men and women were tested with independent 
t-test for continuous variables and chi-square test for categorical variables. To test our main 
hypothesis an interaction term between sex and Val66Met polymorphism was entered 
in a linear regression model, corrected for covariates and with serum BDNF level as the 
independent variable. Then, to estimate the effect size in both sexes,  the same model was 
tested in an analysis stratified for sex.  
Results
The total sample consisted of 548 subjects (267 males). The subjects’ age ranged from 50 
to 72 years (mean age 62.8 ± 5.4 years). Mean serum BDNF concentration was 7.6 (SD 2.9) 
ng/ml, with no differences between males and females (7.4 (SD 2.5) and 7.7 (SD 3.2) ng/ml, 
respectively, p = .26). Additional population characteristics, specified for sex can be found 
in Table 4.1. The genotype frequency for Val/Val (n = 340, 169 males, mean age 63.0 (SD 
5.3) years), Val/Met (n = 193, 93 males, mean age 62.4 (SD 5.5) years) and Met/Met (n = 
15, 5 males, mean age 62.9 (SD 5.1) years) was 62%, 35% and 3%. Due to the low number 
of methionine homozygotes we merged Val/Met and Met/Met genotypes and used a 
dichotomous variable in subsequent analyses. 
No significant differences in serum BDNF level were found between Met-carriers and Val/
Val homozygotes (β = .03, p = .49). However, a regression analysis with serum BDNF level as 
the dependent variable demonstrated a significant interaction between sex and Val66Met 
genotype (p = .02). In the sex-stratified analyses, we found that male Met-carriers had 
significantly higher serum BDNF levels than male Val/Val homozygotes (β = 0.17, p = .013), 
while BDNF levels in female Val/Val homozygotes were not different from those of Met-
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carriers (β = -.07, p = .28). If anything, serum BDNF levels in the female Met-carriers rather 
seemed lower than those of Val/Val homozygotes (Figure 4.1).
Figure 4.1
Table 4.1. 
Sample characteristics
All (n=548) Women (n=281) Men (n=267) p*
Serum BDNF, ng/ml (SD) 7.6 (2.9) 7.7 (3.2) 7.4 (2.5) > .05
Met-carriage,n (%) 208 (38%) 98 (37%) 110 (39%) >.05
Age, years (SD) 62.8 (5.4) 60.4 (5.2) 65.3 (4.3) <.01
Smoking
   Never, n (%) 187 (34.2) 79 (29.6) 108 (38.7) >.05
   Former, n (%) 273 (50.0) 144 (53.9) 129 (46.2)
   Current, n (%) 86 (15.8) 44 (16.5) 42 (15.1)
BDI, sumscore (SD) 5.2 (4.6) 5.8 (4.5) 4.6 (4.7) <.05
Abbreviations: SD = standard deviation. BDI = Beck depression inventory
* p value for difference between women and men 
BD
N
F 
le
ve
l n
g/
m
l
8,25
8,00
7,75
7,50
7,25
7,00
6,75
* p = .013
Gender * genotype interaction on serum BDNF levels
BDNF Val66Met
polymorphism
 val/val
 met allele carrier
Bars reflect +/- 1 SE
All Male Female
*
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Discussion
In summary, in a community sample, the association between BDNF Val66Met genotype and 
serum BDNF levels is sex-specific with levels being determined by genotype only in males. 
This sex difference suggests that the association between serum BDNF and the val66met 
polymorphism depends on the male/female ratio within individual studies and thus may 
explain inconsistencies between studies. Lang and coworkers, who included more males 
than females, found higher serum BDNF level in Met-carriers (Lang et al., 2009). In contrast, 
in predominantly female samples lower or equal serum BDNF levels in Met-carriers were 
observed (Ozan et al., 2010; Yoshimura et al., 2011). 
Male-female ratios cannot fully account for the differences found. First, the study by Minelli 
et al. reported higher serum BDNF levels for Met-allele carriers in a sex-balanced population 
(2011). In addition, the study by Ozan et al. (2010) excluded the possibility that their results 
interacted with sex, by formally testing the interaction term. However, acknowledging the 
small effect-sizes we found, this latter study could have been underpowered. Secondly, 
differences in the association between Val66Met and serum BDNF levels could further be 
explained by differences in psychopathology, as two studies included depressed subjects 
(Ozan et al., 2010; Zhou et al., 2011), and race, as two studies were carried out in Asian 
populations (Yoshimura et al., 2011; Zhou et al., 2011), whereas others included Caucasians 
(Lang et al., 2009; Minelli et al., 2011; Ozan et al., 2010). 
Major depression has consistently been associated with lower serum BDNF levels (Brunoni 
et al., 2008; Molendijk et al., 2011). Against expectation, in male Met allele carriers, the 
sex showing association of this genotype with an increased risk for major depression 
(Verhagen et al., 2010), higher serum BDNF levels were found. Elevated serum BDNF levels 
might be explained by a compensatory rise in BDNF to protect individuals with the less 
functional variant of the BDNF gene (i.e. Met allele) from a lack of neurotrophic support in 
stressing circumstances. As the Met allele variant hampers intracellular BDNF transport and 
subsequently impairs adaptation to stressful events, these higher BDNF levels can also be 
considered a general compensatory response to maintain adequate neurotrophic support 
(Elzinga et al., 2011).  
Strengths and limitations - A strength of this study is the, compared to previous studies, 
large sample size providing an opportunity to test for a sex interaction and correct for 
potential confounders, among which depressive symptoms. Nonetheless, for proper 
interpretation some limitations have to be addressed. Rather than a clinical population, 
we measured serum BDNF and BDNF genotype in a non-hospitalized sample of middle-
aged and older adults. Therefore we cannot make any inferences on the clinical diagnosis 
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of major depressive disorder. Moreover a bias towards the more healthy group could have 
occurred. In addition, as an age effect on serum BDNF levels exists (Bus et al., 2011; Bus et 
al., 2012) and we measured subjects in the age range 50 – 72 only, extrapolation to other 
age groups should be made with caution.  
Conclusion – The association of BDNF genotype with the concentration of serum BDNF is 
sex-specific, with levels being determined by genotype in males only. Importantly, this may 
partly explain inconsistent findings of earlier association studies, with results of individual 
studies depending on male/female ratios. Higher BDNF levels in male Met allele carriers 
might reflect a compensatory elevation in response to a higher risk of psychopathology due 
to carrying the less functional BDNF allele. This hypothesis of a compensatory upregulation 
should, however, be further explored within a longitudinal design.
Increase in serum BDNF in Met-allele carriers of the BDNF val66met polymorphism is specific to 
males
69
References
Alexander, N., Osinsky, R., Schmitz, A., Mueller, E., Kuepper, Y. & Hennig, J. 2010. The BDNF Val66Met 
polymorphism affects HPA-axis reactivity to acute stress.  Psychoneuroendocrinology  35, 949-953.
Angelucci, F., Brene, S. & Mathe, A. A. 2005. BDNF in schizophrenia, depression and corresponding 
animal models.  Mol. Psychiatry  10, 345-352.
Bus, B. A., Molendijk, M. L., Penninx, B. J., Buitelaar, J. K., Kenis, G., Prickaerts, J., Elzinga, B. M. & 
Voshaar, R. C. 2011. Determinants of serum brain-derived neurotrophic factor.  Psychoneuroendocri-
nology . 36, 228-239.
Bus, B. A., Tendolkar, I., Franke, B., de, G. J., Heijer, M. D., Buitelaar, J. K. & Oude Voshaar, R. C. 2012. 
Serum brain-derived neurotrophic factor: Determinants and relationship with depressive symptoms in 
a community population of middle-aged and elderly people.  World J. Biol. Psychiatry 13, 39-47
Beck, A. T. & Steer, R. A. 1984. Internal consistencies of the original and revised Beck Depression Inven-
tory.  J. Clin. Psychol.  40, 1365-1367.
Brunoni, A. R., Lopes, M. & Fregni, F. 2008. A systematic review and meta-analysis of clinical studies 
on major depression and BDNF levels: implications for the role of neuroplasticity in depression.  Int. J. 
Neuropsychopharmacol.  11, 1169-1180.
Duman, R. S. & Monteggia, L. M. 2006. A neurotrophic model for stress-related mood disorders.  Biol. 
Psychiatry  59, 1116-1127.
Elzinga, B. M., Molendijk, M. L., Oude Voshaar, R. C., Bus, B. A., Prickaerts, J., Spinhoven, P. & Penninx, 
B. J. 2011. The impact of childhood abuse and recent stress on serum brain-derived neurotrophic fac-
tor and the moderating role of BDNF Val(66)Met.  Psychopharmacology (Berl)  214, 319-328.
Hoogendoorn, E. H., Hermus, A. R., de, V. F., Ross, H. A., Verbeek, A. L., Kiemeney, L. A., Swinkels, D. W., 
Sweep, F. C. & den Heijer. M. 2006. Thyroid function and prevalence of anti-thyroperoxidase antibod-
ies in a population with borderline sufficient iodine intake: influences of age and sex.  Clin. Chem.  52, 
104-111.
Karege, F., Schwald, M. & Cisse, M. 2002. Postnatal developmental profile of brain-derived neuro-
trophic factor in rat brain and platelets.  Neurosci. Lett.  328, 261-264.
Kiemeney, L. A., Sulem, P., Besenbacher, S., Vermeulen, S. H., Sigurdsson, A., Thorleifsson, G., Gudb-
jartsson, D. F., Stacey, S. N., Gudmundsson, J., Zanon, C., Kostic, J., Masson, G., Bjarnason, H., Palsson, 
S. T., Skarphedinsson, O. B., Gudjonsson, S. A., Witjes, J. A., Grotenhuis, A. J., Verhaegh, G. W., Bishop, 
D. T., Sak, S. C., Choudhury, A., Elliott, F., Barrett, J. H., Hurst, C. D., de Verdier, P. J., Ryk, C., Rudnai, P., 
Gurzau, E., Koppova, K., Vineis, P., Polidoro, S., Guarrera, S., Sacerdote, C., Campagna, M., Placidi, D., 
Arici, C., Zeegers, M. P., Kellen, E., Gutierrez, B. S., Sanz-Velez, J. I., Sanchez-Zalabardo, M., Valdivia, 
G., Garcia-Prats, M. D., Hengstler, J. G., Blaszkewicz, M., Dietrich, H., Ophoff, R. A., van den Berg, L. H., 
Alexiusdottir, K., Kristjansson, K., Geirsson, G., Nikulasson, S., Petursdottir, V., Kong, A., Thorgeirsson, 
T., Mungan, N. A., Lindblom, A., van Es, M. A., Porru, S., Buntinx, F., Golka, K., Mayordomo, J. I., Kumar, 
R., Matullo, G., Steineck, G., Kiltie, A. E., Aben, K. K., Jonsson, E., Thorsteinsdottir, U., Knowles, M. A., 
Rafnar, T. & Stefansson, K. 2010. A sequence variant at 4p16.3 confers susceptibility to urinary bladder 
cancer.  Nat. Genet.  42, 415-419.
Lang, U. E., Hellweg, R., Sander, T. & Gallinat, J. 2009. The Met allele of the BDNF Val66Met polymor-
phism is associated with increased BDNF serum concentrations.  Mol. Psychiatry  14, 120-122.
Licinio, J. & Wong, M. L. 2010. Brain-derived neurotrophic factor in depression: a male problem?  Mol. 
Psychiatry  15, 227.
70
Chapter 4
Minelli, A., Zanardini, R., Bonvicini, C., Sartori, R., Pedrini, L., Gennarelli, M. & Bocchio-Chiavetto, L. 
2011. BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in 
healthy subjects.  Eur. Arch. Psychiatry Clin. Neurosci. 5, 323-9
Molendijk, M. L., Bus, B. A., Spinhoven, P., Penninx, B. W., Kenis, G., Prickaerts, J., Voshaar, R. O. & 
Elzinga, B. M. 2011. Serum levels of brain-derived neurotrophic factor in major depressive disorder: 
state-trait issues, clinical features and pharmacological treatment.  Mol. Psychiatry . 16, 1088-95
Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S, Parada LF, Nestler EJ 2007. Brain-
derived neurotrophic factor conditional knockouts show gender differences in depression-related be-
haviors. Biol Psychiatry 61, 187–197.
Ozan, E., Okur, H., Eker, C., Eker, O. D., Gonul, A. S. & Akarsu, N. 2010. The effect of depression, BDNF 
gene val66met polymorphism and gender on serum BDNF levels.  Brain Res. Bull.  81, 61-65.
Verhagen, M., van der Meij, A., van Deurzen, P. A., Janzing, J. G., Arias-Vasquez, A., Buitelaar, J. K. & 
Franke, B. 2010. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: ef-
fects of gender and ethnicity.  Mol. Psychiatry  15, 260-271.
Sen, S., Duman, R. & Sanacora, G. 2008. Serum brain-derived neurotrophic factor, depression, and 
antidepressant medications: meta-analyses and implications.  Biol. Psychiatry  64, 527-532.
Yoshimura, R., Kish, T., Suzuki, A., Umene-Nakano, W., Ikenouchi-Sugita, A., Hori, H., Otani, K., Iwata, 
N. & Nakamura, J. 2011. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is 
associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in 
depressed Japanese patients.  Prog. Neuropsychopharmacol. Biol. Psychiatry. 35, 1022-5
Zhou, Z., Lu, T., Xu, G., Yue, X., Zhu, W., Ma, M., Liu, W., Zhu, S. & Liu, X. 2011. Decreased serum brain-
derived neurotrophic factor (BDNF) is associated with post-stroke depression but not with BDNF gene 
Val66Met polymorphism.  Clin. Chem. Lab Med.  49, 185-189.
71
Chapter 5
Serum BDNF concentrations 
in major depressive disorder: 
state-trait issues, clinical features 
and pharmacological treatment
M.L. Molendijk, B.A.A. Bus, P. Spinhoven, B.W.J.H. Penninx, G. Kenis, J. Prickaerts,  
R.C. Oude Voshaar, B.M. Elzinga
Published as: 
Serum BDNF concentrations in major depressive disorder: state-trait issues, clinical features 
and pharmacological treatment
Molecular Psychiatry 2011; 16: 1088-1095
72
Chapter 5
Abstract
Recent evidence supports the neurotrophin hypothesis of depression in its prediction that 
Brain-Derived Neurotrophic Factor (BDNF) is involved in depression. However, some key 
questions remain unanswered, including whether abnormalities in BDNF persist beyond the 
clinical state of depression, whether BDNF concentrations are related to the clinical features 
of depression and whether distinct antidepressants affect BDNF concentrations equally. We 
addressed these questions and investigated serum BDNF concentrations in 962 depressed 
patients, 700 fully remitted persons (> 6 months) and 382 healthy controls. We found serum 
BDNF concentrations to be low in antidepressant-free depressed patients relative to controls 
(effect size, Cohen’s d) = 0.19, P < 0.01) and to depressed patients who were treated with an 
antidepressant (d = 0.23, P < 0.01). BDNF concentrations of fully remitted persons (whether 
unmedicated or treated with an antidepressant) were comparable to those of healthy 
controls. Analyzing the sample of antidepressant-free depressed patients showed that BDNF 
concentrations were unrelated to the core clinical features of depression such as its severity 
or having a first versus a recurrent episode. The antidepressant use associated up-regulation 
of serum BDNF concentrations in depressed patients was confined to selective serotonin 
reuptake inhibitors (d = 0.39, P < 0.01) and St John’s wort (d = 0.63, P = 0.03). Our results 
suggest that low serum BDNF concentrations are a state abnormality that is evident during 
depression and that normalizes during remission. Increases in serum BDNF concentrations 
during antidepressant treatment appear to be confined to some antidepressants and do not 
parallel clinical characteristics, such as the severity of depressive symptoms.
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Introduction
Brain-Derived Neurotrophic Factor (BDNF) is a neurotrophin that has been linked to the 
viability of neurons in brain circuits that regulate emotion, memory, learning, sleep and 
appetite (Duman et al., 2000; Sutton and Schuman, 2006). The neurotrophin hypothesis 
of depression is based on these functions of BDNF and postulates that depression results 
from stress-induced decreases in BDNF expression and that antidepressants are efficacious 
because they increase BDNF expression (Duman et al., 1997; Duman and Monteggia, 
2006). Consistent with this hypothesis are the findings that depression is accompanied 
by decreased central and peripheral concentrations of BDNF (Sen et al., 2008), and that 
antidepressants elicit an increase in BDNF concentrations in animal models for depression 
(Angelucci et al., 2005) and in depressed humans (Brunoni et al., 2008). Together with the 
latency of weeks before antidepressants become clinically effective (Nemeroff and Owens, 
2002), these observations shaped the hypothesis that the efficacy of antidepressants 
depend on neuroadaptive changes that are brought about by changes in BDNF signaling 
(Duman and Monteggia, 2006).
Taken together, there is reason to believe that BDNF is involved in depression and in 
antidepressant action. Results inconsistent with the neurotrophin hypothesis, however, 
also have been reported. There are, for example, studies that did not detect alternations 
in BDNF in depressed persons or in the course of treatment with an antidepressant 
(Matrisciano et al., 2009). In addition, some questions remain unanswered so that the 
neurotrophin hypothesis is at best incomplete (Groves, 2007). A major question that needs 
to be answered is whether low BDNF concentrations persist beyond the clinical state of 
depression (Trajkovska et al., 2008). A second question is whether BDNF concentrations are 
related to the clinical features of depression, such as having a first versus a recurrent episode 
(Lee et al., 2007). Yet a third outstanding question is whether all classes of antidepressants 
affect BDNF concentrations equally. We therefore studied, cross-sectionally, serum BDNF 
concentrations of depressed patients, remitted depressed persons and never depressed 
persons. Our efforts had three concerns: (1) to compare serum BDNF concentrations of 
antidepressant-free and antidepressant treated current and fully remitted depressed 
patients and never depressed persons, (2) to explore the associations between some of the 
core clinical features of depression and serum BDNF concentrations and (3) to evaluate the 
association between the use of several distinct classes of antidepressants and serum BDNF 
concentrations.
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Method
Patients and sample collection
Patients were from the Netherland Study of Depression and Anxiety (NESDA). Full details on 
the rationale, objectives and protocol of NESDA are described in Penninx et al. (2008). In brief, 
NESDA is a prospective cohort study (N = 2,981) that recruited patients in mental health care, 
primary care and in the general population. Included were persons with a depressive and/or 
an anxiety disorder, persons with a depressive and/or an anxiety disorder in remission and 
persons without a history of these disorders. Persons who were diagnosed with a psychotic 
disorder, bipolar disorder (type I and II), obsessive-compulsive disorder, or severe alcohol 
use disorder were not eligible. Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition (DSM-IV) diagnoses (APA, 1994) were assigned on the basis of responses to the 
Composite International Diagnostic Interview 2.1 lifetime version (CIDI 2.1; Wittchen et al., 
1991) that was administered by trained interviewers. At baseline, participants provided 
blood samples, underwent a medical examination and gave written informed consent for 
the study that was approved by the Ethical Committees of the participating institutes. 
Our study enrolled 2,044 persons (68.6% of the NESDA sample). On the basis of the assigned 
diagnosis, antidepressant use and the availability of BDNF data, we created five groups: 
antidepressant-free depressed patients (n = 541), antidepressant-treated depressed patients 
(n = 421), antidepressant-free remitted depressed persons (n = 539), antidepressant-treated 
remitted depressed persons (n = 161) and healthy persons who served as controls (n = 382). 
Depressed patients met the criteria for a depressive episode the last 6 months (n = 541). 
The majority of these patients had a current diagnosis of depression (n = 388), but some (n = 
153) had a diagnosis of depression 1–6 months prior to baseline and did not fulfill all criteria 
in the past month. Persons who were in full remission of depression were diagnosed with 
major depression somewhere in their lives, but had been free of depression and anxiety for 
at least 6 months. Persons were included in the control group when they had: (1) no lifetime 
mood or anxiety disorders, (2) no documented family history of depression or anxiety and 
(3) a low score (< 14) on the Inventory of Depressive Symptoms (IDS; Rush et al., 1996).
Data on antidepressants use were acquired through drug container observation and self-
report. Use of an antidepressant was defined as intake of minimally the daily dose as 
recommended by the WHO (2010) during the last month on at least 50% of the days. We 
coded for the use of selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine 
reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), noradrenergic and specific 
serotonergic antidepressants (NaSSAs) and St John’s wort (Hypericum perforatum). The 
duration of antidepressant use was expressed in months.
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Clinical features of depression
All patients were characterized on the symptom severity of depression using the IDS (Rush 
et al., 1996). Patient samples were further characterized on having a first or a recurrent 
depressive episode, the presence of comorbid anxiety, the age at onset of depression, the 
recency of depression, the chronicity of depression and on the presence of suicide ideation. 
The CIDI (Wittchen et al., 1991) served as source of information on the presence of a first- 
or a recurrent depressive episode, the presence of a comorbid anxiety, age at onset of 
depression (i.e., the age at which the first episode occurred) and the recency of depression 
(i.e., fulfilling criteria in the past month versus fulfilling criteria in the past 6 months but 
not in the past month). Depression was considered chronic if symptoms had been present 
for more than 24 months during the last 5 years, which was assessed using the life chart 
method (Lyketsos et al., 1994). The scale for suicide ideation (Beck et al., 1997) was used to 
examine the presence of suicide ideation. 
BDNF measurements A measure of 50 ml of blood was withdrawn into vacuum tubes between 
0730 and 0930 hours after an overnight fast. After blood collection, serum was separated 
and stored at -85 C˚ until it was assayed. BDNF protein concentrations were measured using 
the Emax Immuno Assay system from Promega according to the manufacturer’s protocol 
(Madison, WI, USA), in one laboratory by one technician who was blinded for the clinical 
diagnoses of the participants. Undiluted serum was acid treated as this reliably increased 
the detectable amount of BDNF in a dilution-dependent way. Greiner Bio-One high affinity 
96-well plates were used. Serum samples were diluted 100 times, and the absorbency was 
read in duplicate using a Bio-Rad (Hercules, CA, USA) Benchmark microplate reader at 450 
nm. The intra- and inter-assay coefficients of variation were found to be within 3 and 9%, 
respectively. Four persons had BDNF serum concentrations that were below the reliable 
detection threshold of 1.56 ng ml. These values were set at the lower detection limit. 
Positive outliers (mean > 3 SD, n = 6) were trimmed to the mean + 3 SD value. There were 
no differences between persons with missing and non-missing BDNF with regard to gender 
(P = 0.71), age (P = 0.67) and diagnoses (P = 0.33).
Covariates
Potential variance due to gender, age and educational level was controlled for in all analyses. 
In addition, we controlled for body mass index (BMI), physical activity and smoking as 
these variables are associated with BDNF (Suwa et al., 2006; Rojas-Vega et al., 2006) and 
mood (Simon et al., 2006; Harris et al., 2006; Kendler et al., 1993). Data on weight and 
height were collected, and BMI was calculated (weight/height2). Information on physical 
activity was gathered using the International Physical Activity Questionnaire (IPAQ; Craig 
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et al., 1995) and expressed as the number of met-minutes (i.e., the ratio of the amount of 
energy expenditure during activity to the energy expenditure at rest). Smoking status was 
dichotomized as current versus non-smoker. Time of the morning blood withdrawal and 
duration of serum storage were controlled for since BDNF concentrations vary according to 
variation on these variables (Begliuomini et al., 2008; Trajkovska et al., 2007).
Statistical analyses
All computations were performed in SPSS version 17.0 (SPSS, Chicago, IL, USA). BDNF values 
were controlled for basic covariates in all analyses. Effect sizes on pair-wise comparisons 
were presented as Cohen’s d. (Cohen, 1988). A two-tailed P-level of 0.05 was used to 
determine statistical significance.      
Analysis of variance (ANOVA) was used to compare BDNF concentrations of antidepressant-
free depressed patients and antidepressant-treated depressed patients, antidepressant-
free patients and antidepressant- treated persons who were in remission (< 6 months) and 
controls. Post-hoc tests were performed following a significant F-statistic using Tukey’s test. 
A multivariable regression analysis was used to identify whether the clinical features of 
depression were associated with BDNF concentrations. Regression was performed in patient 
groups in which mean BDNF concentrations deviated significantly from the control group. 
Pearson correlation coefficients between predictors and BDNF concentrations were also 
calculated. Basic covariates were entered in the first step of regression. In the second step, 
the clinical features of depression were entered. The regression model was fit using method 
enter. Tolerance of the predictors and normality of error variances was verified. 
To establish whether the use of an antidepressant affected BDNF concentrations equally 
in current and remitted depression, a 2 (currently depressed versus depression in (full) 
remission) times 2 (antidepressants; yes versus no) ANOVA was performed. Potential 
antidepressant-specific associations between the use of SSRIs, TCAs, SNRIs, NaSSAs and St 
John’s wort and BDNF concentrations were evaluated by contrasting BDNF concentrations 
of persons who used one of these agents against the mean BDNF concentration of the 
antidepressant- free persons. Analyses were repeated with the severity of depressive 
symptoms and the duration of antidepressant use as covariates.
Results
Demographics and clinical features
Demographical and clinical features among the five groups are given in Table 5.1. ANOVA 
and χ2 tests showed that, compared with controls, depressed and remitted persons were 
more likely to be female, to be older, to have received fewer years of education and to 
smoke. BMI was higher in current and remitted antidepressant-treated depressed persons 
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Table 5.1. 
Demographic- and clinical characteristics (mean ± STD or percentages) of participants by 
depression diagnosis (never, current and remitted) and antidepressant use (no versus yes 
AD)
Controls 
(n = 382)
Depressed 
(n = 541)
Depressed 
Antidepressant
(n = 421)
Remitted 
(n = 539)
Remitted 
Antidepres-
sants
(n = 161)
P-value
Female (%) 61.0 66.7 67.0 71.1 70.8 < 0.05
Age 45.7 ± 12.3 39.8 ± 12.6 42.6 ± 11.0 43.1 ± 12.9 45.4 ± 10.8 < 0.001 A,B
Education (years) 13.4 ± 3.3 11.9 ± 3.2 11.7±3.3 12.6 ± 3.1 12.1 ± 3.3 < 0.001
Body mass index 25.4 ± 4.6 25.5 ± 5.4 26.3±5.6 25.3 ± 4.6 26.6 ± 5.6 < 0.01   A,B
Physical activity C 3.7 ± 3.0 3.5±3.3 3.2±3.3 3.8 ± 3.1 3.1 ± 2.8 < 0.01   B
Smoker 16.5 38.7 46.0 35.5 34.3 < 0.001 A
Alcohol dependent 5.4 23.3 20.0 17.0 13.7 < 0.001
Depression severity 5.3 ± 3.5 29.6 ± 12.7 34.5 ± 13.1 16.8 ± 10.3 20.3 ± 10.6 < 0.001 A,B
Age of onset of MDD NA 26.1 ± 12.3 27.4 ± 12.6 27.6 ± 12.2 28.2 ± 11.7     0.35
Chronic depression D NA 27.5 38.3 11.1 18.7 < 0.001 A,B
>1 episode NA 63.6 58.2 54.6 61.5 < 0.05   A
Comorbid anxiety E NA 42.2 47.7 NA NA < 0.05
Suicide ideation NA 22.4 29.3 5.2 6.2 < 0.001 A
Antidepressant medication
 SSRI NA NA 62.7 NA 65.8    0.27
 SNRI NA NA 16.4 NA 13.0    0.06
 TCA NA NA 8.1 NA 13.0    0.19
 NaSSA NA NA 8.6 NA 2.5 < 0.05
 St John’s wort NA NA 4.3 NA 5.6     0.32
 Duration of use F NA NA 7.5 ± 4.9 NA 10.9 ± 3.5 < 0.001
Abbreviations:  NaSSA, noradrenergic and specific serotonergic antidepressant; SNRI, serotonin and 
norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antide-
pressant
A Indicates a significant difference between the antidepressant treated and antidepressant free cur-
rent depressed groups
B Indicates a significant difference between the antidepressant treated and antidepressant free remit-
ted depressed groups
C Mean met-minutes (that is ratio of energy expenditure during activity to energy expenditure at rest) 
divided by 1000
D Symptoms were considered chronic if they were present for at least 24 months during the last 5 years
E Included social phobia, panic disorder with and without agoraphobia, agoraphobia and generalized 
anxiety disorder
F Duration of use is expressed in number of months
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compared with controls and to antidepressant-free depressed and remitted persons. The 
amount of physical activity was low in the antidepressant treated currently depressed group 
relative to the other groups. Post-hoc comparisons on demographical and clinical features 
between the current and remitted depressed groups are given in Table 5.1.
BDNF concentrations in persons with current or remitted depression and 
controls
An ANOVA model showed a main effect of diagnostic status on serum concentrations of 
BDNF (F
1, 1578
 = 4.09, P = 0.01). Pair-wise comparisons (see Figure 5.1) indicated that serum 
BDNF concentrations were low in antidepressant-free depressed patients compared 
with controls (d = 0.19), antidepressant-free persons who were in full remission (d = 
0.15), and antidepressant-treated depressed patients (d = 0.23). BDNF concentrations of 
antidepressant-free persons who were in full remission and depressed patients who were 
treated with an antidepressant were comparable to those of controls.
BDNF and the clinical features of depression
Figure 5.1.
Mean serum BDNF concentrations by diagnosis and antidepressant status. 
Serum BDNF concentrations are low in antidepressant-free depressed patients compared with controls (A: d = 
0.19), antidepressant-free remitted persons (B: d = 0.15) and antidepressant-treated depressed patients (C: d = 
0.23). 
Error bars reflect the SEM.
* Denotes statistical significance at P < 0.05. 
** Denotes statistical significance at P < 0.01.
** A, B
  * C 
Se
ru
m
 B
D
N
F 
ng
/m
l
12
10
8
6
4
2
0
Healthy controls
(n = 382)
Depressed
no antidepressants
(n = 541)
Remitted Depressed
no antidepressants
(n = 539)
Depressed
no antidepressants
(n = 421)
Remitted depressed
antidepressants
(n = 161)
Serum BDNF concentrations in major depressive disorder: state-trait issues, clinical features and 
pharmacological treatment
79
The exploration of the association between the clinical features of depression and serum 
BDNF was restricted to the antidepressant free currently depressed group, as BDNF 
concentrations in this group were low relative to controls. Pearson’s correlation coefficients 
indicated that female gender and being in the early remission phase of depression (1–6 
months) versus having a current episode were negatively associated with serum BDNF. Age, 
BMI, age at onset of depression and the presence of co-morbid anxiety were positively 
associated to serum BDNF (Table 5.2).
Basic covariates were entered in the first step of the multivariable regression analysis, 
followed by the clinical features that were entered in step two. Tolerance of the predictors 
was high (all > 0.70), indicating that our individual predictors were not redundant with one 
another. Error variances were normally distributed. Results of the first step showed that 
gender and age were significant predictors of BDNF concentrations. Women had lower 
Table 5.2. 
Results of correlation and multivariable regression analyses of demographical and clinical 
characteristics with serum levels of BDNF in antidepressant free depressed patients (n = 
541)
r A B 95% CI B β P-value
Gender (1 = male, 2 = female) −0.13** −0.65 −1.24 to −0.06 −0.10 0.03
Age (continuous, years)   0.17**   0.03   0.01 to 0.06    0.11 0.04
Education (continuous, years) −0.04 −0.01 −0.09 to 0.08 −0.005 0.91
BMI (continuous)   0.13**   0.06   0.01 to 0.10    0.09 0.04
Physical activity (continuous per week) −0.02 −0.001 −0.01 to 0.01 −0.009 0.83
Smoker (1=no, 2=yes) −0.02 −0.07 −0.04 to 0.02 −0.02 0.66
Time of Blood withdrawal (continuous) B −0.04 −0.004 −0.12 to 0.02 −0.04 0.23
Duration of serum storage (continuous)   0.02   0.14 −0.40 to 0.68    0.02 0.62
Current (= 1) vs. early remitted (= 2)C −0.11* −0.15 −0.50 to 0.25 −0.04 0.52
Severity (continuous)   0.03 −0.007 −0.04 to 0.02 −0.06 0.24
Single (= 1) vs. recurrent episode (= 2)   0.01   0.05 −0.56 to 0.66    0.007 0.88
Comorbid anxiety (1 = no, 2 = yes)   0.08*   0.31 −0.36 to 0.97    0.05 0.36
Age at onset (continuous)   0.14**   0.08 −0.04 to 0.18    0.07 0.21
Chronic depression (1 = no, 2 = yes)   0.07   0.19 −0.49 to 0.87    0.03 0.58
Suicide ideation (1 = no, 2 = yes)   0.06   0.59 −0.13 to 1.33    0.07 0.12
Abbreviations: BDNF, Brain-Derived Neurotrophic Factor; BMI, Body Mass Index; 95% CI, 95 percent 
Confidence Interval
A Univariate correlation with serum levels of BDNF; Pearson’s r for continuous variables and Spear-
man’s rho for variables
B In minutes from 0600 hours
C The presence of a current (1 month) versus an early remission (1–6 months of remission) diagnosis
*   Denotes statistical significance at P < .05
** Denotes statistical significance at P < .01
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concentrations of BDNF compared with men (ß = -0.10, P = 0.02) and older patients had 
higher concentrations of BDNF (ß = 0.11, P = 0.002) compared with younger patients. 
Results of the second step showed that none of the clinical features (listed in Table 5.2) was 
significantly associated with serum BDNF. Gender and age preserved its significance. BMI 
emerged as a significant (positive) predictor of serum BDNF. Table 5.2 presents the results 
of the second step of the regression analysis.
BDNF and the use of antidepressants
A 2 (currently depressed versus depression in (full) remission) times 2 (antidepressant use; 
yes versus no) ANOVA showed that diagnostic status interacted with antidepressant use 
(F
1, 1578 
= 4.19, P = 0.03), indicating that the use of an antidepressant during a depressive 
episode was associated with higher BDNF concentrations, whereas in the remission phase, 
the use of an antidepressant did not show such an association (see also Figure 5.1). Main 
effects of diagnostic status and antidepressant use were not observed. To uncover potential 
differences between various classes of antidepressants, we compared BDNF concentrations 
of depressed patients who used SSRIs, SNRIs, TCAs, NaSSAs or St John’s wort among each 
other and those of antidepressant-free depressed patients. This analysis was restricted to 
the currently depressed group as the effect of the use of an antidepressant on serum BDNF 
concentrations was confined to this group. In this group, 67% (n = 282) used antidepressant 
for longer than 12 weeks. We observed a main effect of group (F
5, 941 
= 4.29, P < 0.001). Post-
hoc comparisons showed that, relative to not using an antidepressant, the use of SSRIs (d = 
0.39) and St John’s wort (d = 0.63) was associated with high concentrations of BDNF. The use 
of a NaSSA was associated with low concentrations of BDNF relative to SSRI (d = 0.54) and St 
John’s wort (d = 0.85) use. Analyses were run with and without co-varying for the severity of 
depressive symptoms and for the duration of antidepressant use. These analyses revealed 
a similar pattern of results. Furthermore, serum BDNF concentrations were unrelated to 
treatment duration (r = -0.02, P = 0.65), which might suggest that our findings were not 
driven by the duration of antidepressant use.
Discussion
Largely in accord with previous findings (Sen et al., 2008) and with the neurotrophin hypothesis 
of depression (Duman et al., 1997), our data showed that serum BDNF concentrations were 
low in antidepressant-free depressed patients compared with healthy controls. Our data 
further showed that BDNF concentrations were low in depressed patients who were not 
on antidepressant medication compared with antidepressant-free persons who were in 
full remission and that BDNF concentrations of this latter group were comparable to those 
of controls. Herewith, we establish as one of the first (Trajkovska et al., 2008) that low 
Serum BDNF concentrations in major depressive disorder: state-trait issues, clinical features and 
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concentrations of BDNF in serum are a state characteristic of depression. In line with one 
study that reported low concentrations of BDNF in euthymic patients (Monteleone et al., 
2008), we found that patients who were in early remission (1 – 6 months) had serum BDNF 
concentrations that were comparable to those of currently depressed patients. Thus, serum 
BDNF concentrations remain low after clinical improvement has set in. This could indicate 
that low concentrations of BDNF are a consequence of depressive symptoms that persist 
into early remission. Alternatively, the low concentrations of BDNF during early remission 
might also represent a scar of a depressive episode. These explanations could not be fully 
elucidated in the current study and longitudinal designs clearly need to be performed to 
understand this issue.
We were unable to replicate the earlier findings that a higher depression severity (Karege 
et al., 2002; Shimuzu et al., 2003) having a recurrent compared with a first episode of 
depression (Lee et al., 2007) and the occurrence of suicide ideation (Deveci et al., 2007; 
Kim et al., 2007) are accompanied by lower concentrations of BDNF. In fact, we even found 
that the early remission phase, which was accompanied by a lower symptom severity of 
depression (mean IDS scores were 22.4 ± 11.4 versus 32.4 ± 12.1 in early remitted and 
currently depressed patients respectively), was associated with somewhat lower BDNF 
concentrations compared with the current depressive state. The other clinical features 
(that is age at onset of depression, the presence of comorbid anxiety and the chronicity of 
depression) also were unrelated to serum BDNF in multivariable analyses. These findings, 
given the size of the current cohort, give us confidence in excluding the clinical features of 
depression as potential correlates of serum BDNF concentrations. This might be an important 
conclusion, as it hints that other (than specifically depression related) factors may be at play 
in the relative fall of BDNF concentrations during a depressive episode. Interestingly, being 
male and BMI were found to be positively associated with BDNF among antidepressant-
free depressed patients. Although these findings were unsought, they parallel the results of 
some previous studies (Monteleone et al., 2005; Nakazato et al., 2003) and they give ground 
to interesting hypotheses. For example, as weight loss is a prime behavioral abnormality 
of depression (APA 1994) and often a residual symptom in early remission (Paykel 1985; 
Paykel et al., 1995) it could be that, alternations in BDNF concentrations are mediated by 
(transient) changes in eating behavior during, or in the aftermath of, a depressive episode. 
Likewise, weight gain is a documented side effect of antidepressant treatment (Kachur et 
al., 2005; Antilla and Leinonen, 2001) and thus the absence of weight loss could potentially 
explain the absence of a relative fall of BDNF in depressed patients during treatment 
with an antidepressant. Alternative factors that have been proposed to underlie the low 
concentrations of BDNF during depression are exposure to stressful life events. Two studies 
found that adverse life events are associated with lower peripheral BDNF concentrations 
within a depressed and bipolar patient samples (Kauer-Sant’Anna et al., 2007; Grassi-
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Oliveira et al., 2008). Therefore, it seems worthwhile to integrate a wider range of variables, 
notably (early) adverse life events, but also genetic variants and their interactions with 
environmental variables (Gatt et al., 2009) in models that study the link between BDNF and 
depression.
In addition, we found that serum BDNF concentrations were higher in antidepressant-
treated patients compared with patients who were antidepressant free. This finding 
largely is in accord with previous findings (Sen et al., 2008). We were able to expand 
previous findings by showing that the use of an antidepressant is associated with increased 
serum BDNF during a depressive episode but not during remission. This suggests that 
antidepressant-induced increases in BDNF occur in a disease state when BDNF functioning 
might be defective and not in remission when BDNF functioning is normalized. In addition, 
we found the increase in serum BDNF concentrations to be a specific associate of the use 
of SSRIs and St John’s wort and not of the use of SNRIs, TCAs or NaSSAs. Although not 
directly confirmed, this finding might be explained by increased availability of extra-synaptic 
concentrations of serotonin. It is known that serotonin stimulates the expression of BDNF 
(Mattson et al., 2004; Martinowich and Lu, 2008). In line with this, we found the highest 
BDNF concentrations in patients who were treated with an agent that generally leads to an 
increase in the availability of serotonin, that is, SSRIs and St John’s wort (Mann, 2005; Gaster 
and Holroyd, 2000). Furthermore, we found the lowest concentrations of BDNF in patients 
who were treated with agents that have little or no impact on the availability of serotonin, 
that is, NaSSAs (Kent, 2000; Antilla and Leinonen, 2001). Nevertheless, this antidepressant-
specific finding seems at odds with the prediction of the neurotrophin hypothesis, stating 
that increases in BDNF concentrations are a key mediator for an antidepressant response 
to occur (Duman and Monteggia, 2006). According to this prediction, one might expect 
that antidepressants that are known to be about equally efficacious in the treatment of 
the symptoms of depression (Gaster and Holroyd, 2000; Kent 2000; Berton and Nestler, 
2006) would have similar effects on serum BDNF concentrations. Yet another finding that 
seems hard to reconcile with the neurotrophin hypothesis is that the group of depressed 
persons who used antidepressants (for prolonged period and on a frequent base) had the 
highest BDNF concentrations, but also the highest symptom severity of depression. This 
suggests, to our belief that increases in peripheral BDNF concentrations do not parallel 
clinical effectiveness, or at least have no direct effects on depression characteristics such 
as its severity. Such a conclusion on the absence of direct effects could also be drawn 
on the findings that the severity of a depressive episode was unrelated to serum BDNF 
concentrations and that persons who were in early remission had similar concentrations of 
BDNF yet a marked lower depression severity as compared to currently depressed patients. 
Caution, however, is warranted when interpreting these findings because our patients were 
not randomly assigned to the various drugs (or no drug) conditions. Thus, our findings might 
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be confounded by indication. An additional limitation of our study is that we relied on data 
that were collected in a single wave, precluding any form of causality. Furthermore, we 
measured serum concentrations of BDNF and assume that these measurements mirror the 
amount of BDNF in the brain. This assumption is validated on preclinical work that showed 
that cortical and peripheral concentrations of BDNF are correlated (Sartorius et al., 2009; 
Klein et al., 2010) but remains complicated, because in addition to neurons, several other 
tissues serve as sources of BDNF in serum (Karege et al., 2002). Various strengths of our 
study also seem evident and these include the use of multivariable techniques and the large 
sample size (that relates positive to all previous studies and to two previous meta-analyses 
(Brunoni et al., 2008).
In conclusion, we believe that our data indicate that low concentrations of BDNF in blood 
serum are a state characteristic of depression and thus an abnormality that is evident during 
the clinical state and the early remission phase of depression but not when the symptoms of 
depression are in full remission. Our findings further suggest that some of the core clinical 
features of depression are unrelated to serum concentrations of BDNF. Finally, increases in 
serum concentrations of BDNF appear to be a specific pharmacological effect of a subset 
of antidepressants that does not parallel depression characteristics such as the severity of 
depression.
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Low serum BDNF levels in depressed patients 
cannot be attributed to individual depressive 
symptoms or symptom cluster.
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Abstract
Low serum BDNF levels have been found in depressed patients. No study has systematically 
investigated whether individual symptoms or symptom profiles within a depressed 
population contribute to low BDNF levels found in depressed subjects. 
All 1070 patients with a past 6-month diagnosis of major depressive disorder from 
the Netherlands Study of Depression and Anxiety (NESDA) were included. Composite 
International Diagnostic Interview (CIDI) and Inventory of Depressive Symptoms (IDS) 
items were tested individually in separate multiple regression analyses with serum BDNF 
level as the dependent and the CIDI or IDS item as independent variable. Subsequently, 
we compared BDNF levels between patients with seasonal affective disorder (based on 
the Seasonal Pattern Assessment Questionnaire) and melancholic depression, atypical 
depression and moderate depression (based on a latent class analysis). All analyses were 
adjusted for confounders. 
Only one item was significantly associated with serum BDNF levels, namely the CIDI item 
“loss of interest” (β = .14; p<.01). Counterintuitively the presence of this symptom was 
associated with higher BDNF levels. Other items and the comparison between different 
types of depression did not reveal significant differences.
Decreased serum BDNF levels in depression cannot be attributed to a specific symptom or 
symptom cluster. 
Low serum BDNF levels in depressed patients cannot be attributed to individual depressive 
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Introduction
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of 
growth factors and is involved in the plasticity of neurons in several brain regions. It has 
been hypothesized that BDNF expression is attenuated by experiencing psychological 
stress and that consequently a lack of neurotrophic support causes depression (Duman 
and Monteggia, 2006). Lower BDNF levels have indeed been found in depressed subjects 
(Molendijk et al, 2013). Initial studies reporting on lower serum BDNF levels in depressed 
patients have shown considerably large effect-sizes (Molendijk et al., 2013). However, our 
attempts to replicate this finding with a large sample size in representative cohorts of both 
healthy people (Bus et al., 2012) and depressed patients (Molendijk et al., 2011) resulted in 
significant yet relatively small effects. 
Besides a general effect in depressed subjects, BDNF has been associated with a large 
variety of (neuro)psychiatric symptoms. For example, lowered serum BDNF levels have 
been associated with sleep disturbances among non-depressed patients with chronic 
sleep disorders (Faraguna et al., 2008). Recently, Giese and colleagues (2013) reported on 
significantly lower serum BDNF levels in subjects with insomnia, compared to subjects with 
normal sleep. They hypothesize that the decreased BDNF in depressed patients may be 
driven by a principal effect of sleep. BDNF has indeed been described to enhance sleep in 
earlier studies as well (Faraguna et al., 2008). Supposedly sleep need results from the overall 
amount of synaptic plasticity during the day hence BDNF has been hypothesized to be a key 
mediator in sleep induced synaptic renormalization (Bushey et al., 2011). 
It must be noted that the results of the study by Giese et al. are found in a group of subjects 
who are currently free from depression, so it remains unclear whether these results can be 
extrapolated to sleep disturbances within a depressed population.
In addition to sleep, within depressed patients a specific association has been reported with 
suicidality (Kim et al., 2007) and dissociative symptoms (Dell’Osso et al., 2010). This may 
suggest that differences in BDNF levels between healthy individuals and depressed patients 
may be moderated by individual symptoms within the syndrome of depression. 
As no study has systematically tested all individual symptoms of depression it remains 
unclear whether individual symptoms are responsible for the findings of lower BDNF levels 
in depressed subjects. Based on previous literature, we expect that the presence of sleep 
disturbances and suicidality will be associated with a further decrease in BDNF level.      
A second goal of this study is to explore the differences in BDNF levels between patients 
with different (sub)types of depression, i.e. melancholic versus atypical depression and 
seasonal depression. Since no literature has appeared linking BDNF to any particular subtype 
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of depression, we had no a priori hypothesis. Nonetheless, serum BDNF levels are lower 
following the winter months, which could point toward a depletion due to a lack of ambient 
sunlight (Molendijk et al.,2012), so we hypothesised that BDNF might be associated with 
seasonal affective disorder.  
The present study was set up to examine the association between various depressive 
symptoms, symptom profiles and serum BDNF levels using a large (n= 1070) cohort of 
currently depressed patients. 
Methods
Population
Data are from the baseline measurement of the Netherlands Study of Depression and 
Anxiety (NESDA). NESDA is a multi-site naturalistic cohort study aimed to describe the 
course and consequences of depressive and anxiety disorders and to integrate biological 
and research paradigms within an epidemiological approach. Recruitment took place in the 
general population, in general practices and in mental health organizations. The baseline 
sample consists of 2,981 participants aged 18 through 65 years of which 2,625 were 
selected on the basis of a current or life-time history of depression and/or anxiety disorder, 
belonging to a high-risk group because of a family history or subthreshold depressive or 
anxiety symptoms, and 356 healthy controls. Patients with a primary psychiatric disorder 
not subject of NESDA, such as psychotic disorder, obsessive compulsive disorder, bipolar 
disorder, or severe addiction were excluded as well as those not being fluent in Dutch. 
The Medical Ethics Committees of participating institutes have approved this study and 
all respondents provided written informed consent. All respondents received a structured 
diagnostic interview using the Composite International Diagnostic Interview (CIDI version 
2.1) in order to assess current and lifetime DSM-IV diagnoses. 
Based on these diagnoses, subjects with a Major Depressive Disorder (MDD) diagnosis in 
the last six months (n = 1070) were included in the present paper. The 4-hour baseline 
assessment further included written questionnaires, interviews, a medical examination, a 
cognitive computer task and collection of blood and saliva samples. All measurements and 
interviews were carried out by specially trained staff according to a previously determined 
protocol. For a more detailed description of the objectives and methods of NESDA, we refer 
to Penninx et al. (2008). 
Depressive symptoms
In the current study we included persons with a current diagnosis of MDD in the last six 
months. DSM-IV diagnoses were assigned on the basis of responses to the CIDI lifetime 
version that was administered by trained interviewers. Symptom severity was measured 
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using the Inventory of Depressive Symptoms (IDS), a well-validated and reliable instrument 
to assess depression severity (Rush et al., 1996). The IDS contains 30 items that cover all 
symptoms of depressive disorder in the DSM-IV, including those symptoms specific for 
subtypes like melancholic or atypical depression. All items have been rated on the 4-point 
scale; most of them are coded absent (1), present less than half of the time (2), present 
more than half of the time (3), nearly always present (4). 
In the context of a different study, with the same population, a latent class-analysis was 
performed within the subjects with a major or minor depressive disorder in the past month 
(n = 818) based on the CIDI and IDS items. This analysis revealed three classes underlying 
the depressive symptomatology; ie. a severe melancholic class, a severe atypical class and 
a class with moderate severity of depression. The results of this latent class-analysis are 
published elsewhere (Lamers et al., 2010) and were used in this study.  
Seasonality in depressive symptoms was assessed using the Seasonal Pattern Assessment 
Questionnaire (SPAQ). The SPAQ is a self-rating screening instrument for seasonal affective 
disorders (SAD) that retrospectively measures seasonal patterns. In our study the SPAQ was 
administered one year after the baseline measurements. The SPAQ consists of 12 questions 
concerning symptoms of depression for each of which the participants can indicate whether 
the symptom is worst in a particular month. Initially the SPAQ was developed as a screening 
tool to indicate which participants should subsequently receive a follow-up interview. 
Nevertheless, Kasper et al. (1989) have developed criteria from which one can reliably 
determine in which cases of depression there was a high likelihood of a seasonal component 
or not. Besides the use in other studies, These criteria were used and extensively described 
in another paper from the NESDA consortium (Winthorst et al., 2013). The presence 
of a seasonal affective disorder could be reliably determined in 813 subjects. The same 
dichotomous variable was used in our analyses.   
Use of antidepressants
Data on the use of antidepressants were collected through container observation and 
self-report. For the current study we defined the use of antidepressants as the minimal 
daily dose recommended by the World Health Organization. We considered all selective 
serotonin reuptake inhibitors (SSRI’s), serotonergic and noradrenergic reuptake inhibitors 
(SNRI’s), Tricyclic Antidepressants (TCA’s), noradrenergic and specific serotonergic reuptake 
inhibitors (NaSSa’s) and St John’s Worth (Hypericum perforatum). These definitions are 
equal to the our previous study, where we found antidepressants to have a significant effect 
on serum BDNF levels (Molendijk et al., 2011).
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Based on these previous study, besides analyses for the whole group, we also stratified 
for the use of antidepressants  since antidepressant use could overrule symptom cluster 
findings (Molendijk et al., 2011).
BDNF assessment
BDNF measurement has been extensively described before (Bus et al., 2012) and can 
be summarized as follows. For BDNF assessment blood was extracted in the morning 
after an overnight fast and immediately transferred to the local laboratory-sites to start 
processing within one hour. Serum samples for BDNF measurement were stored at -85 
°C. Measurement took place at the Department of Psychiatry and Neuropsychology of the 
university of Maastricht (The Netherlands) using the Emax Immuno Assay system from 
Promega according to the manufacturer’s protocol. The undiluted serum was acid treated 
as described in the protocol and, subsequently, serum samples were 100 times diluted and 
stored again at -80 °C until BDNF assessment the next day Greiner Bio-One high affinity 
96-well plates were used and the resulting absorbance was read in duplicate using a Biorad 
Benchmark microplate reader at 450 nm. After dilution, the BDNF measurements were 
well within the range of the standard curve (7.8 pg/ml  500 pg/ml). Serum BDNF protein 
levels were expressed in ng/ml. According to the manufacturer’s protocol the BDNF Emax 
kit demonstrates very low cross-reactivity (< 3%) with related neurotrophic factors NGF, 
NT-3 and NT-4/5 at concentrations as high as 100 ng/ml. The assay sensitivity threshold was 
ascertained at 1.56 ng/ml reflecting the minimum level of BDNF in the serum that could be 
reliably determined. Based on a pilot including six serum samples of subjects not included 
in the study, the coefficients of variance were determined to range from 2.9% to 8.1%. 
Measures of the intra-assay variance in the present study resulted in coefficients of variance 
of 0.0% and 3.1%, well below the maximum intra-assay variance of 8.8% as specified by the 
manufacturer. 
 
Covariates
Based on our previous research of, potential variance due to age, gender, sample storage time, 
time of sampling, fasting status at time of measurement, urbanicity of living environment, 
smoking behavior and drinking behavior was taken into account (Bus et al., 2011; Bus et 
al., 2012). An urban environment variable was defined according to the classification of 
the Dutch Office for statistics and dichotomized into more or less than 1000 addresses per 
square kilometer. Smoking was dichotomized as smoker versus non-smoker. Alcohol use was 
evaluated by creating four groups: abstainers, mild drinkers (drinking less than 1 unit a day), 
moderate drinkers (drinking 1-2 units a day) and excessive (drinking 2 units or more a day). 
Alcohol categories were entered as dummy variables. 
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Statistical analysis
Serum BDNF levels were normally distributed, with the exception of 3 (0,6%) positive outliers 
(i.e. level higher than 3SD above mean). Outliers were handled by trimming all serum BDNF 
levels above 3 standard deviations (SD) above the mean to the 3SD value to prevent that 
results are driven by single influential cases. 
As a first step, CIDI and IDS items were tested individually in separate multiple regression 
analyses with serum BDNF level as the dependent variable and the CIDI or IDS item as 
independent variable. Some items were deconstructed, since the items appetite and weight 
can indicate both an increase/decrease of symptoms. Therefore we analyzed an increase 
and a decrease of both appetite changes and weight changes as dummy variables. All 
analyses were corrected for potential confounders as described above as well as the severity 
of depressive symptoms (IDS sum score). This latter correction was used in order to test the 
additional value of each individual symptom rather than the effect of depression (severity) 
itself.  
Both the non-stratified as well as the analyses stratified for antidepressant use will be 
presented. In the non-stratified analysis use of antidepressants was included as a covariate. 
To test the differences in BDNF levels between the subjects with a seasonal affective 
component and those without any seasonal differences, we used a multiple linear 
regression model, with the inclusion of al previously mentioned covariates, by entering the 
dichotomous variable that was created using the SPAQ. 
Based on a latent class analysis of our population, as was reported before (Lamers et al., 
2010), the differences in  mean BDNF levels between patients suffering from melancholic 
depression, atypical depression and moderate depression were compared by analysis of 
covariance. All covariates previously mentioned were taken into account. However, since the 
empirical determination of depression subgroups was partly based on the results of the IDS 
sumscore and one of the groups identified was a group with moderate severity, depression 
severity was not considered as a covariate in this analysis. Both the non-stratified as well as 
the analyses stratified for antidepressant use are shown. In the non-stratified analysis use of 
antidepressants was included as a covariate.
NESDA is a broad study that aims to gain insight into many aspects of depression and anxiety. 
Several individual symptoms could be explored further than the corresponding item in the 
IDS or the CIDI. Therefore, as a second step, significant findings from the above mentioned 
primary analyses were further explored with data collected in the broader context of NESDA 
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as far as appropriate questionnaires were available. For an overview of questionnaires used 
in NESDA we refer to Penninx et al. (2008)
All computations were carried out using SPSS 16.0 (SPSS, Chicago, IL, USA). Collinearity and 
heteroscedasticity were carefully checked for and no problems emerged. To reduce the 
chance of a type I error due to multiple testing a stringent two-tailed α level was chosen by 
applying a Bonferroni correction. For the analysis of the CIDI items a p level of .0038 (α = 
0.05/13) and for the IDS items a p level .0016 (α = 0.05/32) was considered significant. 
Sensitivity analyses
Several additional analyses were carried out in order to test the robustness of the findings. 
Since not all patients with a six-month diagnosis of major depressive disorder necessarily 
meet these criteria within the past month, we repeated our analyses by including subjects 
who had a diagnosis of major depressive disorder in the past month. Previous research has 
shown that those who are currently depressed (within the last month) had a significantly 
higher BDNF than those who had a diagnosis of depression between one and six months ago 
(Molendijk et al., 2011). Looking specifically in the population with a depression in the last 
month, could potentially reveal different results.
Next, we repeated our analyses without the correction for the severity of depression. This 
correction was first applied to test the additional value of each individual symptom rather 
than the effect of depression (severity) itself. By doing so, we could have theoretically 
‘overcorrected’ the association with the item, thereby reducing the power to find significant 
results. If this is the case, then bigger effects would be seen in the analyses without 
correction for severity.    
Last, in order to address the problems that arise by multiple testing we repeated our 
regression analysis on the IDS items using a forward selection procedure. Applying a 
Bonferroni correction can be considered too strict. The forward selection procedure was 
used to test whether any different items would be identified that would otherwise be 
undiscovered.  
Results
The 1070 depressed participants had a mean age of 40.9 years (SD=12.8) and 731 (68.3%) 
were female. The mean BDNF level was 9.0 ng/ml (SD=3.4; range: 1.6-19.2 ng/ml). Basic 
demographics are displayed in table 6.1.   
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Table 6.1.
Baseline characteristics of all subjects, stratified by the use of antidepressants.
All depressed 
(<6months) 
(n = 1070)
Depressed no AD  
(n= 577)
Depressed AD  
(n=493)
Age (SD) 40.9  (12.8) 39.7 (12.6) 42.3 (11.2)
% Female (n) 68.3 (731) 68.3 (394) 68.4 (337) 
BDNF level ng/ml (SD) 9.0 (3.4) 8.7 (3.2) 9.3 (3.6)
IDS sumscore (SD) 32.3 (13.0) 30.2 (12.7) 34.6 (12.9)
Storage time days (SD) 1263.6 (220.1) 127001 (217.0) 1256.0 (223.7) 
% non-adherence to fasting protocol (n) 4.3 (46) 4.7 (27) 3.9 (19) 
Measurement time minutes after 6am (SD) 168.5 (30.5) 170.5 (37.8) 166.1 (18.3)
% living in urban environment (n) 83.3 (891) 85.6 (494) 80.5 (397) 
Drinking behaviour
    % Abstainer 38.2 (409) 38.5 (222) 37.9 (187) 
    % Mild < 1U/day 26.3 (281) 29.1 (168) 22.9 (113) 
    % Moderate 1-2U/day 7.3 (78) 8.0 (46) 6.5 (32) 
    % Heavy > 2U/day 4.6 (49) 5.0 (29) 4.1 (20) 
% smoker (n) 45.0 (482) 42.3 (244) 48.3 (238) 
IRS sum score (SD) 10.5 (5.4) 10.3 (5.2) 10.7 (5.5)
Subtypes of depression
    % Severe, Melancholic (n) 33.6 (360) 30.0 (173) 37.9 (187)
    % Severe, Atypical (n) 17.6 (188) 16.3 (94) 19.1 (94)
    % Moderate (n) 17.9 (192) 22.5 (130) 12.6 (62)
% Seasonal affective disorder (n)1 17.6 (143) 17.2 (76) 13.6 (67)
CIDI responses
   % feeling sad (n) 94.7 (1013) 91.9 (530) 98.0 (483)
   % with loss of interest (n) 95.9 (1026) 95.3 (550) 96.6 (476)
   % with fatigue (n) 94.8 (1014) 93.4 (539) 96.3 (475)
   % with loss of appetite (n) 44.6 (273)2 46.1 (155) 42.8 (118)
   % with increase of appetite (n) 28.9 (177)2 29.5 (99) 28.3 (78)
   % with loss of sleep (n) 66.5 (337)3 68.8 (196) 63.5 (141)
   % with increase of sleep (n) 17.4 (88)2 15.4 (44) 19.8 (44)
   % with psychomotor agitation (n) 75.3 (805) 73.1 (422) 77.8 (383)
   % feeling worthless/guilty (n) 86.4 (924) 83.4 (481) 89.9 (443)
   % with diminished concentration (n) 99.0 (1059) 98.8 (570) 99.2 (489)
   % with suicidal thoughts (n) 64.7 (692) 59.4 (343) 70.8 (349)
Abrreviations: SD, standard deviation; BDNF, brain-derived neurotrophic factor; IDS, inventory of de-
pressive symptoms, U, units; IRS, Insomnia Rating Scale; AD, Antidepressants 
1 Information available in 813 subjects 
2 Information available in 612 subjects
3 Information available in 507 subjects
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The severity of depression as measured by the sumscore on the IDS was not significantly 
associated with serum BDNF levels (β = -0.03; p = .40). When covariates were not taken into 
account there was no effect at all (β < 0.01; p = .99). 
The use of antidepressants was significantly associated with higher serum BDNF levels (β = 
0.09; p = .002). This finding remained statistically significant after correction for all covariates 
(β = 0.085; p = .006).  
Table 6.2 presents the results of the analyses with the CIDI-items. Even without correction 
for multiple testing, none of the CIDI items was significantly associated with serum BDNF 
levels. In the stratified analysis, in depressed patients not using antidepressants, subjects 
with a loss of interest (β = 0.14 ; p < .01)and those with fatigue (β = 0.11 ; p = .01) had 
a higher serum BDNF level than those who did not have that symptom. In the group of 
subjects currently using antidepressants higher BDNF levels were found in those who 
experienced an increase in sleep compared to those who had diminished sleep. When the 
Bonferroni correction was applied only the item “loss of interest” in the group not using 
antidepressants remained significant. It must be noted that only 27 of those 577 subjects 
reported an absence of loss of interest.  
Table 6.3 presents the association of each IDS-item with the serum BDNF level separately for 
users and non-users of antidepressants. None of the items reached statistical significance 
after Bonferroni correction was applied. Some items showed a trend towards significance 
(i.e.  a significant result when multiple testing was unaccounted for), among which the item 
waking too early, feeling sad and feeling slowed down. All three had the largest effect size in 
the group of subjects not currently taking antidepressants. 
Moreover, serum BDNF levels did not significantly differ between patients with melancholic 
depression (mean 9.3 ng/ml; SD 3.5 ng/ml), atypical depression (mean 9.0 ng/ml; SD 3.4 
ng/ml) and moderate depression (mean 8,9 ng/ml; SD 3.35 ng/ml) (F=0.557, df=2, p= .57). 
No significant differences were found in the stratified analyses either (p = .16 without 
antidepressants; p = .44 with antidepressants). 
Also no significant differences were found between subjects with and without a seasonal 
affective disorder (β < 0.01; p = .94). This result did not significantly change when the group 
was stratified for the use of antidepressants.
The finding of a trend toward a significant association between waking too early and serum 
BDNF levels has led us to explore the association of sleep and BDNF in more depth. Therefore 
the sum-score on the Insomnia Rating Scale (IRS) was used in a regression model, corrected 
for all our covariates, with BDNF as the dependent variable. The IRS is a reliable questionnaire 
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Table 6.2.
Individual criteria of depression diagnosis and serum BDNF level
All currently depresseda Currently depressed AD-b Currently depressed AD+c
B β p B β p B β p
CIDI feeling sad (uncontrolled) 0.83 .06 .07 0.56 .05 .26 1.07 .04 .35
CIDI feeling sad (controlled for 
covariates*)
0.86 .06 .07 0.67 .06 .18 1.34 .05 .24
CIDI loss of interest 
(uncontrolled)
0.98 .06 .08 2.28 .15 <.01 -1.20 -.06 .18
CIDI loss of interest (controlled 
for covariates*)
0.92 .05 .08 2.15 .14 <.01 -1.09 -.06 .22
CIDI fatigue (uncontrolled) 1.05 .07 .03 1.33 .10 .02 0.20 .01 .81
CIDI fatigue (controlled for 
covariates*)
1.04 .07 .02 1.44 .11 .01 0.49 .03 .58
CIDI dummy no change vs. loss 
appetite (uncontrolled)
-0.14 -.02 .68 -0.10 -.01 .82 -0.10 -.01 .84
CIDI dummy no change vs. 
appetite (uncontrolled)
-0.21 -.02 .57 -0.05 -.01 .92 -0.34 -.03 .55
CIDI dummy no change vs. 
loss appetite (controlled for 
covariates*)
-0.10 -.01 .77 -0.07 -.01 .88 -0.22 -.02 .67
CIDI dummy no change vs. 
increase appetite (controlled for 
covariates*)
-0.11 -.01 .78 -0.07 -.01 .88 -0.21 -.02 .71
CIDI dummy no change vs. loss 
sleep (uncontrolled)
-0.26 -.03 .54 0.12 .01 .82 -0.70 -.06 .28
CIDI dummy no change vs. 
increase (uncontrolled)
0.33 .03 .53 -0.23 -.02 .74 0.77 .06 .33
CIDI dummy no change vs. loss 
sleep (controlled for covariates*)
-0.34 -.03 .41 0.06 .01 .91 -0.99 -.09 .13
CIDI dummy no change vs. 
increase sleep (controlled for 
covariates*)
0.29 .02 .57 -0.25 -.02 .71 0.77 .06 .33
CIDI psychomotor (uncontrolled) -0.20 -.03 .41 -0.24 -.03 .44 -0.24 -.03 .53
CIDI psychomotor (controlled for 
covariates*)
-0.26 -.03 .29 -0.29 -.04 .35 -0.54 -.01 .89
CIDI guilt (uncontrolled) -0.51 -.05 .10 -0.26 -.03 .48 -1.21 -.10 .02
CIDI guilt (controlled for 
covariates*)
-0.48 -.05 .12 -0.19 -.02 .60 -1.01 -.09 .06
CIDI concentration (uncontrolled) 1.03 .03 .32 1.34 .05 .28 0.32 .01 .86
CIDI concentration (controlled for 
covariates*)
1.26 .04 .22 1.54 .05 .21 0.73 .02 .68
CIDI thoughts of death 
(uncontrolled)
0.03 <0.01 .89 -0.01 >-.01 .97 -0.10 -.01 .77
CIDI thoughts of death 
(controlled for covariates*)
-0.02 >-0.01 .93 -0.07 -.01 .80 0.08 .01 .82
* Controlled for: age, gender, duration of storage, time of measuring, fasting on withdrawal day, urba-
nicity, IDS sumscore, smoking, drinking and AD (in unstratified analyses)
a All subjects with a MDD diagnosis in past 6 months 
b Subjects with a MDD diagnosis in past 6 months not currently using antidepressants 
c Subjects with a MDD diagnosis in past 6 months currently using antidepressants
CIDI loss of interest in AD- group: criterium negative n = 27; criterium positive n = 550
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Table 6.3. 
IDS items and serum BDNF levels
IDS All 6 monthsa* 6 months AD-b* 6 months AD+c*
B â p B â p B â p
1 falling asleep -0.08 -.02 .60 -0.02 -.01 .88 -0.19 -.06 .20
2 sleep during night -0.01 -.03 .32 <0.01 <.01 .99 0.12 .03 .48
3 waking too early -0.23 -.07 .03 -0.28 -.09 .04 -0.01 -.02 .67
4 sleep too much 0.15 .04 .25 -0.07 -.02 .73 0.28 .07 .11
5 feeling sad 0.37 .09 .02 0.60 .15 <.01 0.15 -.05 .34
6 feeling irritable 0.01 <.01 .97 0.21 .05 .31 >-0.01 -.01 .79
7 feeling anxious 0.19 .05 .24 0.21 .05 .29 0.18 .04 .31
8 mood responsiveness 0.28 .07 .06 -0.01 -.04 .41 0.41 .10 .06
9a mood fluctuation -0.08 -.02 .49 -0.05 -.01 .77 -0.09 -.02 .60
9b morning, evening 0.15 .02 .46 0.16 .03 .55 0.14 .02 .64
9c environment effect 0.10 .01 .76 >-0.01 -.02 .68 0.33 .03 .50
10 quality of mood 0.05 .02 .66 0.13 .04 .39 -0.07 -.02 .69
11a decreased appetite -0.15 -.02 .63 -0.07 -.02 .75 -0.22 -.02 .73
11b increased appetite -0.01 -.02 .49 -0.06 -.01 .83 -0.29 -.04 .35
13a decreased weight -0.01 -.03 .40 -0.19 -.05 .27 0.27 .06 .22
13b increased weight 0.10 .01 .67 0.04 .01 .90 0.04 .01 .92
15 concentration 0.06 .02 .68 0.25 .07 .20 -0.12 -.03 .60
16 view of myself -0.11 -.04 .29 0.01 <.01 .97 -0.27 -.09 .08
17 view of my future 0.13 .03 .40 0.38 .09 .07 -0.15 -.03 .53
18 thoughts of death -0.06 -.02 .67 -0.06 -.01 .77 -0.01 >-.01 .98
19 general interest 0.21 -.06 .11 0.25 .07 .16 0.21 .05 .33
20 energy level 0.22 .05 .15 0.25 .07 .19 0.22 .05 .34
21 capacity for pleasure -0.01 -.05 .20 0.31 .08 .15 0.03 .01 .90
22 interest in sex 0.07 .02 .54 -0.10 -.03 .52 0.21 .06 .23
23 feeling slowed down 0.29 .08 .02 0.41 .11 .02 -0.02 -.06 .26
24 feeling restless -0.11 -.03 .38 -0.15 -.04 .35 -0.01 -.03 .55
25 aches and pain 0.17 .04 .24 0.14 .03 .48 0.25 .06 .24
26 other bodily symptom -0.10 -.02 .54 -0.01 -.03 .54 -0.33 -.07 .18
27 panic/phobia 0.02 .01 .87 -0.01 -.04 .43 -0.12 -.03 .49
28 constipation diarrhea -0.08 -.02 .51 -0.09 -.02 .61 -0.08 -.02 .65
29 interpersonal sensitivity 0.18 .06 .12 0.09 .03 .55 0.26 .08 .13
30 leaden paralysis 0.10 .03 .44 0.22 .06 .20 -0.03 -.01 .90
* Controlled for: age, gender, duration of storage, time of measuring, fasting on withdrawal day, urba-
nicity, IDS sumscore, smoking, drinking and AD (in unstratified analyses)
a all subjects with a MDD diagnosis in past 6 months included
b Subjects with a MDD diagnosis not currently using antidepressants included
c Subjects with a MDD diagnosis currently using antidepressants included
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to assess sleeping problems (Levine et al., 2003). No statistically significant association was 
found between the sumscore on the IRS (β = -.017; p = .36), nor for the individual item 
“waking earlier than planned” (β = -.013; p = .48) and serum BDNF levels.      
Sensitivity analysis
Three sensitivity analyses were carried out. First, we restricted our sample to those patients 
with major depressive disorder within the past month (N=784, 73.3% of the original sample). 
Effect sizes were generally comparable to those in the population with a six-month diagnosis 
and after correction for multiple testing none of the items reached statistical significance 
(data not shown). 
Second, we re-analyzed all data without adjustment for depressive symptom severity. 
These analyses also revealed comparable results and none of the items reached statistical 
significance (data not shown). 
Third, in order to address the problems that arise by multiple testing we repeated our 
regression analysis on the IDS items using a forward selection procedure. With a threshold 
of p = .05, this revealed results comparable to our previous analyses. In the un-stratified 
analysis the items “feeling sad” (β = .088; p = .02), “feeling slowed down” (β = .080; p = 
.02) and “waking up too early (β = -.065; p = .04) were significant in the final model. When 
the analysis was stratified for the use of antidepressants we found that none of the items 
were kept in the model in the group using antidepressants and in the group not using any 
antidepressants only “feeling sad” (β = .158; p = .003) and “feeling slowed down” (β = .120; 
p = .01) were significantly associated with serum BDNF.   
Discussion 
In contrast with our hypothesis that the presence of insomnia and/or suicidality in a 
depressed population would be associated with lower BDNF levels, we found that variance 
in BDNF levels in depressed patients cannot be attributed to a particular symptom of 
depression. Also none of the previously defined subsets of symptoms (i.e. melancholic, 
atypical and seasonal depression) of depression were significantly associated with serum 
BDNF.
Therefore, the hypothesis that differences in effect sizes of studies on BDNF and depression 
are caused by the existence of (sets of) symptoms cannot to be substantiated by our data. 
A potential explanation lies in the stress hypothesis of BDNF and depression. Recent stress 
is an underlying factor causing both attenuated BDNF levels (Duman and Monteggia, 
2006; Elzinga et al., 2011) as well as a broad range of psychopathology, among which 
depression, and not specific symptoms. As such, low BDNF can be considered a general 
feature of psychopathology. As a result, selecting a population with depression would mean 
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selecting a “low BDNF population”. The same would occur when selecting on other types of 
psychopathology. However, it would not necessarily mean that a differential effect will be 
found for comorbid disorders or additional symptoms in a population with depression, since 
subjects would already have a low BDNF. 
In the initial analysis in the group free of antidepressants, only one symptom reached a 
statistically significant level when correction for multiple testing was accounted for, namely 
the CIDI item “loss of interest”. It must be noted however that only 27 of 577 subjects 
scored negative for this item, so the clinical impact of this finding is probably negligible. 
Nevertheless, since those who reported loss of interest were large in numbers, it could have 
impacted the effect sizes in our previous study where we found lower BDNF levels, albeit 
small effect sizes, in subjects with a depression (Molendijk et al., 2011).  
Recently, Giese and colleagues (2013) reported on significantly lower serum BDNF levels 
in subjects with insomnia, compared to subjects with normal sleep. We have only found 
a trend towards significance for the IDS item “waking too early”, but further exploration 
with the Insomnia Rating Scale did not reveal any significant association, thus we conclude 
that our data show that within a depressed sample there is no additional effect of sleep on 
serum BDNF level. 
For proper interpretation it should be noted that we analysed different symptoms and 
symptom profiles within a depressed population. Therefore, the finding of a higher BDNF in 
subjects with a loss of interest is to be considered in the context of other depressed subjects. 
It remains unclear whether these findings can be extrapolated to other populations. Along 
the same lines, the lack of other significant findings does not refute the notion that depressed 
subjects have lower BDNF levels than healthy subjects. An effect that has been shown in the 
NESDA population (Molendijk et al. 2011), as well as in many other populations (Molendijk 
et al. 2013).
A limitation of this study is that some of the results on the analysis of the CIDI items 
were underpowered. This was particularly true for all analyses with the item ‘diminished 
concentration’ and the stratified analysis, in the group using antidepressants, for the item 
‘feeling sad’, where respectively only eleven and ten subjects scored negative. On other 
items numbers of subjects scoring negative were large enough to give reliable results, 
despite the unbalance between the two possible answers on the items. In addition, we are 
reporting on the absence of an effect rather than the presence and since the effect sizes 
found tended to be very small, it strengthens the notion that there is no true difference 
between the groups.   
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Also, our study has a cross-sectional design which precludes making any causal inferences. 
In addition, although BDNF is believed to be transported over the blood-brain barrier 
(Karege et al., 2002) and significant correlations have been found between perihperal BDNF 
and measures of central neuroplasticity (Lang et al. 2007; Sartorius et al. 2009), we cannot 
be sure that measuring serum BDNF not reflects the BDNF brain expression adequately. Up 
until today, in the context of large epidemiological studies, measuring BDNF in peripheral 
blood is the only feasible method as other methods would be far more invasive.
Furthermore, one should note that, because of the storage of BDNF in platelets (Nakahashi 
et al., 2000), the number of platelets could influence the serum concentration of BDNF. 
Nevertheless, even though a platelet count was not present in this study, our results can 
reliably be interpreted in the light of previous findings of previous findings since the majority 
of studies on this subject did not include platelet count as a confounder.  
Besides the effect of platelets, one should also note that our ELISA kit could not distinguish 
between pro-BDNF and mature BDNF. Differential associations between the two have been 
described with regard to depression (Yoshida et al. 2012). Despite the fact that we could 
not relate low BDNF levels to specific symptoms or symptom profiles, we cannot exclude 
the possibility that differences in the ratio pro-BDNF : mature BDNF could still be present. 
Also, residual confounding due to the level of physical activity performed directly before 
blood withdrawal (e.g. cycling to the hospital) could have occurred, as we did not have that 
information. However, we have analyses the effect of the general level of physical activity in 
our sample before and concluded that physical activity was not related to serum BDNF levels 
(Bus et al. 2011) and thus by definition cannot be a confounder.
 To sum up, we conclude that lower serum BDNF levels are a general feature of depression 
that cannot be explained by the heterogeneity due to specific symptoms or symptom 
profiles within depression. 
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Abstract
Whereas animal models indicate that Brain-Derived Neurotrophic Factor (BDNF) plays 
a role in anxiety-related behavior, little is known about BDNF in patients with an anxiety 
disorder. We therefore tested the hypothesis that serum BDNF concentrations are low in 
patients with an anxiety disorder as compared to healthy controls. We further examined the 
associations of gender and some of the clinical characteristics of anxiety with serum BDNF 
concentrations. Hereto, serum BDNF concentrations were determined in 393 unmedicated 
patients with social anxiety disorder, panic disorder, agoraphobia, and generalized anxiety 
disorder (66.7% females) and in 382 healthy controls (62.0% females). Overall, there were 
no differences in BDNF concentrations among patients and controls, regardless of type of 
anxiety disorder. Analyses stratified by gender, however, revealed that female patients had 
lower concentrations of BDNF relative to female controls (P < 0.05, effect size (Cohen’s d) = 
0.19), which was stronger in female patients with > 1 anxiety disorder (P < 0.01, d = 0.32). 
BDNF concentrations were similar among male patients and male controls and unrelated to 
the clinical characteristics of anxiety. Our results mirror preclinical findings indicating that 
gender plays a role in the association between BDNF and anxiety and suggest that BDNF 
might be involved in the pathophysiology of anxiety in women.
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Introduction
Brain-derived neurotrophic factor (BDNF), a neurotrophin that regulates neuronal survival 
and plasticity (Bramham and Messaoudi 2005), has been attracting growing attention in 
relation to major depressive disorder. The neurotrophin hypothesis of depression predicts 
that aberrant support by BDNF is associated with neuronal atrophy and an increased risk 
of depression (Duman et al., 1997; Duman and Monteggia 2006). Consistent with this 
neurobiological concept on depression are the replicated findings that BDNF concentrations 
are low in central and peripheral tissues during a depressive episode (Dwivedi et al., 2003; 
Molendijk et al., 2010). Depression is often accompanied by anxiety and it is believed that 
these disorders share similarities in their etiology and pathophysiology (Kendler et al., 1992, 
1995; Klaassen et al., 1998; Maron et al., 2004; David et al., 2009). Therefore, some authors 
sought to extend the neurotrophin hypothesis of depression to the anxiety disorders. The 
first attempts to investigate the link between BDNF and anxiety used rodent models for 
anxiety-like behavior. Chen et al. (2006) for example genetically manipulated male mice so 
that the secretion of BDNF from neurons got depleted, which was associated with behavior 
that resembled human anxiety. Findings of Monteggia et al. (2007) on the other hand, seem 
to indicate that the conditional knockout of BDNF is associated with decreased anxiety-like 
behaviour in female mice, while having no effect on anxiogenic behavior in male mice. Finally, 
Govindarajan et al. (2006) reported that an enhanced expression of BDNF had a facilitatory 
effect on anxiety-like behavior in male mice. Thus, these data, although intriguing, remain 
inconclusive with regard to whether the neurotrophin hypothesis also applies to anxiety 
like-behavior. However, the data do support sex differences with regard to the association 
between BDNF and anxiety-like behavior. Data on BDNF protein concentrations in humans 
with an anxiety disorder is limited to two relatively small-scale studies in patients with 
panic disorder. The evidence from these studies is conflicting. The first of these studies 
found similar BDNF concentrations in 42 patients with panic disorder as compared to 31 
controls (Kobayashi et al., 2005), whereas the second found lower BDNF concentrations in 
12 patients with panic disorder as compared to 12 controls (Strohle et al., 2010). Data on the 
associations between BDNF and other anxiety disorders than panic disorder, such as social 
anxiety disorder or generalized anxiety disorder, are not available. Such data, however, 
are relevant because it could increase our understanding of the pathophysiology that may 
underlie anxiety (Martinowich et al., 2007). Here we addressed this important issue and 
determined serum BDNF concentrations in 393 unmedicated patients (66.7% females) with 
social anxiety disorder, panic disorder, agoraphobia, and generalized anxiety disorder, or a 
combination of these disorders and in 382 healthy controls (62.0% females). All patients 
were currently free of depression. We tested the hypothesis that serum BDNF concentrations 
are low in patients with an anxiety disorder as compared to controls in analyses that were 
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controlled for a range of demographical and behavioral confounders. We further performed 
analyses on gender differences with regard to serum BDNF concentrations. Finally, in our 
patient sample, we tested whether and to what extent the type of anxiety disorder, the 
severity of anxiety, the chronicity of anxiety, the age at onset of anxiety, and having had 
MDD were related to serum BDNF concentrations.
Methods
Study population
The data analyzed are from the Netherlands Study of Depression and Anxiety (NESDA; see 
Penninx et al., 2008 for an overview). Briefly, the NESDA is a prospective cohort study on 
2,981 persons (66.4% female, aged 18 through 65) who were recruited in specialized mental 
health care, primary care, and in the general population. Included in NESDA were persons 
with a current or a remitted anxiety and/or mood disorder and persons without a lifetime 
diagnosis of an anxiety or mood disorder. Persons with a psychotic, bipolar, obsessive–
compulsive or severe addiction disorder were not eligible. Diagnoses of anxiety disorders 
(i.e., Social Anxiety Disorder (SAD), Panic Disorder (PD), Generalized Anxiety Disorder (GAD), 
and Agoraphobia (Agr), and depressive disorders (i.e., major and minor depressive disorder 
and dysthymia) were determined on the basis of responses to the Composite International 
Diagnostic Interview 2.1 (CIDI) life-time version (Wittchen et al., 1991) according to the 
criteria set forth in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
(DSM-IV; APA 1994). The CIDI is a commonly used diagnostic instrument and has a high 
reliability (Wacker et al., 2006) and validity (Wittchen et al., 1991). At baseline, participants 
also underwent a medical examination and provided blood samples. All subjects gave 
written informed consent for the study that was approved by the Ethical Committees of the 
participating institutes. The sample that was examined here consisted of NESDA participants 
who were diagnosed with PD, SAD, Agr, GAD, or a combination of these disorders within 
the last 6 months and of healthy controls. To allow a study on the association of BDNF with 
anxiety without the confounding effects of depression and psychotrophic medication use 
(associations that our group previously confirmed, see Molendijk et al., 2010) we selected 
patients who were currently free of depression and who were untreated with anxiolytics 
(ATC code N05B) and antidepressants (ATC codes N05B, N06A, and N06AX; WHO 2010) and 
St John’s Wort. Healthy controls were eligible for inclusion if they were free of life-time 
anxiety and mood disorders, not at high risk for these disorders because of a documented 
family history of these illnesses, and if they scored low on Beck’s Anxiety Inventory (BAI; < 
10; Beck et al., 1988) and on the Inventory of Depressive Symptoms (IDS; < 14; Rush et al., 
1996). We included a total of 393 patients and 382 lifetime healthy controls.
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BDNF protein measurements
Serum samples were obtained before 10:00 h after an overnight fast and stored at –85 C˚. 
Serum BDNF protein concentrations were measured, in duplicate, using the Emax Immuno 
Assay system from Promega according to the manufacturer ‘ s protocol (Madison, WI, 
USA) by one technician who was blind to clinical diagnoses. Measurement procedures are 
described in detail elsewhere (Bus et al., 2011). In brief, serum samples were diluted 100 
times, and the resulting absorbency was read in duplicate using a Bio-Rad (Hercules, CA, 
USA) Benchmark microplate reader at 450 nm. The intra- and inter-assay coefficients of 
variation were within 3 and 9% respectively.
Clinical characteristics
Four clinical characteristics were examined with regard to their association with serum BDNF 
concentrations. These included the severity of anxiety symptoms, the chronicity of anxiety, 
the age at onset of anxiety, and a history of MDD. Continuous scores based on BAI (Beck et 
al., 1988) were used as a measure for the severity of anxiety symptoms. BAI is a 21-item self-
report measure that has good validity (Kabacoff et al., 1997) and test–retest reliability (Beck 
et al., 1988). The measure for the chronicity of anxiety was based on the life chart interview, 
a commonly used method to describe the course of psychopathology (Lyketos et al., 1994). 
The life chart refreshes memory by determining life events that occurred during the last 4 
years and based on these “memory anchors” subsequently assesses the presence of anxiety 
symptoms during this interval. This yields a score in the range 0 – 48 months with avoidance 
behavior and/or panic attacks during the past 4 years. The CIDI interview (Wittchen et al., 
1991) served as source of information on the age at onset of anxiety (i.e., the age in years 
when the first episode of anxiety occurred) and on the presence of a depressive episode in 
the past (> 6 months ago).
Covariates
Previously we described that age, body mass index (BMI), smoking, alcohol intake, physical 
activity, time of the day of blood draw (in minutes from 06:00 h), and number of months of 
serum storage are associated with serum BDNF concentrations (Bus et al., 2010; Molendijk et 
al., 2010). Therefore, we took the possible confounding role of these variables into account 
by including them as covariates in all analyses. Data on age, BMI (weight/height2), smoking 
(dichotomized as smoker versus non smoker), and alcohol use (coded as non-drinker, 0–1 
units a day, 1–2 units a day, and > 2 units a day) were collected using standard methods 
(Penninx et al., 2008). Information on physical activity was gathered using the international 
physical activity questionnaire (Craig et al., 2003) and expressed as number of met-minutes 
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(i.e., the ratio of the amount of energy expenditure during activity to the energy expenditure 
at rest). Together, this set of variables will be referred to as the set of basic covariates.
Statistical analysis
Demographical and clinical characteristics between patients and controls were compared 
using analyses of variance and Students t-tests for continuous data and χ2 tests for categorical 
data. 
Analysis of variance (ANOVA) with correction for the set of basic covariates was performed 
to assess differences in serum BDNF concentrations between all patients with an anxiety 
disorder and healthy controls. This analysis was repeated with diagnosis and gender as 
factors (2 times 2 ANOVA: any anxiety diagnosis versus controls and gender) to explore 
whether serum BDNF concentrations were comparable among female and male patients and 
controls and to test a possible interaction between diagnosis and gender. Next, a multiple 
linear regression analysis was performed to investigate whether serum BDNF concentrations 
differed between the subtypes of anxiety diagnoses (i.e., SAD, PD, Agr, GAD, or > 1 anxiety 
disorders) and controls. In this analysis the set of basic covariates was entered in a first step 
of regression and dummy variables coding for the presence of each of the anxiety disorders 
were entered in a second step. The control group served as reference category. 
In the patient sample, a regression analysis, corrected for the basic covariates, was 
performed to assess whether serum BDNF concentrations were associated to the severity-, 
the chronicity-, and the age at onset of anxiety and a history of a depressive episode. 
Computations were performed in SPSS 18.0 (Chicago, IL). A P-value of < 0.05 (two-tailed) 
was considered as the threshold for statistical significance. Effect sizes on between-group 
comparisons were presented as standardized Cohen’s d (Cohen 1988). Standardized 
regression weights (β values) were used as an index of the strength and the direction of the 
associations that were obtained in the regression analyses. Tolerance of the predictors and 
normality of error variances was verified in all regression models.
Results
Sociodemographic and clinical characteristics
Table 7.1 displays the demographical and clinical characteristics of patients and controls. 
Patients were on average younger, received fewer years of education, and were more likely 
to smoke and to use alcohol as compared to controls. 
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Table 7.1. 
Demographic and clinical characteristics (mean ± standard deviation or percentages) by 
diagnosis and gender
            Patients (n = 393) Controls (n = 382) P-value
Female
(n = 262)
Male
(n =  131)
Female
(n = 237)
Male
(n = 151)
Age 40.1 ± 13.2 43.1 ± 12.9 44.1 ± 12.3 48.3 ± 11.9 < .001 a, b, c, d
Education (years) 12.0 ± 3.2 12.2 ± 3.3 13.3 ± 3.2 13.5 ± 3.5 < .001 c, d
Body Mass Index 24.7 ± 5.0 25.9 ± 4.4 24.8 ± 4.8 26.3 ± 4.1 .41    a, b
Smoker (%) 39.8 36.5 14.1 20.1 < .001 a, c, c
Physical activity 1 3.6 ± 2.9 3.8 ± 3.4 3.8 ± 2.9 3.8 ± 3.2 .94
Alcohol Use
Non-drinker (%) 51.3 31.9 60.5 48.2 < .01    a, b, c, d
Drinker 1-2 units a day (%) 45.5 55.7 38.5 46.8 < .01    a, b, c, d
Drinker > 2 units a day (%) 3.2 12.4 1.0 5.0 < .01   a, b, d
Social anxiety disorder (%) 52.2 48.9 NA NA .47
Panic disorder 2 (%) 46.2 38.9 NA NA .17
Generalized anxiety   (%) 17.6 22.1 NA NA .27
Agoraphobia (%) 17.2 14.5 NA NA .34
> 1 anxiety disorder (%) 17.6 22.1 NA NA .12
Anxiety characteristics
Anxiety severity, BAI 15.2 ± 9.3 12.4 ± 8.8 2.7 ± 2.9 1.6 ± 2.2 < .001 a, b, c, d
Age at onset of anxiety 20.1 ± 12.6 21.9 ± 13.3 NA NA .15
Chronicity of  anxiety 3 22.6 ± 20.1 20.6 ± 20.2 NA NA .12
History of depression (%) 45.0 32.1 NA NA < .01
BDNF (ng/ml) 8.9 ± 3.2 9.9 ± 3.4 9.5 ± 3.2 9.5 ± 3.1 < .05    b, c
Abbreviations: BAI; Beck’s Anxiety Inventory, BDNF: Brain-Derived Neurotrophic Factor
1 Mean met-minutes (i.e., ratio of energy expenditure during activity to energy expenditure at rest)
2  Percentages do not add up to 100% due to  comorbidity among the anxiety disorders.
3  Number of months with anxiety symptoms in the past 4 years
4  Mean BDNF levels, corrected for the basic covariates (see Method section)
a Indicates a statistical significant difference (P < .05) between female and male controls
b Indicates a statistical significant difference (P < .05) between female and male patients
c Indicates a statistical significant difference (P < .05) between female controls and female patients
d Indicates a statistical significant difference (P < .05) between male controls and male patients
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Serum BDNF concentrations in patients and controls
ANOVA (any anxiety diagnosis versus controls) revealed no main effect of diagnosis (mean 
BDNF anxiety = 9.31, SD = 3.38 versus healthy controls = 9.49, SD = 3.18, P = 0.49). This 
analysis was repeated with gender as additional factor (2 times 2 ANOVA: any anxiety 
diagnosis versus controls times gender) to explore whether serum BDNF concentrations 
were comparable among female and male patients and controls and to test an interaction 
between diagnosis and gender. Adding the factor gender to the analysis revealed a 
diagnosis-gender interaction (F 
1,754
 = 4.02, P = 0.05) apart from a main effect of gender (F 
1,753
 = 4.24, P = 0.05), with males having higher serum BDNF concentrations than females. 
Pair-wise comparisons on least square differences revealed that female patients had lower 
concentrations of BDNF (mean = 8.90, SD = 3.24) relative to female controls (mean BDNF 
= 9.49, SD = 3.20; t 
485
 = 2.02, P = 0.05, d = 0.19) and to male patients (mean BDNF = 9.94, 
SD = 3.44; t 
376
 = 3.16, P = 0.01, d = 0.30). Male controls had BDNF concentrations (mean = 
9.51, SD = 3.10) that were comparable to those of female controls (P = 0.95) and to male 
patients (P = 0.28). Importantly, possible confounds that might have had occurred because 
of between-group differences in age, educational attainment, smoking, and alcohol use 
were statistically controlled for. Mean corrected BDNF concentrations are plotted in Figure 
7.1 for persons with an anxiety disorder and healthy controls by gender.
Figure 7.1. 
Mean serum BDNF concentrations by diagnosis and gender
Serum BDNF concentrations are low in female patients with an anxiety disorder as compared with 
female controls (A: d = 0.19) and male patients with an anxiety disorder (B: d = 0.30).
The diagnosis-gender interaction effect is significant at P < .05. 
Error bars reflect the SEM.
* Denotes statistical significance at P < 0.05. 
** Denotes statistical significance at P < 0.01.
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The role of gender (indicated by the main effect of gender and the diagnosis–gender 
interaction) was ascertained by modeling all subsequent analyses separately for female and 
male subjects as well as for the whole sample. Using multivariable regression analyses, with 
correction for the basic covariates, we investigated whether BDNF concentrations differed 
between the subtypes of anxiety diagnoses (i.e., SAD, PD, Agr, GAD, or > 1 anxiety disorder) 
versus healthy controls. Tolerance of the predictors was close to 1 (range: 0.91 – 0.97), 
indicating no redundancy among the predictors. Furthermore, error variances were normally 
distributed. Overall, there were no differences in serum BDNF concentrations between each 
of the types of anxiety diagnoses versus controls (see Table 7.2). In analyses stratified for 
gender it appeared that BDNF concentrations were low in female patients with > 1 anxiety 
diagnosis as compared to female controls (P < 0.05). BDNF concentrations of male patients 
with > 1 anxiety diagnosis, instead, were somewhat higher as compared to male controls (P 
= 0.10). The differences among female patients and female controls and among female and 
male patients in serum BDNF concentrations, as they were found in analysis of covariance, 
thus were largely driven by patients who had > 1 anxiety diagnosis. Indeed, effect sizes for 
the comparison of corrected BDNF concentrations among female patients versus female 
controls (d = 0.19) became larger when comparing BDNF concentrations of female patients 
with > 1 anxiety diagnosis versus female controls (d = 0.32). Similarly, the difference among 
female and male patients (d = 0.30) also became more apparent when comparing BDNF 
concentrations of female patients with > 1 anxiety diagnosis versus male patients with > 1 
anxiety diagnosis (d = 0.66). 
Additional regression analyses, corrected for the set of basic covariates were run to elucidate 
whether variation in some of the clinical characteristics of anxiety or a history of depression 
Table 7.2. 
Results of univariable correlation and multivariable regression analyses on serum BDNF 
levels in patients with an anxiety disorder contrasted versus healthy controls (n = 775)
   Whole sample (n = 393)           Female (n = 262)          Male (n = 131)
r 1 B ± SEM ß r 1 B ± SEM ß r 1 B ± SEM ß
  Social phobia  -.04  -0.28 ± 0.27  -0.04   -.08*  0.78 ± 0.54   0.10    .03   0.11 ± 0.48   0.02
  Panic disorder   .02   0.14 ± 0.30  -0.02    .03  0.50 ± 0.53   0.07    .12*   0.77 ± 0.52   0.09
  Agoraphobia   .01  -0.16 ± 0.44   0.01   -.02  0.62 ± 0.72   0.06    .06   0.64 ± 0.79   0.05
  Generalized anxiety  -.01  -0.01 ± 0.40  -0.01   -.03  0.19 ± 0.81   0.02    .04   0.40 ± 0.64   0.04
1 Spearman’s rho with variables coded as: 1 = not present, 2 = present.
* Statistical significance at P < .05
Note. The healthy controls served as the reference category in the multivariable model. B’s and ß’s 
thus represent the association of the specific anxiety disorders versus having no anxiety disorder
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could account for variation in serum BDNF concentrations. The clinical characteristics 
correlated among each other (ranging from –0.04 to 0.28), yet the tolerance of the individual 
predictors was close to 1 (range: 0.80 to 0.98) indicating no redundancy among the 
predictors. Furthermore, error variances were normally distributed. The regression showed 
no association of the severity and chronicity of anxiety, and having had an episode of major 
depression with serum BDNF concentrations (see Table 7.3). Age at onset of anxiety was 
positively associated with serum BDNF in univariable analyses, which seemed to be largely 
driven by the male patients in the sample (see Table 7.3). However, also in male patients 
this association did not reach full statistical significance and in multivariable analyses only a 
trend-like finding (P = 0.09) was observed. Finally, the difference between female patients 
and male patients in serum BDNF concentrations was observed in all regression models. 
Hence the gender difference in serum BDNF concentrations could not be attributed to 
between-gender differences in the demographical, behavioral, and clinical variables on 
which we focused in the current study.
Table 7.3. 
Results of univariable correlation and multivariable regression analyses on the association 
of the clinical facets of anxiety with serum BDNF levels in patients with an anxiety disorder 
(n = 393)
   Whole sample (n = 393)           Female (n = 262)          Male (n = 131)
r 1 B ± SEM ß r 1 B ± SEM ß r 1 B ± SEM ß
Anxiety characteristics 1
  Anxiety severity  -.01  -0.01 ± 0.02  -0.01   -.01 -0.01 ± 0.02  -0.02   .07    0.01 ± 0.04   0.02
  Age at onset   .11*   0.02 ± 0.02   0.06    .06 -0.01 ± 0.02  -0.02   .16*    0.06 ± 0.03   0.22*
  Chronicity of anxiety   .07   0.02 ± 0.01   0.09    .06  0.01 ± 0.01   0.08   .09    0.01 ± 0.02   0.06
  >1 anxiety disorder 2  -.07  -0.02 ± 0.41  -0.05   -.12* -0.84 ± 0.01  -0.12†   .11    0.98 ± 0.81   0.12
  History of depression 2  -.03  -0.02 ± 0.35  -0.02     .01  0.01 ± 0.08   0.01  -.07  -0.05 ± 0.15  -0.03
1 Pearson’s r when continuous variables are involved and Spearman’s rho if dichotomous are involved
2  Dichotomous variables are coded as: 1 = not present, 2 = present
†  Indicates a trend at P = .07. * Statistical significance at P < .05
Discussion 
The primary goal of this study was to test the hypothesis that serum BDNF concentrations 
are low in patients with an anxiety disorder as compared to healthy controls. Our results, 
controlled for a range of demographical and behavioral variables, did not confirm this 
hypothesis as overall no differences between patients with an anxiety disorder (i.e., social 
anxiety disorder, panic disorder, agoraphobia, and generalized anxiety disorder) and 
healthy controls were found in the amount of BDNF in blood serum. Given these data, it 
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seems unlikely that BDNF is involved in the pathophysiology of anxiety disorders per se. 
Nevertheless, additional analyses on gender differences in serum BDNF concentrations 
revealed that female patients with an anxiety disorder had low serum BDNF concentrations 
as compared to female controls and to male patients. BDNF concentrations in male patients 
tended to be slightly higher as compared to male controls. BDNF concentrations among 
female and male controls were similar. Thus, our gender specific finding, showing lower 
concentrations of BDNF only in female and not in male patients with an anxiety disorder, 
might point in the direction that BDNF is related to the pathophysiology of anxiety in female 
but not in male patients. Other than the here reported data, very little is known on the 
relation between BDNF and human anxiety. As referred to in the introduction, to date, only 
two studies addressed this issue and these studies present conflicting results. Kobayashi 
et al. (2005) found no differences in serum BDNF concentrations between patients with 
panic disorder and healthy control subjects. Our analyses that were run in the whole sample 
confirmed this finding. Strohle et al. (2010) on the other hand did find lower concentrations 
of BDNF in patients with panic disorder as compared to healthy control subjects. The sample 
that was studied by Strohle et al. however consisted mostly of females (75%). Therefore it 
could be that the large proportion of females drove the results that were reported in this 
particular paper. 
Interestingly, our findings are in agreement with the observation that anxiety in female mice 
is more susceptible to changes in BDNF than in males (Monteggia et al., 2007). Of note is 
that the methods that were used to manipulate BDNF expression in these preclinical studies 
were rigorous (e.g., a complete knockout or ~ 10-fold over-expression of BDNF; Govindarajan 
et al., 2006; Monteggia et al., 2007). Therefore, the outcomes of these studies might lack 
the necessary ecological validity to be directly comparable to the outcomes of studies using 
human subjects (Groves 2008). However, our gender-specific findings also compare well 
with some studies in patients with depressive disorders showing lower concentrations of 
BDNF in female depressed patients as compared to male depressed patients (Karege et al., 
2002a; Huang et al., 2008). The origins of our gender specific findings are unknown. Here, 
and also in a previous study on depressed subjects (Molendijk et al., 2010) we found that 
the differences in serum BDNF concentrations between female and male patients were not 
driven by demographical (e.g., age), behavioral (e.g., smoking), or clinical (e.g., severity) 
variables. In the current study, we further found that the difference between female and 
male patients could not be attributed to a specific subtype of anxiety. A general deduction 
from this, and from our finding that serum BDNF concentrations are similar among female 
and male controls, is that the origins of our gender-specific findings may lie in a female 
specific associate of anxiety. One interesting candidate that might serve as an explanation 
for our gender specific findings is an explanation in terms of alternations in the expression 
of the ovarian hormone estrogen in females during the state of anxiety. The expression of 
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estrogen typically is low in females with an anxiety disorder (Seeman, 1997; Almeida et al., 
2005; Walf and Frye, 2006) and this might be of relevance here since estrogen is a signaling 
molecule upstream of BDNF that triggers the expression of BDNF (Scharfman and MacLusky, 
2004; Begliuomini et al., 2007). Furthermore, estrogen has been shown to have therapeutic 
effects in psychiatric conditions such as major depression and schizophrenia (see for 
example Kulkarni et al., 2008; Young and Korszun, 2010), disorders in which peripheral BDNF 
concentrations also are low, as confirmed by recent meta-analyses (Sen et al., 2008; Green 
et al., 2010). Therefore, the interaction of estrogen with BDNF might be of importance in our 
understanding of low BDNF concentrations in female patients in general. 
In addition to gender-specific findings we found that serum BDNF concentrations are similar 
across the subtypes of anxiety disorders and thus peripheral BDNF measurements do not 
have the specificity to categorize anxiety disorders. Furthermore, it should be noted that 
peripheral BDNF measurements lack specificity to categorize psychiatric disorders outside 
the spectrum of anxiety (see also Gass and Hellweg, 2010 for a review) as low concentrations 
of BDNF have been shown in depression (Karege et al., 2002a), schizophrenia (Green et al., 
2010), and eating disorders (Nakazato et al., 2003). Interestingly, the number of anxiety 
disorder, on the other hand, did show associations with serum BDNF concentrations. In female 
patients serum BDNF concentrations tended to decrease as the number of anxiety disorders 
increased, whereas in male patients serum BDNF concentrations tended to increase as the 
number of anxiety disorders increased. Interestingly, some studies using predominantly 
female patients have shown a worse clinical course and a greater impairment in patients 
who suffer from multiple anxiety disorders (Bruce et al., 2005; Kroenke et al., 2007) and 
thus having multiple anxiety disorders might be considered an indication of anxiety severity. 
However, our findings that a higher symptom severity of anxiety or a more chronic course 
do not go along with lower concentrations of BDNF seems to suggest that no associations 
exist between BDNF and the severity of anxiety. In addition, a later age at anxiety onset 
appeared to be associated with higher concentrations of BDNF, particularly in male patients. 
However, in multivariate analyses this association did not reach full statistical significance. 
Finally, we found a history of depression to be unrelated to serum BDNF concentrations in 
patients with a current anxiety disorder, which is in line with our previous finding that BDNF 
concentrations are low during a depressive episode but return to normal in the course of 
depression remission (Molendijk et al., 2010). 
 A salient strength of our study is that we report on a large sample of various anxiety disorders 
that allowed for analyses stratified by gender. Moreover, all analyses were controlled for 
possible confounding effects of various demographical and behavioral variables, showing 
that the current findings could not be explained by such factors. Moreover, we could 
eliminate the confounding effects of depression and the use of psychotrophic medication. 
Thus, we believe that our results advance the understanding of the role of BDNF in anxiety. 
Gender specific associations of serum BDNF concentrations in anxiety
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Notwithstanding this, we do wish to emphasize some limitations of our study. First, we 
evaluated correlative associations and therefore we do not know whether our main 
finding of low concentrations of BDNF in female patients with an anxiety disorder are 
causally involved in anxiety or whether they are merely a consequence of being anxious. 
Furthermore, although some between-group differences in the current study reached 
statistical significance, the effect sizes on these associations typically were small leading 
to the question whether or not our findings are of any clinical relevance. Yet another 
limitation might be that we studied easily accessible serum BDNF concentrations and can 
only assume that these measurements mirror the amount of BDNF in the brain (Sartorius 
et al., 2009; Klein et al., 2010). This, however, only is an assumption since there are many 
possible other sources of BDNF in blood serum (Karege et al., 2002b). Given that especially 
platelets constitute a source of peripheral BDNF concentrations, it might be worthwhile to 
control for platelet count in future studies on between-group differences in serum BDNF 
concentrations (Karege et al., 2005; Ziegenhorn et al., 2007). Finally, we studied BDNF 
concentrations in isolation of other hormones, neurotransmitters, and receptors that might 
interact with BDNF and as such could have explained the associations that we observed 
(Kapczinski et al., 2010). 
In sum, this large-scale study in patients with anxiety disorders shows that serum BDNF 
concentrations are low in female patients with an anxiety disorder but not in male patients 
with an anxiety disorder. These results were not driven by differences in demographical, 
behavioral, or clinical variables and thus suggest that low concentrations of BDNF might 
be specifically related to the pathophysiology of anxiety in females. Future research is 
needed to clarify whether these lower concentrations of BDNF in females contribute to 
anxiety or whether they are merely a consequence of having one or more anxiety disorders. 
Furthermore, the clinical significance of our findings requires examination and hereto 
longitudinal studies are needed.
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Abstract
One of the leading neurobiological hypotheses on depression states that decreased 
expression of Brain-Derived Neurotrophic Factor (BDNF) contributes to depression. 
This is supported by consistent findings of low serum BDNF levels  in depressed patients 
compared to non-depressed controls. Whereas it has been generally assumed that this is 
a state characteristic of depression, strong inferences about state or trait effects require 
a longitudinal study design. To investigate the longitudinal association between serum 
BDNF and depression, we measured serum BDNF, (current and past) depression status, 
use of antidepressants, and all potential covariates at baseline and after two years in 1751 
individuals, consisting of patients with an incident (n=153), remitted (n=420) and persistent 
depression (n=310) and non-depressed controls (n=868). We analyzed change/differences 
in serum BDNF across these four groups with analyses of covariance adjusted for covariates 
and baseline BDNF value, together with the effects of starting and stopping antidepressant 
treatment. Our analyses revealed a significant difference for the depression course groups (p 
= .007). Compared to non-depressed controls, persistently depressed and remitted patients 
had a steeper decrease of BDNF levels over time (-1.33 ng/ml (p=.001) and -0.97 ng/ml 
(p=.011), respectively), whereas BDNF reductions in patients with incident depression were 
similar to those in healthy controls. Initiation or discontinuation of antidepressants was not 
associated with BDNF change (p=.72). These findings suggest that BDNF not only contributes 
to depression, but that depression in turn may also contribute to low BDNF.
Chronic depression is associated with a pronounced decrease 
in serum brain-derived neurotrophic factor over time
127
Introduction
According to the neurotrophic hypothesis of depression, stress leads to a lack of neurotrophic 
support, which insufficiency increases the vulnerability to depression (Duman and 
Monteggia, 2006). Depression often presents with a chronic or intermittent course (Penninx 
et al., 2011; Vos et al., 2004). Each recurrence seems to increase the likelihood of further 
recurrences (Kendler et al., 2001), implicating that eventually even small stressors can elicit 
a new episode. Stress-related neurobiological changes may be underlying this ‘kindling’ 
effect (Kendler et al., 2001), so that long-term changes in the stress response of depressed 
patients can be notably different from the state-related changes early in the course of 
depression. However, despite a multitude of papers on the aversive effects of stress on 
neurotrophy, studies on chronic recurrent depression are underrepresented. even though 
long-term changes in the stress response of depressed patients can be notably different 
from the state-related changes early in the course of depression. For instance, there are 
indications that the higher HPA-axis response in depressed patients eventually shifts toward 
a blunted response in chronically depressed patients (Booij et al., 2013). Studies comparing 
first versus recurrent episodes of depression are underrepresented in the literature on the 
neurotrophic hypothesis, however, and it is hence relevant to extend with longer-term 
studies of chronic depression.  
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth 
factors and is involved in the plasticity of neurons in several brain regions. The neurotrophic 
hypothesis is supported by consistent findings of lower serum BDNF concentrations in 
depressed patients compared to non-depressed controls (Molendijk et al., 2013). Recently, 
we addressed the question whether low BDNF is a state or a trait characteristic and showed 
that BDNF was lower in currently depressed patients compared to patients with a remitted 
depression (Molendijk et al., 2011). Based on this result we tentatively concluded that low 
serum BDNF levels are a state characteristic of depression. Nevertheless, it remains unknown 
whether these lower values occurred before the onset of depression, as the neurotrophic 
hypothesis implies, or become lower during the depressed state. In the current study we 
extend our findings with longitudinal data, allowing a comparison of serum BDNF levels 
of in patients with persistent, remitted and incident depression. Longitudinal serum-BDNF 
studies largely consist of open-label medication trials with a 12-week pre-post design, mainly 
confirming that low BDNF is a state rather than a trait characteristic of depression (Molendijk 
et al., 2013). These designs, however, cannot disentangle effects of medication and course. 
To our knowledge, only one study examined fluctuations in serum BDNF levels during the 
natural course of depression, with results showing that BDNF increased with remission and 
decreased again with the recurrence of depression, confirming the hypothesis that low 
BDNF is a state effect (Yoshimura et al., 2013). As that study only included 20 participants 
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that were selected from a larger study based on their clinical course (depressed, remitted 
and relapsed), replication with more patients and different courses is warranted. 
In the current study we therefore investigate the longitudinal association between serum 
BDNF and depression in a large cohort (n=1751). On the basis of the emerging evidence 
regarding state-linked BDNF in depression we hypothesize that BDNF levels will decrease 
when non-depressed individuals go into depression and that levels will increase when 
depressed patients go into remission. Notwithstanding that we are the first to compare 
longitudinal data of persistently depressed patients with data of individuals in a non-
depressed state, our logical expectations would be that BDNF would further decrease in 
persistently depressed patients. 
Materials and Methods
Patients and sample collection 
Patient data were obtained from the Netherlands Study of Depression and Anxiety 
(NESDA), an ongoing longitudinal cohort study on the long-term course and consequences 
of depression and anxiety. Full details on NESDA’s rationale, objectives and protocol are 
described by Penninx et al. (2008). In brief, NESDA is a multi-site naturalistic prospective 
cohort study (N= 2981) aimed at describing the 8-year course and consequences of 
depressive and anxiety disorders and to integrate biological and research paradigms within 
an epidemiological approach. Study participants were recruited from mental health care, 
primary care and the general population to secure different stages of psychopathology, i.e., 
patients with a current or remitted depressive and/or anxiety disorder (78%), and healthy 
controls (22%). Exclusion criteria were insufficient command of the Dutch language or having 
a primary other psychiatric disorder (e.g., psychotic, bipolar, obsessive compulsive or severe 
alcohol use disorder). Current or remitted depressive and anxiety states were established at 
baseline and at a 2-year follow-up using the Composite International Diagnostic Interview 
(CIDI; version 2.1). Collected by specially trained researchers, the data cover a wide range 
of domains, among which are demographics, psychopathology, public health consequences 
of mental disorders, biological and genetic measures. The study was approved by the 
Ethical Review Boards of all participating centers. All participants provided written informed 
consent. 
The present study drew on the NESDA baseline and two-year follow-up data of 1751 
participants who had completed both measurements and fulfilled our criteria (see Figure 
8.1. for details on the selection process), ie., the presence of a major depressive disorder 
at baseline or follow-up. Participant data were divided into four groups (see Results for 
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numbers), with the first, the incident depression group, consisting of patients with a 
6-month diagnosis of major depressive disorder (MDD) at follow-up, but not at baseline. The 
second, the remitted depression group, included patients with a 6-month diagnosis of MDD 
at baseline but not at follow-up. The third, the persistent depression group, incorporated 
patients with a 6-month MDD diagnosis at both baseline and follow-up, while the final 
group comprised non-depressed controls, i.e.,. individuals that had (1) no diagnosis of MDD 
at baseline or follow-up, (2) no current anxiety disorder 6 months preceding baseline or 
follow-up, and (3) no minor depressive episode/dysthymia based on the CIDI interview at 
baseline and follow-up.  
Figure 8.1. 
Flowchart of selection process of study population. 
Antidepressant use
Use of antidepressants was by self-report and checked through container observation. We 
defined antidepressant use as the minimal daily dose as recommended by the World Health 
Organization of selective serotonin reuptake inhibitors (SSRIs) (ATC code N06AB), tricyclic 
antidepressants (TCAs) (ATC code N06AA) and serotonergic and noradrenergic reuptake 
inhibitors (SNRIs) (ATC code N06AF/AX). 
The effect of antidepressants on BDNF levels was estimated by creating four groups 
similar to the depression groups, i.e., ex-users (antidepressant at baseline, not at follow-
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  RemiPed	  
depression	  
(n=420)	  
	  
	  
Persistent	  
depression	  
(n=310)	  
	  
Non-­‐
depressed	  
controls	  
(n=868)	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up, n=128), new users (antidepressant at follow-up, not at baseline, n=78), persistent 
users (antidepressants at baseline and follow-up, n=244), and persistent non-users (no 
antidepressants at either baseline or follow-up, n=1265).
Post-hoc, we extended this categorization by including information on the change in (type 
of) antidepressant usage in terms of continued (non)use, initiation or discontinuation of 
SSRIs, SNRIs, and TCAs, and all possible drug switches. 
Clinical features
Phenotypic characteristics - Depression symptom severity was determined using the 
Inventory of Depressive Symptoms (IDS) (Rush et al., 1996). Age of depression onset 
was established with the CIDI. Additionally, we assessed depression duration, expressed 
as a percentage of the total time “of being depressed,” between the first and the second 
measurement using the life chart method (Lyketsos et al., 1994). The insomnia rating scale 
(IRS) was used as a reliable indicator of sleep disturbances (Levine et al., 2003). Based on the 
CIDI 2.1 interview, comorbid anxiety was considered present when there was a confirmed 
diagnosis in the last six months of a generalized anxiety disorder, a panic disorder (with or 
without agoraphobia) or a social phobia.
Psychological stressors - Childhood abuse was assessed retrospectively using a semi-
structured childhood trauma interview, previously used in the Netherlands Mental Health 
Survey and Incidence study (de Graaf et al., 2004). As a measure for the amount of stress 
between baseline and follow-up the occurrence of 12 stressful life events was assessed using 
the List of Threatening Events Questionnaire (LTE-Q), which has a good test-retest reliability 
and a high agreement with interview-based ratings (Brugha et al., 1985; Brugha et al., 1990). 
Stressful events were divided into positive and negative experiences (e.g., marriage and 
death of a relative, respectively). Answers were coded as the total number of life events. 
BDNF assessment
Blood (50 ml) was extracted from the brachial vein in the morning after an overnight 
fast, processed within an hour and consequently stored at -85 °C. After the assessment 
waves were finalized, both baseline and follow-up samples were measured at the same 
location i.e., the Department of Psychiatry and Neuropsychology at Maastricht University 
Hospital (the Netherlands) using the same assay (Emax ImmunoAssay system (Promega, 
Madison, WI)) according  to the manufacturer’s protocol on both occasions (for details, 
also see Bus et al. (2011 and 2012). Greiner Bio-One high affinity 96-well plates were used 
and the resulting absorbance was read in duplicate at 450nm using a Biorad Benchmark 
microplate reader for baseline samples and a Perkin Elmer 2030 Multireader Victor X3 for 
the follow-up. All baseline and follow-up samples were measured in duplicate with another 
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duplicate containing only buffer on each plate to assess the unspecific absorption binding, 
i.e. background. The (mean) background value was subtracted from all measured values on 
each plate. The background was maximally 50% of the measured absorption of the minimum 
amount of BDNF of the standard curve containing 7.8 pg/ml. The assay sensitivity threshold 
was ascertained at 1.56 ng/ml reflecting the minimum level of BDNF in the serum that could 
be reliably determined. The inter-assay coefficients of variance were determined to range 
from 0.2% to 9.6% at this follow-up compared to 2.9% to 8.1% at baseline. Measures of the 
intra-assay variance in the present follow-up study resulted in coefficients of variance of 
0.53% to 7.5% and 0.0% to 3.1% at baseline. Of note, this is well below the maximum intra-
assay variance of 8.8% as specified by the manufacturer. 
In order to investigate the change in BDNF levels, a variable was created by subtracting the 
baseline from the follow-up value, with a positive resultant value reflecting an increase and 
a negative value a decrease in BDNF. 
Covariates
Based on previous research of the baseline sample, potential variance due to comorbid 
anxiety, age, gender, sample storage time, time of sampling, fasting status at time of 
measurement, smoking behavior and drinking behavior was taken into account (Bus et al., 
2011; Bus et al., 2012). Age and gender were entered into the analyses without further 
changes, but for other covariates we created variables that coded for change. A covariate 
was included for fasting behavior indicating whether a participant had adhered to the 
pretest fasting protocol. Smoking behavior was coded as smokers versus non-smokers. 
The frequency of alcohol use was evaluated by the Alcohol Use Identification Test (AUDIT) 
(Babor et al., 1989), with problematic alcohol use being coded as present when more than 
13 (female participants) or 15 units (male participants) of alcohol a week were consumed. 
Statistical analysis
BDNF levels were normally distributed, but both the baseline (n=15) and the follow-up 
measurement (n= 9) contained several outliers, i.e., levels three standard deviations (SDs) 
above the mean. To prevent results from being driven by these potentially influential cases, 
all BDNF levels exceeding three SDs of the respective mean were trimmed to the +3 SD 
value. Values below the sensitivity threshold (baseline: n=4; follow-up: n=58) were recoded 
to the 1.56 ng/ml level as they are likely to reflect a ‘true’ low level with the exact value 
remaining indeterminable. 
Analyses of variance (ANOVA) and χ2 tests were used to evaluate group differences on 
demographic variables and the covariates. The within-subject correlation between the 
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baseline and follow-up BDNF measures was determined by calculating the Pearson 
coefficient. 
To determine whether a different course of depression would coincide with a difference in 
change in BDNF, analyses of covariance (ANCOVA) were used with the change in BDNF levels 
as the dependent variable the four depression categories and the change in antidepressant 
use as independent variables. Contrasts were calculated for the three depression groups and 
the non-depressed controls. The baseline BDNF value was added as a covariate to correct for 
the potential occurrence of regression to the mean, with all analyses being fully corrected 
for all previously mentioned covariates. As covariates can change within individuals in the 
course of two years and since these changes may influence BDNF, we took possible changes 
in covariates into account by using change variables; for continuous variables we subtracted 
the baseline from the follow-up value and for categorical variables we entered a variable 
that indicated whether participants had moved from one category to another.
The same model was repeated by replacing the antidepressant variable with an extended 
version in which we coded all possible longitudinal changes in antidepressant classes.
Using several multiple linear regression analyses, we further explored the impact of 
phenotypic clinical characteristics and psychosocial stressors on the course of BDNF in 
patient groups where the course of serum BDNF level over the 2-year period significantly 
differed from that obtained for the non-depressed controls. In these models we used change 
in BDNF as the dependent variable. The baseline BDNF value, age, gender, smoking behavior 
and alcohol use were entered as covariates.  For the IDS and IRS sum scores a change 
variable (follow-up value minus baseline value) was used. Dummy variables were created 
to analyze the change in comorbid anxiety. For each clinical characteristic under study, a 
separate model was calculated. Hence a total of 16 multiple linear regression analyses were 
performed. Correcting for multiple comparisons is controversial, with some arguing against 
such procedures because they increase the risk of type II errors (Rothman, 1990). However, 
we have also indicated in the table the p-values that remained significant (p=.0031; i.e. 
0.05/16) following Bonferoni correction for multiple testing (Bland and Altman, 1995). 
All computations were performed with SPSS version 20 (IBM, Chicago, IL, USA). A two-tailed 
α level of 0.05 was used to determine statistical significance.
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Results
Study sample
Of the 1751 participants 153 were categorized in the incident depression group, 420 in the 
remitted depression group, and 310 in the persistent depression group, while 868 were 
classified as non-depressed controls. Of the total sample, 1137 (64.9%) participants were 
women and the mean age was 44.4 (SD 13.3) years. A more detailed overview of our study 
population and depression course group differences in demographics are given in Table 8.1. 
Overall, mean serum BDNF levels were lower at follow-up than at baseline (mean 9.0 ng/ml 
(SD 3.3 ng/ml) versus 7.9 ng/ml (SD 5.1 ng/ml)). Statistically, baseline and follow-up BDNF 
values did not correlate significantly (r=-.04; p=.10).
 
Course of depression and effect of antidepressant change
Longitudinal analyses of covariance, fully adjusted for covariates and regression to mean, 
revealed a significant group difference in the change in BDNF levels (F=4.097; df(3); p=.007) 
for the different courses of depression. 
Post-hoc contrast estimates revealed that BDNF had decreased during the 2-year interval 
in all groups. Compared to the non-depressed controls, the chronically depressed patients 
and the remitted patients showed a steeper decrease in BDNF concentrations over time 
(-1.33 ng/ml (p=.001) and -0.97 ng/ml (p=.011), respectively). Comparison of the incident 
depression group and the non-depressed controls (p=.60) did not yield a significant 
difference. The results are illustrated in Figure 8.2.
No significant differences were found in BDNF changes and (changes in) antidepressant 
use (F=0.441; df(3); p=.72). A further exploration of the effect of the various classes of 
antidepressants on BDNF change revealed that there was no significant group effect 
(F=0.426; df(11); p=.95). When contrasts were calculated comparing each of the possible 
switches between types of antidepressants with subjects who did not use an antidepressant 
at both measurements, no significant results were found either. SSRIs were the most 
frequently used antidepressants in our study and were significantly associated with BDNF 
in the baseline measurement (Molendijk et al., 2011). Therefore we also looked at switches 
to and from SSRIs specifically, but found no significant group effect (F= 0.531; df(5); p=.75).
Clinical features and psychological stressors 
Within the persistent depression group, the BDNF decrease, the steepest of all patient 
groups, was inversely associated with the number of negative life events (β=-.10; p=.03): 
those patients that had experienced more negative life events showed a sharper decrease 
in their serum BDNF levels. Within the same group, patients without a comorbid anxiety 
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Table 8.1. 
Demographic and clinical characteristics
Incident 
depression 
(n=153)
 Remitted 
depression 
(n=420)
Persistent 
depression 
(n=310)
Non-
depressed 
controls 
(n=868)
p
Demographics and covariates
  Age (SD) 44.1 (12.9) 42.9 (12.5) 44.9 (11.9) 44.9 (14.2) .17
  % Female (n) 75.2 (115) 64.3 (270) 65.2 (202) 63.4 (550) .05
  BDNF ng/ml – baseline (SD) 8.85 (3.59) 8.89 (3.25) 9.45 (3.63) 9.02 (3.14) .11
  BDNF ng/ml – follow-up (SD) 8.31 (5.59) 7.49 (5.26) 6.98 (4.04) 8.35 (5.19) <.001
  % with comorbid anxiety – baseline (n) 47.7 (73) 59.8 (251) 67.1 (208) NA <.0011
  % with comorbid anxiety – follow-up (n) 55.6 (85) 30.5 (128) 57.4 (178) NA <.0011
  Days of sample storage – baseline (SD) 1333 (228) 1274 (223) 1268 (220) 1293 (222) .01
  Days of sample storage – follow-up (SD) 1289 (224) 1241 (226) 1236 (220) 1262 (223) .07
  Time of sampling (Minutes after 6am) –  
  baseline (SD)
165 (15) 166 (16) 167 (21) 167 (15) .72
  Time of sampling (Minutes after 6am) –  
  follow-up (SD)
171 (22) 173 (28) 176 (33) 171 (31) .08
  % Adhered to fasting protocol – baseline (n) 99.3 (152) 97.6 (410) 95.5 (296) 96.8 (840) .16
  % Adhered to fasting protocol – follow-up 
(n)
94.8 (145) 92.9 (390) 92.6 (287) 94.4 (819) .65
  % smokers – baseline (n) 40.5 (62) 38.8 (163) 43.5 (135) 29.8 (259) <.001
  % smokers – follow-up (n) 33.3 (51) 33.6 (141) 40.6 (126) 24.1 (209) <.001
  % with problematic alcohol use – baseline 
(n)
5.2 (8) 7.2 (30) 10.0 (31) 3.2 (28) <.001
  % with problematic alcohol use –  
  follow-up (n)
6.5 (10) 5.5 (23) 10.6 (33) 3.8 (33) <.001
  % duration of depressive complaints  
  between baseline and follow-up (SD)
43.1 (31.3) 28.7 (34.1) 54.7 (31.4) 0 (0) <.001
  IDS sum score – baseline (SD) 21.5 (10.1) 28.9 (12.0) 35.1 (12.3) 9.8 (7.8) <.001
  IDS sum score – follow-up (SD) 23.7 (11.4) 17.0 (10.9) 28.5 (12.9) 8.0 (6.7) <.001
Use of antidepressants
  % taking an antidepressant – baseline (n) 21.6 (33) 42.1 (177) 46.5 (144) 4.7 (41) <.001
  % taking an antidepressant – follow-up (n) 30.1 (46) 29.8 (125) 42.9 (133) 4.8 (42) <.001
  % taking an SSRI – baseline (n) 15.7 (24) 29.0 (122) 30.6 (95) 3.6 (31) <.001
  % taking an SSRI – follow-up (n) 21.6 (33) 19.0 (80) 20.6 (64) 3.8 (33) <.001
  % taking an SNRI – baseline (n) 4.6 (7) 7.6 (32) 17.1 (53) 0.6 (5) <.001
  % taking an SNRI – follow-up (n) 3.9 (6) 10.0 (42) 12.3 (38) 0.3 (3) <.001
  % taking a TCA – baseline (n) 2.0 (3) 4.5 (19) 3.9 (12) 0.8 (7) <.001
  % taking a TCA – follow-up (n) 3.9 (6) 4.1 (17) 5.8 (18) 0.6 (5) <.001
1 calculated with the exclusion of the non-depressed control group
Abbreviations: SD: standard deviation, SSRI: selective serotonergic reuptake inhibitor, SNRI: serotoner-
gic and noradrenergic reuptake inhibitor, TCA: tricyclic antidepressant.
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disorder at baseline and follow-up had a significantly sharper decrease in BDNF than their 
peers who had reported an anxiety disorder at follow-up (β=.13; p=.03 for incident anxiety 
and β=.16; p=.002 for persistent anxiety). The other clinical features for this group and all 
features of the remitted patient group yielded non-significant results. Results are shown in 
Table 8.2.
      
Discussion
Main Finding
We found the 2-year decrease in serum BDNF levels to be more profound in the patients 
with persistent and remitted depression than in the non-depressed controls, whereas the 
incident depression group did not differ significantly from the non-depressed controls. 
Changes in the use of antidepressants had not led to significant changes in BDNF levels. The 
occurrence of negative life events was found to be associated with a sharper decrease in 
BDNF in the patients with a persistent depression.
Effect of psychopathology
Previous findings of our group suggested that reduced serum BDNF might be a state rather 
than a trait characteristic (Molendijk et al., 2011). Based on our current results it seems 
difficult to maintain that hypothesis. If BDNF expression indeed reflects state levels of 
Figure 8.2. 
Mean adjusted*** changes in serum BDNF levels from baseline to follow-up for the four 
courses of depression. 
* Denotes a statistical significance at p =.011; ** Denotes a statistical significance at p = .001; ***Adjusted 
for course of depression, gender, age, smoking, alcohol consumption, comorbid anxiety, adherence to 
the pretest fasting protocol, time of blood withdrawal and storage time. Whiskers reflect ± 1 SE. Ab-
breviations: BDNF: Brain-derived neurotrophic factor 
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depression, one would expect to find a decrease in BDNF concentrations with transitions 
from a healthy or remitted state to a depressive state and an increase when depression 
goes into remission. Yet, we did not find that pattern. Hence, we propose the hypothesis 
that low BDNF is characteristic for episodic depression, particularly occurring some time 
after the onset of depression and that in persistently depressed subjects BDNF levels may 
even decrease further. This premise corresponds with findings from neuroimaging studies, 
where in episodic depression lower volumes of the hippocampus, a brain region directly 
influenced by neurotrophic support, are seen, which reduction is more pronounced in 
depressed patients with a longer duration of disease (McKinnon et al., 2009). In addition, 
we found similar reductions in BDNF in remitted patients, which is in line with previous 
findings that being in the early remission phase of depression (1–6 months) versus having a 
current episode is associated with lower serum BDNF levels (Molendijk et al., 2011).  Taken 
together, these findings suggests that depression episodes may contribute to decreases in 
BDNF rather than low BDNF contributing  to depression. However, we do want to point out 
that, unlike our current design, a prospective cohort with participants without a history of 
depression at baseline would be required to truly disentangle the state-trait issues.     
We found chronically depressed patients to exhibit the steepest decline in serum BDNF over 
the course of two years.  Exploring potential factors that might have contributed to these 
results, we found a significant association between the number of negative life events and 
reduced BDNF. As this correlation was not seen in the remitted patients, it seems specific for 
persistent depression. Chronic stress is known to downregulate BDNF expression in the brain 
(Duman and Monteggia, 2006), which in turn renders the brain vulnerable to depression. 
Conversely, BDNF is known to exert an antidepressant effect (Siuciak et al., 1997), even 
when administered peripherally (Schmidt and Duman, 2010). Additionally, an early change 
in peripheral BDNF levels predicts a favorable outcome in depression patients (Dreimuller et 
al., 2012; Tadic et al., 2011; Sen et al., 2008). 
The largest decrease in BDNF was found in persistently depressed patients that had no 
comorbid anxiety disorder. Previous cross-sectional studies reported reduced serum BDNF 
for patients that suffered from an anxiety disorder only (Molendijk et al., 2012) but not for 
depressed patients with a comorbid anxiety disorder (Molendijk et al., 2011), which suggest 
that the strongest effects are found in non comorbid disorders. 
In summary, based on our results it seems plausible to suggest that a persistent decrease in 
serum BDNF, or a deficient upregulation during a depressive episode, underlies the chronicity 
of the disorder. However, due to the naturalistic nature of our data, no inferences can be 
made about causality or the direction of the association. Hence, the alternative hypothesis 
that persistent depression causes a depletion of available BDNF may also hold true.
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Effect of medication
The BDNF-inducing effect of antidepressants has been extensively investigated and 
described (Molendijk et al., 2011; Molendijk et al., 2013; Sen et al., 2008). Collectively, the 
studies suggest an upregulation of peripheral BDNF levels by antidepressants. Although 
some of our subgroup analyses may have been underpowered, even our strongest powered 
results did not show any significant antidepressant-related differences in BDNF levels over 
the course of two years. 
Considering that selection in cross-sectional studies may be confounded by indication and 
open-label treatment studies to date only included short-term follow-up data, our study 
extends previous findings and, by examining antidepressant use to correct for different 
courses in an observational design, we have limited the influence of bias by indication as 
much as possible. 
The rise in BDNF that in the previous studies is often ascribed to the use of antidepressants 
co-occurs with remission of the depressive episode (Molendijk et al., 2013). Yet, our stratified 
analyses did not reveal any significant effects of changes in the type or use of antidepressants, 
not even in the remitted patient group. We accordingly conclude that the effects seen in the 
short-term after starting antidepressant treatment cannot be extrapolated to the longer 
term. This may potentially be attributable to the development of tolerance to the effect 
of antidepressants on neuroplasticity. Medication trials have shown that antidepressants, 
although effective in the short-term, might be less effective as a maintenance drug (Pies 
2012). Along these lines, a translation of our results to clinical practice would then imply 
that the beneficial effect of antidepressants on elevated neuroplasticity may be reduced 
with long-term administration.  
Limitations 
For a proper interpretation of our results some limitations should be addressed. First, one 
should bear in mind that the correlations between baseline and follow-up BDNF levels were 
low, pointing to high between-subjects variability of change in serum BDNF over time, with 
the existence of comorbid anxiety and negative life events possibly contributing to this 
variation to a certain extend. Additionally or alternatively, in light of the small effect sizes, the 
high inter-individual variation may also point to the existence of other relevant subgroups 
than those we investigated. Moreover, BDNF was measured with a two-year interval, which 
limited the possibility to pick up transient changes of BDNF during that interval. Similarly, 
by restricting our study to depression status at the time of measurement, we do not know 
whether patients classified as having a persistent depression might have achieved remission 
followed by a recurrence. Information on the patients’ depression status in the intermediary 
period could only be determined retrospectively, which we considered to be too imprecise. 
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Rather than rendering our current claims on the 2-year changes unreliable, we feel these 
imperfections merely prevented us from interpreting what may have happened in between. 
Furthermore, one should note that, because of the storage of BDNF in platelets (Ziegenhorn 
et al., 2007; Lommatsch et al, 2005; Karege et al., 2005) and the association between 
antidepressant use and platelet count (Lederbogen et al., 2003), the number of platelets 
could influence the serum concentration of BDNF. Yet, even though a platelet count was not 
present in this study, our results can be reliably interpreted in the light of previous findings 
since the majority of studies on this subject did not include platelet count as a confounder.
Conclusion
With our naturalistic cohort study, we are the first to show that a persistent and a remitted 
major depressive disorder are associated with a substantial decline in serum BDNF: the 
decrease in BDNF levels was significantly more pronounced in these groups of patients than 
it was in non-depressed controls. Taken together, these findings suggests that depression 
episodes may contribute to decreases in BDNF rather than low BDNF contributing  to 
depression.
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The aim of the present thesis was to address the validity of peripheral assessments of BDNF 
and the biological role of BDNF in studying depression. First potential confounders were 
identified. Then the association between depression and BDNF was determined and further 
studied in depth by looking at specific symptoms and symptom profiles. Lastly, we have 
looked at the longitudinal association between depression and BDNF. In this chapter the 
results from previous chapters will be summarized, and integratively discussed within the 
context of current scientific literature. In addition some methodological considerations of 
the current scientific work will be discussed. Then the clinical and scientific relevance will be 
discussed. This chapter finishes with recommendations for future research. 
Summary of main findings
What are the main determinants of serum BDNF levels?
In Chapter 2 of this thesis we have looked at potential determinants of serum BDNF levels. 
In a non-depressed sample drawn from the NESDA population, we have found that BDNF 
levels were higher when measurement took place earlier in the day, samples had a shorter 
duration of storage, subjects obeyed the study fasting protocol, and for subjects who live in 
an urban area, do smoke and refrain from drinking alcohol. An interaction was present for 
sex and age, i.e. BDNF levels were higher for older female subjects, whereas no significant 
effect of age was found for men (Chapter 2). As a next step, we tried to replicate these 
findings in the NBS sample. Replication of previous findings was obtained for the effect of 
time of measurement, storage duration and smoking. In this latter analysis we did not find 
a statistically significant effect for excessive alcohol use. An interaction effect was found for 
sex and age in the NBS data as well, yet an opposing effect was seen, i.e., lower BDNF levels 
for older women and, again, no significant age effect for males. The variables fasting and 
urbanicity were not available in the NBS dataset and could therefore not be assessed in our 
replication study (Chapter 3). The effect of body mass index (BMI), metabolic syndrome, 
physical activity and comorbid somatic conditions were not significantly associated with 
serum BDNF levels in both studies. 
Sex differences in serum BDNF levels have been described in many studies. Besides being a 
confounder, sex also appears to be an effect modifier in several associations of BDNF with 
other variables. However, various conflicting results regarding sex-specific effects have 
been shown. For example, Autry et al. (Autry et al., 2009) have shown that low BDNF in a 
stress paradigms leads to depressive behaviour in female mice, but not in male mice. Hence 
they come to the conclusion that the neurotrophic hypothesis of depression is particularly 
true for females. A year later the editor of molecular psychiatry suggests that BDNF in 
depression is a particularly male problem (Licinio and Wong, 2010).  Age and sex were 
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specific determinants that interacted in both samples, although the effects were opposite in 
both samples. Since the age effects were most prominent in women, we further sought an 
explanation for this difference in the effect of menopause. We were able to show that pre-
menopausal women had a positive association with age, while post-menopausal women 
had a negative association, suggesting that hormonal factors might also be associated 
with serum BDNF. Additionally we have shown that the male carriers of the met-allele of 
the val66met polymorphism had higher serum BDNF levels compared to their val-allele 
carrying counterparts (Chapter 4). The Met-allele was generally considered the risk allele 
for depression, but a recent meta-analysis identified an association of depressive disorder 
with the Met-variant of the Val66Met polymorphism in men only (Verhagen et al., 2010)
Our selection process of the potential determinants was based on careful investigation 
of the available literature. However we do not want to implicate that we have described 
all determinants exhaustibly. This is due to several factors. First, some determinants have 
simply never been implicated in relation to BDNF. A good example is the association between 
seasonality and depression (Molendijk et al., 2012), which had never been described before 
the publication of Molendijk et al. Second, not all potential determinants were available 
as a variable in our data. As described above, we have found an effect of menopause on 
BDNF. Preferably we would have analysed the effects of sex hormones and the use of post-
menopausal oral contraceptives. These data were either not available or the sample size 
was too small to give reliable results. Third, the existence of inflated type I error in multiple 
testing prevented us from using the available data to its full extent.
It must be noted that the size of our samples provided a high power to find significant 
effects. Individual effect sizes of the determinants of serum BDNF are rather small, the 
largest β found being .098 for smokers, which makes the explained variance by this variable 
less than 1%. The individual contribution of each determinant to the BDNF level on a 
clinical level is probably limited. Since the effect sizes of psychopathology on BDNF are of 
the same magnitude (Molendijk et al., 2013), for research purposes these findings are still 
relevant. The overarching conclusion is that BDNF is a neurotrophin that is involved in or 
influenced by many biological systems. This means that all potential effects, also those of 
psychopathology, are a small part of the total variance. It is therefore useful to control for 
potential variance in the data due to confounders. Note that many of the determinants 
are also associated with depression, which increases the necessity to control for potential 
confounders in order to get reliable results. 
Taken together, for future studies on serum BDNF levels it seems justified to correct for 
the determinants that exhibited significant results twice (ie., time of sampling, storage 
time, age, sex and smoking). Furthermore, it seems wise to still consider including non-
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replicated variables and variables with negative results as potential confounders. Reasons 
for this are the existence of conflicting results in literature. For example, physical activity 
has been extensively described as a significant determinant of serum BDNF (de Almeida 
et al., 2013; Grassi-Oliveira et al., 2008; Nofuji et al., 2008; Russo-Neustadt et al., 2000). 
Another reason is the potentially interacting effect of psychopathology with determinants. 
This would implicate that some determinants would render negative results in a population 
without depression, but be meaningful determinants in the context of a depressed sample. 
An example is the significant association between BMI and serum BDNF in a selection of 
depressed subjects in the NESDA data, and the absence of an effect for smoking in the same 
selection (Chapter 5). When a priori selection of covariates fails due to absent or conflicting 
results in literature a data driven approach might be necessary, of which a bootstrapping 
method is most preferable (Budtz-Jorgensen et al., 2007). 
Is low BDNF associated with depression?
In this thesis we have shown that BDNF associated with depression severity in a population 
sample (Chapter 3). Next, we have shown that significantly lower BDNF levels are present in 
subjects with a current depression and that subjects with a remitted depression have BDNF 
levels that are comparable to healthy controls (Chapter 5). In addition, in Chapter 8 we have 
found that over time a decrease in BDNF was particularly present in patients with a high 
burden, i.e. having a recurring or persistent depression. Besides the implications for our 
view on the role of BDNF in depression, I will discuss some methodological aspects below. 
Our studies have made substantial contributions to the literature by their large sample size 
and approach to correct for all potential confounders we had previously identified. With 
this strategy we confirmed the notion that depressed subjects have low BDNF levels and 
therefore strengthened the evidence. The publication of many additional studies on this 
subject has recently led to the publication of a new meta-analysis addressing the question 
whether the cumulative evidence still proves lower BDNF levels in depressed subjects 
(Molendijk et al., 2013). The pooled effect size revealed a significant yet small effect (Cohen’s 
d = -0.71). However a large between-study heterogeneity was found, which correlated 
significantly with sample size and year of publication, with larger samples and more 
recently published findings being associated with smaller between-group differences. Taken 
together, this can indicate publication bias. Authors should therefore also be encouraged 
to publish their negative results. Further research would be required to give a definitive 
answer. Nevertheless, some other explanations can be put forward for conflicting results.
First, commercial ELISA kit, as used most BDNF studies to date, cannot differentiate between 
mature BDNF and pro-BDNF. Only recently, for the first time, new techniques have made it 
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possible to measure mature BDNF and pro-BDNF separately. It was shown that pro-BDNF 
levels are elevated in major depression and mature BDNF levels are decreased (Zhou et al., 
2013). This is in line with previous literature describing a detrimental effect of pro-BDNF 
on brain health due to a decreased neuroplasticity caused by pro-BDNF (Koshimizu et al., 
2010). Ideally, for a proper interpretation of our results we would have taken the level of 
pro-BDNF into account. Despite of a potential elevated pro-BDNF in depressed subjects, 
we have found lower “overall BDNF” in our population. Nevertheless, we can assume that 
taking the disruptive effect of pro-BDNF into account would have led to stronger rather than 
smaller effects.
Second, differences in exposure to certain confounding factors might play an important role. 
Potential confounding was extensively addressed in our studies. Nevertheless, we cannot 
exclude the possibility that additional (undiscovered) confounders might still be present. 
Also other lower powered studies did not have the possibility to correct for many potential 
confounders. Since BDNF expression is decreased by exposure to stress, potential variation 
between studies in stress exposure, such as childhood trauma (Elzinga et al., 2011) and 
stressful life events (Chapter 8), could be an explanation for conflicting results.
Third, BDNF levels in men are influenced by the Val66Met polymorphism (Chapter 4). The 
distribution of the alleles is not equally dispersed among human races. Since the presence 
of the met-allele is considered a risk allele in men, differences in the inclusion of subjects 
from different races could conversely lead to differences in outcome. 
Can lower BDNF levels in depressed subjects be ascribed to specific 
symptoms of depression?
In Chapter 6 we have investigated the contribution of individual symptoms of depression 
and symptom profiles to the serum levels of BDNF.  We conclude that low BDNF in 
depressed subjects cannot be ascribed to specific symptoms of depression. This study was 
based on the hypothesis of differential effects of individual symptoms or symptom clusters 
due to opposing mechanisms of BDNF on different brain regions involved in depression. 
Antidepressant effects of BDNF on the hippocampus are described (Siuciak et al., 1997), 
while conversely pro-depressant effects of BDNF on the ventral tegmental area and nucleus 
accumbens, the brain’s reward circuit involved in anhedonia, have been described (Eisch 
et al., 2003). Interestingly, anhedonia was associated with higher BDNF levels (Chapter 6). 
This result however was based on the absence of anhedonia in only 27 of 577 subjects. 
Further research with a selective recruitment of participants with/without the presence of 
anhedonia is therefore needed.   
The other way around, BDNF is also associated with other psychiatric disorders. The 
significant association of low BDNF in males with anxiety is a striking example (Chapter 7), 
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but other studies have shown several psychiatric conditions being associated with BDNF 
as well (Fernandes et al., 2013). Besides potential confounding effects of related somatic 
conditions in many psychiatric disorders, another potential explanation is that BDNF is a 
general marker for brain health rather than a marker for a specific psychiatric condition. 
Stress is known to reduce the availability of BDNF in blood (Chapter 8 and (Elzinga et al., 
2011)) and brain tissue (Bath et al., 2013). Stress is a general marker that is either caused 
by or causes a myriad of psychiatric disorders. As such, stress-induced low BDNF, resulting 
in reduced neuroplasticity, could serve as the final common pathway of several psychiatric 
disorder. Nevertheless, animal studies have shown that the potent effects of stress on BDNF 
are highly dependent on the form, duration and timing of the stress as well as the sex of the 
recipient and the brain region studied (Bath et al., 2013). 
Are lower BDNF levels in depressed patients a state or a trait characteristic?
The neurotrophic hypothesis of depression suggests that low BDNF levels in depressed 
subjects are a state characteristic rather than a trait characteristic, as it states that a lack of 
neurotrophic support leads to a clinical depression and that this effect is reversible due to 
the influence of antidepressants. Our cross-sectional analyses of the NESDA data (Chapter 
5) partly supported this assumption. Lower BDNF levels are indeed found in those with 
a current depression, but those with a remitted depression exhibited BDNF levels that 
were comparable to the healthy controls. However, these cross-sectional analyses cannot 
provide a definitive answer, as they are merely comparisons between groups rather than 
effects within subjects. In addition, the lowest BDNF levels were seen in early remission as 
compared to late remission. The longitudinal analyses of the data (Chapter 8) could provide 
more insight as this data is particularly suitable to study within-subject changes. In contrast 
to what was found in the cross-sectional analysis, the longitudinal analysis did not confirm 
that depression effects on BDNF are state dependent as BDNF levels decreased in remission. 
Several explanations can be put forward for these seemingly contradicting findings. The 
first explanation might be differences in the reliability of the diagnostic data with respect 
to earlier depressive episodes. In the cross-sectional analysis the diagnosis of a remitted 
depression by definition is established with retrospective information, which is therefore 
vulnerable to recall bias. In the longitudinal analysis recall bias cannot affect the results 
as only current diagnoses are used. A second explanation might be that differences in the 
cross-sectional analysis could have been driven by subsets of patients in some categories. 
In the baseline analysis (Chapter 5), the depression group consists of patients with a long 
history of depression and subjects with a recent onset. In the longitudinal analysis (Chapter 
8) we have found that these two distinct categories differ in their BDNF levels, hence low 
BDNF levels in the depression group at baseline could have been driven by those with a 
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longer duration of depression. It must be noted however, that the additional results in the 
baseline analysis did not reveal an effect for duration of depression. 
Third, lower BDNF levels in depressed subjects might in reality not be a state effect after 
all. It should be noted however that a large proportion of the correlative evidence does not 
point toward this last explanation as pre-post treatment studies have collectively indicated 
that recovery of depression is associated with higher BDNF levels (Sen et al., 2008). 
Taken together, there is ample evidence for a state effect of the association between 
depression and low BDNF. However, our findings provide evidence for a temporal relation 
that is opposite of what is suggested by the neurotrophic hypothesis of depression; low 
BDNF levels follow depression rather than low precede it.  
Nevertheless, this research question is best addressed by assessing whether incident 
depression coincides with a decrease in serum BDNF. Therefore, the sample should be 
free of depression at baseline and BDNF should be measured at baseline when depression 
occurs. However, the amount of subjects needed for such a design would be very large and, 
conversely, thus far no study has been published with this kind of design.
Methodological considerations
Potential limitations of the individual studies have already been discussed in the previous 
chapters. Here, some overarching issues will be discussed. 
Brain versus peripheral BDNF
Since we are primarily interested in brain neuroplasticity, BDNF would preferably have been 
measured directly in the brain. However, in large-scale epidemiological studies assessments 
of biomarkers need to be easily accessible. Our choice to use blood samples, however, poses 
the question whether peripherally measured BDNF is a good proxy for BDNF expression 
in the brain. BDNF crosses the blood-brain barrier by a high capacity, saturable transport 
system (Pan et al., 1998). In animal models, cortical BDNF levels are highly correlated with 
peripheral serum BDNF levels (Karege et al., 2002; Sartorius et al., 2009), but evidence on 
the contrary has been shown as well (Elfving et al., 2010). 
Due to the involvement of BDNF in the vascular and immunological tracts (Donovan et al., 
2000; Ernfors et al., 1990; Esteban et al., 1995; Hiltunen et al., 1996; Kerschensteiner et al., 
1999; Maisonpierre et al., 1990; Maisonpierre et al., 1991; Nemoto et al., 1998; Scarisbrick 
et al., 1993; Yamamoto and Gurney, 1990), peripheral measurements should therefore 
be adequately corrected for potential influence of somatic factors. In this thesis we have 
carefully selected potential confounders (Chapter 2). 
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Nevertheless, even when potential confounders are adequately corrected for, the effect sizes 
presented in this manuscript are relatively small. This suggests that other, unknown, factors 
may play an important role as well. Therefore, inferences about neurotrophin functioning in 
the brain based on research with peripheral measures should always be made with caution. 
Serum versus plasma BDNF
In our study BDNF was measured in serum. Although most studies were confined to serum 
BDNF levels, several studies have measured BDNF in plasma, whole blood or platelets. 
Because of the storage of BDNF in platelets, the concentration of BDNF in serum and plasma 
differs by a factor of 200 (Rosenfeld et al., 1995). As BDNF in platelets does not originate 
from megakaryocytes or other precursor cells of the mature platelet (Fujimura et al., 2002), 
it is likely that most of the BDNF in human platelets is sequestered from blood (Nakahashi et 
al., 2000). Furthermore, BDNF is released by platelets during the clotting process (Rosenfeld 
et al., 1995). This means that differences in platelet functioning, either by their ability to 
release BDNF or sequester BDNF from blood, may result in differences between serum and 
plasma BDNF levels. 
Lower values of BDNF in depressed subjects have been found in both plasma and serum 
(Brunoni et al., 2008). Nevertheless, it has been suggested that low platelet counts are the 
driving factor behind the low serum BDNF levels in depressed patients (Karege et al., 2005), 
which cannot be the case for plasma as plasma does not contain platelets by definition. On 
the other hand, the half-life of plasma BDNF in the blood is estimated to be less than one 
minute (Poduslo and Curran, 1996). Hence, it seems logical to assume that plasma BDNF is 
a reflection of the real time excretion of BDNF into the blood, while serum BDNF in addition 
to the real time excretion also reflects the accumulation of BDNF in the last five to ten days, 
which is the average life-span of a platelet (Dale, 1997). Moreover, the short half-life of 
plasma BDNF makes it unlikely that the BDNF in plasma drawn from the brachial vein is truly 
“brain derived”.
A definite conclusion on which method is preferable depends on the study objectives. For 
psychiatric research, I would still prefer measurement in serum  for the following reasons. 
First, the BDNF measured could in fact have originated in the brain. Second, it may be a 
better fit for psychiatric disorders as they tend to wax and wane over a longer period and 
serum measurements better reflects this pattern since it is probably an accumulation of 
sequestered BDNF over the course of weeks. For the same reason, serum BDNF may be 
more accurate as it is less vulnerable to disruption by day to day fluctuations in severity and 
clinical expression of the psychiatric disorder. 
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Reliability of the serum BDNF measurement
The reliability of BDNF measurements has been challenged in several papers (Gass and 
Hellweg, 2010; Zuccato et al., 2011). A myriad of studies investigating serum BDNF levels 
in humans reported mean levels ranging from 9.1 ng/ml to 42.5 ng/ml (Monteleone et al., 
2008; Yoshimura et al., 2007), indicating that there is a high variability between studies. 
Several commercially available ELISA kits to measure BDNF are on the market. Currently, 
no unified measurement protocol exists, which results in a high variability between labs. 
Teche et al (Teche et al., 2013) have made a systematic inventarisation of methods used and 
found that the kits from Emax, R&D, Chemicon and EK0307 Boster Biomedical were most 
frequently used. Only 60.7% of studies mentioned that BDNF was measured in duplicate 
and 32.1% mentioned blood collection during fasting. In Chapter 2 we have demonstrated 
that sampling variables, such time of sampling, fasting and storage time, are associated 
with serum BDNF levels. The wide variation between studies limits comparability between 
studies, but that does not necessarily imply that individual study results are biased assuming 
that the variation is random. This variation does however plead for a more uniform 
measurement across labs.       
Clinical implications and future directions
The effect sizes for the association between depression and BDNF presented in this thesis 
can be considered small by most standards. In addition, lower BDNF levels were not specific 
to depressive states. Although no formal statistical model was used to test whether BDNF 
would be a suitable biomarker to discriminate depressed patients from non-depressed 
patients, it can be deferred that BDNF would be unsuitable as such a biomarker. At this 
point it must be concluded that peripheral BDNF measurements have no implications for 
current clinical practice yet. 
Nevertheless, some aspects have been studied insufficiently to exclude the possibility of 
potential clinical use of serum BDNF in the future. For example, literature concerning the 
possibility to use serum BDNF as a predictor for the course of depression and/or the success 
of an antidepressant treatment is scarce. 
Future research goals in this respect should therefore be twofold: 1) test the predictive 
power of serum BDNF on the course and treatment prediction of depression (and other 
psychiatric disorders), 2) charting potential variables that exert effects on neurotrophins and 
subsequently focusing on whether neuroplasticity can be influenced in a manner supporting 
recovery from depression.
  
In relation to the first research goal, data such as available from the NESDA consortium 
could shed light on the predictive power of BDNF on the course of depression. In addition, 
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other designs are necessary to elucidate the potential predictive power of a change in 
BDNF early in the course of treatment. Indeed studies have shown that an early increase 
in either serum or plasma BDNF are associated with recovery of depression after the start 
of antidepressant treatment (Dreimuller et al., 2012; Tadic et al., 2011). However, to date, 
prospective studies investigating the predicting power of BDNF on the course of depression 
are scarce. Within these studies, one should take into account that a potential association 
might not be straightforward. In this context the theory of undirected change susceptibility 
has been postulated (Branchi, 2011). This enunciates that in a state of low neural plasticity 
a barrier exists to switch from a healthy to a depressed state, whereas in a state of high 
plasticity one can readily shift from a depressed state into a healthy state and vice versa. 
This could mean that a high BDNF could be both protective in depressed subjects as well as a 
risk factor in currently non-depressed subjects with a high risk profile due to intra-individual 
and environmental factors.   
With regard to the second goal more observational longitudinal designs and experimental 
designs are necessary. As a first step, data available in NESDA could be used to associate 
stressors, such as negative life events, with the change in BDNF over the two-year interval. 
However, particularly suitable for this goal would be an experienced sampling method 
in which actual subjective stress levels and other day-to-day variation can be associated 
with short-term change of BDNF levels. In addition, a design in which BDNF is measured 
in plasma and serum would be particularly suitable to assess fundamental differences in 
assaying plasma versus serum BDNF as it provides an opportunity to determine short and 
long term variation in both methods. 
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Depressie is een psychiatrische aandoening waar bijna 1 op de 5 Nederlanders op enig 
moment in hun leven mee te kampen heeft (Weissman, Bland et al. 1999). De ziekte 
manifesteert zich vaak tijdens de meest actieve levensjaren en interfereert sterk met het 
dagelijks leven (Mathers and Loncar 2006). Hierdoor komt depressie in het Westen op de 
tweede plaats qua ziektelast, alleen voorbij gestreefd door hart- en vaatziekten.
We spreken van een depressieve stoornis wanneer iemand gedurende minimaal twee 
weken tenminste vijf van de negen symptomen van depressie heeft die zijn beschreven 
in de DSM-IV, het handboek van de Amerikaanse vereniging voor psychiatrie waarin alle 
psychiatrische stoornissen staan beschreven. Daarnaast moet een verlaagde stemming of 
niet meer kunnen genieten tenminste een van deze symptomen zijn en dient dit  gepaard te 
gaan met lijdensdruk of beperkingen in het functioneren. Verdere symptomen van depressie 
zijn slaapproblemen, moeheid, afgenomen of toegenomen eetlust met veranderingen 
in lichaamsgewicht, concentratiestoornissen, innerlijk gevoel van onrust of remming, 
schuldgedachten en gedachten aan de dood. 
In de loop der tijd zijn er verschillende (biologische) modellen ontwikkeld voor het ontstaan 
van depressie, waaronder de neurotrofe hypothese van depressie. 
De neurotrofe hypothese van depressie stelt dat het ontstaan en voortduren van depressieve 
symptomen veroorzaakt wordt door een verstoring in de aanpassings- en herstelcapaciteit 
van zenuwcellen in het brein, oftewel een verstoring van de neuronale plasticiteit (Duman 
en Monteggia, 2006) . Deze neuronale plasticiteit wordt gereguleerd door specifieke 
eiwitten, ook wel neurotrofe stoffen genoemd. Brain-derived neurotrophic factor (afgekort 
BDNF) is één van de belangrijkste neurotrofe stoffen. Het BDNF functioneert als een soort 
pokon voor het brein omdat het ervoor zorgt dat zenuwcellen in de hersenen wortel gaan 
schieten en dat die wortels zich stevig hechten aan elkaar. Deze nieuwe verbindingen zijn 
noodzakelijk voor de signaaloverdracht tussen zenuwcellen.  Uit eerder onderzoek blijkt 
BDNF betrokken te zijn bij hersenziekten in het algemeen en depressie in het bijzonder. In 
kleine groepen ernstig depressieve patiënten zijn BDNF-spiegels in het bloed sterk verlaagd 
en na behandeling met medicatie of elektroshock therapie normaliseren deze waarden. 
In dit onderzoek hebben we gebruik gemaakt van BDNF metingen uit bloed van depressieve 
patiënten en niet-depressieve controles. De proefpersonen zijn afkomstig uit een tweetal 
grote epidemiologische studies: de Nederlandse studie naar depressie en angst (NESDA) en 
de Nijmegen biomedische studie (NBS). 
Bij aanvang van deze studie dienden verschillende vragen opgehelderd te worden om de 
neurotrofe hypothese van depressie beter te begrijpen.
Ten eerste is niet bekend welke factoren (determinanten) bepalend zijn voor de bloedspiegels 
van BDNF bij mensen. Ondanks dat de naam (Brain-derived, oftewel afkomstig uit de 
hersenen) anders suggereert, wordt BDNF niet alleen door zenuwcellen geproduceerd. 
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Daardoor kunnen grote hoeveelheden van het BDNF in het bloed ook afkomstig zijn van 
andere weefsels. Dit kan de resultaten van studies verstoren tenzij er goed voor wordt 
gecorrigeerd. Nooit eerder was er een grootschalig onderzoek verricht om zicht te krijgen 
op potentieel verstorende factoren. Eerder werk over de neurotrofe hypothese van 
depressie zou daardoor mogelijk vertekend kunnen zijn, omdat men niet in staat was voor 
deze factoren te corrigeren.
Ten tweede is nooit eerder onderzocht of lagere BDNF waarden enkel kenmerkend zijn voor 
een depressieve episode (state afhankelijk) of dat mensen kwetsbaar zijn voor depressie 
omdat ze een laag BDNF hebben (trait afhankelijk). We weten wel dat het BDNF stijgt 
als mensen succesvol zijn behandeld voor een depressie met medicatie of elektroshock 
therapie, maar niet of de normalisatie van de BDNF spiegels die hiermee gepaard gaat, 
veroorzaakt wordt doordat de depressie in remissie is of een direct fysiologisch effect van 
de genoten behandeling is. 
Ten derde is niet eerder nauwkeurig onderzocht of lagere BDNF waardes bij depressieve 
patiënten samenhangen met specifieke symptomen of karakteristieken van de depressie. 
Depressie is een heterogene ziekte met verschillende verschijningsvormen. Laag BDNF zou 
daardoor gedreven kunnen zijn door individuele symptomen of symptoomclusters in plaats 
van door de aanwezigheid van depressie als geheel.
Dit proefschrift geeft antwoord op de volgende vragen:
1.  Wat zijn de determinanten van serum BDNF waardes?
2.  Zijn lage BDNF serum spiegels geassocieerd met depressieve klachten en/of een 
depressieve stoornis?
3.  Zijn lage BDNF waardes geassocieerd met specifieke symptomen of symptoomclusters 
van depressie?
4.  Zijn lage BDNF waarden een state of een trait afhankelijk kenmerk voor depressie?
Ik zal hieronder de bevindingen van het onderzoek per vraag behandelen.
Ad 1. Wat zijn de determinanten van serum BDNF waardes?
In Hoofdstuk 2 en 3 van dit proefschrift hebben we potentiële determinanten van serum 
BDNF spiegels (bloedwaarden) onderzocht. Hiertoe onderzochten we de niet-depressieve 
deelnemers in de leeftijd van 18-65 jaar uit de Nederlandse Studie naar Depressie en 
Angst ( NESDA) en mensen in de leeftijd van 50-70 jaar uit de Nijmeegse Bevolkingsstudie 
(NBS). Beide studies verschilden enigszins in de maten die naast het BDNF gemeten waren. 
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Consistent over beide studies vonden we dat BDNF hoger was als het vroeger op de dag 
gemeten was, als de bloedmonsters korter waren opgeslagen in de vriezer en bij mensen 
die roken. We vonden in beide studies ook dat er geen verband bestaat tussen BDNF en 
body mass index, metabool syndroom, fysieke activiteit en lichamelijke ziektes. In de NESDA 
studie vonden we een lager BDNF bij mensen die excessief alcohol gebruiken, maar dit 
effect werd niet gezien in de NBS populatie. 
Enkele variabelen waren alleen in NESDA beschikbaar. Daarmee toonden we tevens aan 
dat het BDNF lager was bij mensen die nuchter geprikt waren en bij mensen die in niet-
stedelijke gebieden wonen. 
In beide studies vonden we een effect voor leeftijd op de serum BDNF spiegel. Dit effect 
bleek alleen te bestaan voor vrouwen. Het effect van leeftijd op BDNF bij vrouwen bleek 
bij beide studies echter tegengesteld. In jonge populatie van NESDA (18-65 jaar) zagen we 
dat oudere vrouwen een hoger BDNF hadden en in de oudere populatie van NBS (50-70 
jaar) vonden we daarentegen een lager BDNF voor oude vrouwen. Dit verschil zou verklaard 
kunnen worden door het effect van menopauze (Hoofdstuk 2). Ondersteunend daarbij was 
de bevinding dat bij een groep vrouwen van gelijke leeftijd het BDNF lager was als ze reeds 
postmenopauzaal waren.
Verder keken we naar het effect van genetica op de serum BDNF spiegels. Een bekende 
genetische variatie in het BDNF gen is het val66met polymorfisme. Hiervan zijn twee 
varianten bekend; het met-allel en het val-allel, waarbij de eerste bekend staat als een 
risicogen voor depressie bij mannen, maar niet bij vrouwen (Verhagen et al., 2010). In 
tegenstelling tot onze verwachting vonden wij juist een hoger BDNF bij mannen die het 
met-allel dragen in vergelijking met mannelijke val-allel dragers. Bij vrouwen was er geen 
significant verschil (Hoofdstuk 4). 
Ad 2. Zijn lage BDNF serum spiegels geassocieerd met depressieve klachten 
en/of een depressieve stoornis?
In dit proefschrift heb ik aangetoond dat een lage BDNF spiegel samenhangt het hebben van 
meer depressieve symptomen (Hoofdstuk 3). Verder hebben we laten zien dat patiënten 
met een huidige depressieve stoornis een lagere BDNF spiegel hebben dan gezonde 
controles (Hoofdstuk 5). Daarnaast hebben we in Hoofdstuk 8 gevonden dat BDNF daalt bij 
patiënten die langdurig of frequent een depressieve stoornis hebben.
Ad 3. Zijn lage BDNF waardes geassocieerd met specifieke symptomen of 
symptoomclusters van depressie?
In Hoofdstuk 6 laat ik zien dat de BDNF waardes die gevonden worden bij depressieve patiënten 
niet gedreven worden door individuele symptomen van depressie of symptoomclusters. 
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De onderliggende hypothese was dat er wellicht tegengestelde effecten van verschillende 
symptomen zouden kunnen bestaan op grond van het feit dat verschillende symptomen 
voortkomen uit defecten in verschillende hersengebieden. Dit zou ook verklaren waarom 
de effect-groottes van het verband tussen BDNF spiegels en depressie veel kleiner waren 
dan aanvankelijk gedacht (Hoofdstuk 5). Uit eerdere literatuur is bijvoorbeeld gebleken dat 
BDNF een antidepressieve werking heeft op de hippocampus (Siuciak et al., 1997), terwijl 
het juist depressieve symptomen zou veroorzaken in het ventrale tegmentale gebied en de 
nucleus accumbens, het hersengebied dat betrokken is bij motivatie (Eisch et al., 2003). 
Een interessante bevinding uit onze studie was dat het symptoom “gebrek aan motivatie” 
geassocieerd was met hogere BDNF spiegels (Hoofdstuk 6). Echter aan deze bevinding kan 
niet veel zekerheid worden toegekend aangezien slechts 27 van de 577 proefpersonen geen 
last had van dit symptoom. Om dit verder te onderzoeken zou in de toekomst een grotere 
groep depressieve patiënten onderzocht moeten worden die geen last hadden van een 
gebrek aan motivatie of zou via beeldvormende technieken (bijv. MRI) het verband tussen 
BDNF en dit hersengebied specifiek onderzocht kunnen worden.
Omgekeerd is BDNF wel geassocieerd met verschillende andere psychiatrische aandoeningen 
(Fernandes et al., 2013), waaronder angststoornissen, zoals beschreven in Hoofdstuk 7. 
Ad. 4. Zijn lage BDNF waarden een state of een trait afhankelijk kenmerk 
voor depressie?
De neurotrofe hypothese van depressie postuleert dat de BDNF expressie onder invloed 
van stress vermindert en dientengevolge tot lage BDNF serum spiegels leidt. De eerder 
genoemde behandelstudies suggereren dat lage BDNF spiegels bij depressie een state 
afhankelijk kenmerk zijn. Onze analyse van NESDA data op één meetmoment (Hoofdstuk 5) 
ondersteunt deze aanname. We vonden daadwerkelijk lagere BDNF waardes in een huidige 
depressieve groep in vergelijking met gezonde controles en patiënten bij wie de depressie 
reeds in remissie was. Helaas kunnen deze data geen definitief antwoord geven aangezien 
het vergelijkingen tussen groepen betreffen op één meetmoment. Het herhalen van 
metingen na twee jaar (Hoofdstuk 8) verschaft meer helderheid, omdat daarmee bekeken 
kan worden hoe de BDNF spiegel verandert als de depressie in remissie gaat. In tegenstelling 
tot onze verwachting vonden we dat het BDNF juist harder daalt bij patiënten waar de 
depressie in remissie gaat dan bij gezonde controles. Mensen die op twee meetmomenten 
depressief waren lieten ook een significant sterkere daling van het BDNF zien dan niet-
depressieve mensen. Daarmee is het minder aannemelijk dat lage BDNF levels een state 
afhankelijk kenmerk zijn van de depressie. In tegenstelling tot wat de neurotrofe hypothese 
van depressie postuleert, lijkt de BDNF serum spiegel niet te dalen op een stressor, maar 
lijkt een laag BDNF juist te volgen op het ontstaan van een depressie. 
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Conclusie
Waar men in dierexperimenteel onderzoek veelal BDNF in het brein zelf kan onderzoeken, 
is men in grote mensgebonden onderzoeken beperkt tot het meten van BDNF in het 
bloed. Het onderhavige proefschrift heeft hier een bijdrage aan geleverd door BDNF te 
onderzoeken in zowel een bevolkingsstudie als een klinisch cohort. Niet alleen de omvang 
van de steekproeven van beide studies was uniek in dit onderzoeksveld, ook werden voor 
het eerst op grote schaal herhaalde metingen verricht naar het beloop van de BDNF spiegel 
over de tijd. Zoals de neurotrofe hypothese van depressie stelt, tonen we in onze studie aan 
dat een laag BDNF geassocieerd is met depressie. Met BDNF gemeten in het bloed vinden 
we echter kleine effectgroottes. Dit zou veroorzaakt kunnen worden door het feit dat BDNF 
een stof is die door vele factoren wordt beïnvloed.
Deze bevindingen suggereren bovendien dat de neurotrofe hypothese van depressie 
complexer is dan aanvankelijk gedacht. Waar dierexperimenteel onderzoek een verband 
laat zien tussen het ervaren van stress en een verminderde BDNF expressie in het brein, 
vonden wij bij mensen dat het aannemelijk is dat het BDNF juist daalt als gevolg van de 
depressie. Juist het voortduren van depressie lijkt samen te hangen met een verstoring in 
de BDNF huishouding en dit gegeven dient in vervolgstudies in nauwe samenhang met de 
stressgevoeligheid van het BDNF systeem onderzocht te worden.
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Het onderhavige werk zou nooit tot stand gekomen zijn zonder de hulp van anderen. Ik ben 
dan ook eenieder dankbaar die bijgedragen heeft aan de totstandkoming van dit proefschrift. 
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heb je door je strategisch inzicht als een springplank gefungeerd waardoor je me zonder 
meer het vertrouwen hebt gegeven in het diepe te springen. Je was altijd bereikbaar voor 
overleg, ook toen je naar Groningen verhuisde en zelfs als je op congres was in Canada. 
In onderzoekstermen: je gemiddelde responstijd was ongeveer 15 minuten, met enkele 
outliers als je op Pluto moest passen. Je bent een echte mentor voor me en ik hoop dat je 
die rol ook na mijn promotie nog wilt blijven vervullen.
Jan, jij hebt Richard de ruimte gegeven om als mijn primaire begeleider op te treden. Daarmee 
was je meer op de achtergrond betrokken. Met je scherpe, analytische commentaar wist je 
menig publicatie naar een hoger niveau te tillen. Bedankt voor het vertrouwen dat je in me 
gesteld hebt.  
Met epidemiologisch onderzoek naar BDNF was ik op onze afdeling een beetje een vreemde 
eend in de bijt. Gelukkig was er “het BDNF clubje”. Marc, met niemand kan ik zo goed sparren 
over BDNF als met jou. Men zegt dat de wijzen uit het oosten komen, maar jij bewijst het 
tegendeel. Bernet, Brenda en Jos, bedankt voor jullie altijd rake commentaar. Ik hoop dat 
onze samenwerking niet ophoudt bij de verdediging van dit proefschrift.
Waar ben je zonder je collega’s? In ieder geval niet in Californië. Marten en Janna, dat wij de 
coolste kamer van de afdeling waren dat was wel duidelijk, maar met jullie de Death Valley 
bezoeken was ook echt hot!
Coolste kamer of niet, het moet gezegd worden dat het wel een close call was met zo’n leuke 
onderzoekers op de afdeling. Denise, Desiree, Marloes, Janneke, Nikki, Danique en Rose en 
alle onderzoekers die langer of korter op onze afdeling werkten, bedankt voor de gezellige 
lunches, het sparren en alle ik-kom-even-binnenlopen-koffie-drinken-momentjes.
Het leuke van onderzoek combineren met de opleiding tot psychiater is dat je deelgenoot 
wordt van twee groepen collega’s. Alle AIOS en psychiaters wil ik daarom danken voor een 
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fijne collegiale samenwerking. In het bijzonder wil ik ook Lianne, Peter, Bouke, Rob en Niels 
bedanken voor alle leerzame en gezellige intervisieavonden.
Om naast wetenschap het vak ook in bestuurlijk opzicht bij het SAP te kunnen uitoefenen is 
een voorrecht. Wieneke, Renee, Astrid, Jeroen, Tirza, Lianne en Jelly, samen hebben we veel 
voor elkaar gekregen. Bedankt!
Dan nog een woord aan alle vrienden die zorgden voor de broodnodige afleiding en 
vermaak. Allereerst mijn paranimfen. Niels, soms ben je onnavolgbaar, maar daardoor wel 
altijd verassend. Dank voor het mogen gebruiken van jouw metafoor BDNF als hersenpokon. 
Je begon als collega en bent inmiddels vriend. Ik hoop dat dat nog lang zo mag zijn. 
Bram, als psychiater is het soms heel ontnuchterend om even met ‘normale’ dokters te 
praten. Onze vriendschap geeft daar ruim de gelegenheid toe, hoewel samen een wedstrijdje 
bij NEC bezoeken ook heel ontnuchterend kan werken.  
Marieke, vanaf de eerste minuut van de intro klikte het. Als bonus bracht je Bruno mee 
die ik nog kende van de basisschool. Jullie zijn een goede reden om af en toe weer mijn 
geboortestad op te zoeken. Roy en Linda, de afstand Nijmegen-Tilburg maakt dat we elkaar 
niet vaak kunnen zien, maar het is altijd erg gezellig om af te spreken. Samen met Bram erbij 
zijn we een leuk clubje ‘studievrienden’.
Anne en Alex, Maartje en Gerben, Femke en Mark, jullie begonnen als vrienden van “de kant 
van Hilke”, maar zo voelt het al lang niet meer. Ik hoop dat we jullie nog lang over de vloer 
mogen krijgen.
Dan door naar de schoonfamilie, Rieky en Tieny, Boy, Melissa en Kenn, Gert-Jan, Wendy en 
de toekomstige kleine telg, bedankt dat jullie me opgenomen hebben in jullie gezin. Nu het 
nageslacht er is, wordt het alleen maar leuker.
Pap, mam, jullie steun en vertrouwen in mij is oneindig. Daardoor ben ik geworden wie ik nu 
ben. Mijn dank voor jullie kent geen grens.   
Simon, ik ben trots op hoe jij je hebt ontwikkeld van mijn kleine broertje tot een grote kerel. 
Jij bent mijn favoriete broer!
Ook wil ik mijn lieve echtgenote Hilke bedanken, voor het, naast haar fantastische werk in 
de dierentuin, op orde houden van ons dagelijks leven, maar boven alles omdat zij mij met 
beide benen op de grond houdt. Lieve Hilke, zonder jou was ik nergens.  
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Lieve Ellenoor, jouw geboorte markeerde mijn deadline voor het afronden van dit 
proefschrift. Jij hield je precies aan de planning, het proefschrift niet. Desondanks gaat het 
schrijven na jouw geboorte wel een stuk sneller, want elke minuut dat ik eerder klaar ben, 
kan ik jou weer langer knuffelen.
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Stellingen:1. Body-Derived Neurotrophic factor is een betere invulling 
	 voor	het	acroniem	BDNF	dan	Brain-derived	Neurotrofic	 factor. (hoofdstukken 2 en 3)2. Het is aan te bevelen in onderzoek naar BDNF altijd geslacht 
	 als	effect	modificator	te	onderzoeken.	 (hoofdstukken 2-4 en 7)3. Een laag BDNF in het bloed is geassocieerd met depressie, 
	 maar	is	daar	niet	specifiek	voor.	(hoofdstukken	5,	7	en	8)4. Een laag BDNF in het bloed bij depressie kan niet verklaard  worden met effecten van individuele symptomen of 
	 symptoomclusters.	(hoofdstuk	5)
5.	 Het	langdurig	bestaan	van	een	depressie	is	geassocieerd	met	
	 een	verlaging	van	het	BDNF	(hoofdstuk	8)6. Groot epidemiologisch patiënt-controle onderzoek is de  beste methode om bijzaken te onderzoeken. 7. BDNF is pokon voor het brein. (C.P.M. Veth, persoonlijke  communicatie)
8.	 Destigmatisatie	van	psychiatrische	patiënten	is	een	goede  zaak, maar is te ver doorgeschoten vanaf het moment dat  men patiënten cliënt is gaan noemen.9. Met de voorgenomen verkorting van de opleidingsduur voor  de opleiding tot psychiater zal er minder onderzoekstijd  worden toegekend aan AIOS en daardoor zal met name de  wetenschappelijke ontwikkeling van psychiaters onder druk  komen te staan.10. Het verwachten van een dochter is de beste motivator voor  het afronden van een proefschrift.11. Het toepassen van enkele gedragstherapeutische principes  kan het tot stand komen van een proefschrift bevorderen.12. Het valt Brabanders bij het verdedigen van een proefschrift  aan te bevelen het poneren van 11 stellingen te vermijden om  eventuele verwarring met een pronkzitting te voorkomen. 
